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ABSTRACT 
 
The work contained in this dissertation focuses on the synthesis and 
characterization of dirhodium (II,II) compounds and studies of their anticancer activities 
against cervical and ovarian cancer cell lines.  It has been demonstrated that tailoring the 
coordination environment of the dirhodium core and irradiation using low energy light (λ 
> 400 nm) dramatically affects the anticancer properties of the compounds. 
In order to improve the anticancer activity of dirhodium compounds, a series of 
compounds containing two different bridging ligands was prepared and characterized.  A 
new precursor was prepared from the reactions of dirhodium tetraacetate with N,N’-2,6-
o-difluoroformamidinate to afford, [Rh2(F2form)(µ-O2CCH3)3]  (1).  Compound 1 was 
reacted with diimine ligands phen (2) (1,10-phenathroline), dpq (3) (dipyrido[3,2-f:2',3'-
h]-quinoxaline), dppz (4) (dipyrido[3,2-a:2’,3’-c]phenazine) and  (5) dppn 
(benzo[i]dipyrido[3,2-a:2’,3’-h]quinoxaline) to obtain compounds of general formula 
[Rh2(F2form)(µ-O2CCH3)(NN)2]
2+.  Compounds 2-5 exhibit significant photocytotoxic 
activities against HeLa, COLO-316, OVCAR-8 and NCI-ADR/RES.  This new family of 
compounds is capable of depleting mitochondrial potential and inducing cell death on a 
short time scale (~ 10 min) after irradiation with compounds 4 and 5 being the most active 
of the series. 
  The ease of tuning dirhodium compounds prompted the study of another series 
of the mixed-bridging ligand compounds [Rh2(F2form)(µ-O2CCH3)(CH3CN)6]
2+ (6) and   
[Rh2(Ph2P(C6H4))(µ-O2CCH3)(CH3CN)6]
2+ (7).  The presence of strong σ-donating 
 iii 
 
ligands renders the trans CH3CN ligands labile in the dark, whereas the ones trans to the 
acetate are stable.  These compounds were found not to exhibit significant anticancer 
activity against HeLa cells but they may be used as scaffolds for further functionalization 
with biologically or photocatalytically active ligands. 
The antioxidant, antineoplastic molecule 2-pyrrolidinone was used as a bridging 
ligand in the partially solvated dirhodium complexes [Rh2(µ-
NOC4H6)2(NOC4H7)ax(CH3CN)5]
2+
 (8) and [Rh2(µ-NOC4H6)2(NOHC4H6)eq(CH3CN)5]
2+
 
(9).  The aim of this chapter was to design a multifunctional drug that, upon irradiation, 
releases the anticancer drug 2-pyrrolidione and has open coordination sites that are 
available to bind to other biological molecules.  Compound 8 does not exhibit anticancer 
properties upon irradiation, but 9 induces a 22-fold increase in cytotoxicity as compared 
to the dark control.  These results are highly promising indicators that designer heteroleptic 
dirhodium compounds hold considerable potential as prodrugs for photochemotherapy. 
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CHAPTER I  
INTRODUCTION  
 
Cancer 
Cancer is characterized by the uncontrolled cell growth and impaired balance 
between new cell growth and old cell death and the ability of these cells to migrate to other 
areas in the body.1  The disease is caused by inherent factors (mutations, hormones and 
immune conditions) as well as environmental factors (tobacco, diet, radiation, and 
infections organisms).2  Cancer has become one of the leading causes of death worldwide 
and in the US it is second only to heart disease, accounting for 1 of every 8 deaths.3-5  One 
of oldest reports of cancer dates back to the 1600 BC in ancient Egypt, but it has also been 
observed in animal and non-human primate fossils.4-5   
The world’s population in 2020 is expected to increase to ~7.5 billion and with it 
there will be more cancer diagnoses, an estimated ~15 million new cases.6  In 2015 alone 
it is estimated that more than 1.67 million cases of cancer will be reported.3  The increase 
in cancer incidence since the 19th century is mostly attributed to the change in diet and 
sedentary lifestyle which accounts to almost 90-95 % of all cases, the remaining 5-10 % 
is attributed to genetic factors (Figure 1.1).5,7  Among all cancers, lung cancer is the 
leading cause of cancer mortality in both men and women, followed by prostate cancer in 
men and breast cancer in women (Table 1.1).3  There has been an increase in survival 
rates since the 1970’s mostly due to preventive care and early diagnosis, but there is a 
pressing need for new targeted therapies that improve the patient’s quality of life during 
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treatment.  Inorganic medicinal chemistry provides an excellent platform for new 
treatments against cancer. 
 
 
 
 
Figure 1.1  The role of genes and the environment in cancer development.  A) 
Contribution of genetic and environmental factors to cancer.  B) Family risk ratio for 
selected cancers.  C) Contribution of environmental factors to cancer deaths due to a 
specified environmental risk factor.  Adapted with permission from ref. 2.  Copyright 2008 
© Springer Science.
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Table 1.1 Estimated Cancer Deaths in the US in 2015.  Data obtained from ref. 3. 
Men 312,150 Women 277, 280 
Lung & bronchus 28% 26% Lung & bronchus 
prostate 9% 15% breast 
Colon & rectum 8% 9% Colon & rectum 
Pancreas 7% 7% Pancreas 
Liver & intrahepatic bile 
duct 
5% 5% ovary 
Leukemia 5% 4% 
Liver & intrahepatic bile 
duct 
Esophagus 4% 4% Leukemia 
Urinary Bladder 4% 3% Esophagus 
Non-Hodgkin lymphoma 3% 35 Urinary Bladder 
All other sites 24% 
2% Non-Hodgkin lymphoma 
23% All other sites 
 
 
Cisplatin 
It is well stablished that metal-based antitumor agents can target DNA by forming 
covalent interactions or by intercalating into the double helix of DNA.8-9  The formation 
of DNA adducts is known to be an important aspect of the mechanism of activity of 
cisplatin [cis-diamine dichloroplatinum(II)] (cis-Pt(NH3)2Cl2) which is one of the most 
potent anticancer agents that was approved for clinical use in the late 1970’s.  Cisplatin is 
routinely used in the treatment of testicular cancer, Hodgkin’s lymphoma, ovarian, 
bladder, head/neck tumors and other malignancies.10  Once inside the cell the original 
prodrug undergoes hydrolysis producing the positively charged complex cis-
[PtCl(NH3)2(H2O)1]
2+ which first forms mono-adducts and then bis-adducts with DNA.  
This complex can also covalently bind to the DNA duplex forming 1,2-cis-[Pt(NH3)2
2+-
d(GpG)] crosslinks which induce bending and unwinding of the DNA duplex.11-12  
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Cisplatin can also bind to cytoplasmic substrates that contains thiols like glutathione, 
methionine, metallothioneins and proteins.13  The interaction of the drug with these 
molecules shifts the redox balance toward oxidative stress facilitating DNA damage, 
however it can also be deactivated in the same way due to decreased drug concentration 
in the cell.14  Due to its ability to covalently bind the DNA duplex, cisplatin triggers the 
inhibition of replication and transcription, cell cycle arrest and attempted repair of 
damaged nucleotides which in turn cause programmed cell death.11 
 
Drug Resistance 
Despite the huge success of cisplatin in battling various forms of cancer, its use 
has many drawbacks including significant toxic side-effects and acquired drug resistance 
mostly.15  The side-effects are result of the widespread systemic distribution of the drug 
in the body after administration; after 24 h 95% of the complex binds to plasma proteins 
and then localizes in the kidneys (0.4-2.9 µg/g), liver (0.5-3.7 µg/g) and prostate (1.6-3.6 
µg/g).16   It is believed that cisplatin enters the cells through passive diffusion or by active 
protein mediated transport systems such as the human organic cation transporter (hOCT2) 
(mostly for oxaliplatin) or the copper transport protein (Ctr1).17 The mechanism by which 
the cell repairs the platinum lesions is unknown; it is believed, however that reduced drug 
uptake, increased drug efflux, increased intracellular detoxification, and increased DNA 
mismatch repair capacity and base excision are a few of the mechanisms that cause drug 
resistance.18-21   
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Cisplatin drug resistance is a result of many factors that are dependent on the type 
of tumor being treated.  Several factors contributing to drug resistance are (1) reduced 
cisplatin accumulation in the cell due to changes in drug transport, (2) improved 
detoxification mechanism in the cell thought the upregulation of intracellular scavengers, 
(3) improved DNA repair mechanisms, (4) increased tolerance of DNA lesions and (5) 
changes in the signaling pathways that triggers programmed cell death or apoptosis.14,16 
The decrease in drug accumulation in tumors has been attributed to the down 
regulation of the CTR-1 (plasma membrane copper transporter), which controls copper 
homeostasis and evidence suggest it is also involved in cisplatin uptake.22-23  Copper 
export pump proteins ATP7A/ATP7B and MRP2 (plasma membrane transporter) have 
been found to be upregulated in cisplatin resistant cell lines, mostly in ovarian cancer.24-25  
The upregulation of these group of proteins increases drug efflux.  Increased levels of 
intracellular scavengers like glutathione (GSH) and metallothioneins are responsible for 
deactivation of the drug inside the cell by decreasing the concentration of drug available 
in the cell milieu.26-27 
Cisplatin resistant cells have the ability to remove DNA lesions by the nucleotide 
excision repair (NER) mechanism.  The overexpression of ERCC1 (excision repair 
protein) increases the efficiency of the NER repair mechanism.28  Another key mechanism 
into drug resistance is the deficiency in the mismatch repair (MMR) mechanism.29  
Defective MMR pathways prevent MMR proteins from repairing platinated DNA.29-30  On 
target resistance is characterized by an increase in translesion synthesis in drug resistant 
tumors by the upregulation of DNA polymerases that bypasses DNA lesions caused by 
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cisplatin and increased proficiency of BRCA1/BRCA2 proteins (involved in regulation of 
transcription and cell cycle).31-32 Deficiencies in the transduction signaling pathways 
interferes with the apoptotic response in the cell.  The deficiency of proapoptogenic factors 
(BAX/BAK)33, overexpression of antiapoptotic factors (BCL-2 proteins)34, changes in 
activation of caspases (Caspases 3, 6, 7, 8 and 9)35 and mutations to the tumor suppression 
protein p5336 amongst others has been linked to carboplatin and cisplatin resistance as 
well.28   
 
Non-Platinum Metal Based Anticancer Drugs 
The structural and chemical modifications of cisplatin analogs have improved their 
cytotoxicity towards some resistant tumors but their mechanisms of action are fairly 
similar.  Clearly there is a need for alternative chemotherapy agents that have different 
binding properties or mechanisms of actions from that of cisplatin.  Therefore it is 
important to seek different types of antitumor agents that will not exhibit the same 
limitations as cisplatin and its derivatives.37  Metal complexes have the ability to bind to 
different cell targets, including but not limited to DNA, disrupt enzymatic pathways or 
affect mitochondrial function.16 
 
Ruthenium 
Several examples of metal based anticancer compounds have been reported in the 
literature.  Ruthenium based compounds have shown low systemic toxicity when 
compared to cisplatin.38  Another key feature is that Ru based compounds show greater 
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accumulation through highly selective iron transport mechanisms (transferrin).39    Two 
Ru(III) compounds have reached clinical trials, one of them is [H2im][trans-Ru(Him) (S-
DMSO)Cl4] were Him = imidazole and DMSO = dimethyl sulfoxide (NAMI-A, phase II 
clinical trials) (Figure 1.2a).  NAMI-A has shown to have selective activity against tumor 
metastases and it has the ability to bind DNA, induce cell cycle arrest (S phase), and it 
inhibits angiogenesis.40  The second candidate in clinical trials is [H2ind][trans-
Ru(Hind)Cl4] were Hind = indazole (KP1019, phase II clinical trials, Figure 1.2b).  Even 
though KP1019 is structurally similar to NAMI-A, but its anticancer activity is 
significantly different.  KP1019 binds to DNA and accumulates in the nucleus, thus 
inducing an intrinsic apoptotic response, characterized by the permeabilization of the 
mitochondria, triggering a release of cytochrome c which initiates the apoptotic cascade 
of events (activation of caspase-9).41-42  The cytotoxic effects of KP1019 have been limited 
to solid tumors and no dose-limiting toxicity has been observed during phase I clinical 
trials.43 
 
Gold 
Gold compounds are of significant importance, Au(III) is isoelectronic with Pt(II) 
and it have similar chemistry.16  Chelating nitrogen ligands (such as phen, bpy, terpyridine 
(tpy) and ethylenediamine) are needed to stabilize the Au(III).44  Studies have shown that 
Au(III) diimine complexes (like [AuCl(tpy)]2+) are stable in the presence of GSH and 
interact with DNA, they also exhibit good anticancer activity.44-45  Of particular interest 
are Au(I) compounds, auranofin (Ridaura®, Figure 1.2c) has been used as medication for 
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rheumatoid arthritis, but it also exhibits antitumor activity in patients with bladder 
cancer.46  The efficacy of auranofin as anticancer agents is related to its activity as inhibitor 
of thioredoxin reductase (TR, involved in ROS reduction).47-48 Auranofin is currently in 
clinical trials (Phase II) for the treatment of lymphocytic leukemia and several solid 
cancers and it is also been investigated for its activity against skin melanoma.48-49       
 
 
 
Figure 1.2  Schematic representation of the chemical structures of a) NAMI-A, b) 
KP1019, c) Auranofin, d) KP46 and d) tris(3-hydroxy-2-methyl-4H-pyran-4-
onato)gallium(III). 
 
 
Gallium 
Main group element gallium as in the case of gold compounds, has been widely 
used in other applications (e. g. treatment of accelerated bone resorption, autoimmune and 
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infectious diseases and imaging) including cancer therapy.16  The compound Ga(NO3)3 
has been studied in clinical trials (Phase I and II) for the treatment of bladder cancer and 
non-Hodgkin’s lymphoma with good outcomes.50  Coordination of Ga3+ to organic ligands 
has proven an effective strategy to improve intestinal absorption when compared to 
Ga(NO3)3.  Two oral Ga(III) treatments have been selected for preclinical trial namely 
tris(8-quinolinolato)-gallium(III) (KP46)  and tris(3-hydroxy-2-methyl-4H-pyran-4-
onato)gallium(III) (Figure 1.2d-e).51  The higher activity of Ga(III) coordination 
compounds is mostly due to p53 activation facilitated by Ca2+-signaling and generation of 
ROS.52-53 
 The examples provided here are just a small fraction of metal based compounds 
that exhibit anticancer properties and different mechanisms of action than cisplatin.  It is 
evident that medicinal inorganic chemistry is an attractive field for the development of 
anticancer drugs that can circumvent drug resistance through different mechanisms and 
activation pathways that of cisplatin.  
 
Dinuclear Metal-Metal Bonded Anticancer Compounds 
      Dinuclear metal-metal bonded compounds of rhodium are very promising non-
platinum anticancer compounds for anticancer applications.  The Rh2(µ-O2CCH3)4 
compound exhibits excellent anticancer activity against several cell lines including Ehrlich 
ascites tumor, sarcoma 180 and P388 lymphocytic leukemia.54-55  It has been shown that 
dirhodium complexes have the ability to inhibit DNA replication, transcription and protein 
synthesis.56-57  In addition, NMR studies have demonstrated the ability of the dirhodium 
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core to interact with DNA.9,58-60  For example multinuclear NMR data have revealed that 
dirhodium compounds can bind to guanine, adenine and cytosine in a chelating fashion 
through ax-eq, eq-eq and ax positions thereby inducing changes in the base pair stacking 
and disrupting hydrogen bonding interactions of the DNA double helix.58,61  Similarly to 
cisplatin, Rh2(µ-O2CCH3)4 forms 1,2-d(pGpG) intrastrand crosslinks with DNA, but its 
efficacy as an anticancer agent is not limited to this binding mode.60  Modifying the ligands 
around the rhodium centers at axial and equatorial positions offers a variety of possible 
binding sites for reactions with biomolecules.  For example dirhodium compounds can be 
equipped with intercalative binding units, resulting in simultaneous covalent binding to 
the DNA and intercalation between the DNA base pairs (Figure 1.3).62 
 
 
Figure 1.3  Example of combination binding, intercalative and coordinative, by cis-
[Rh2(dap)(-O2CCH3)2(1-O2CCH3)(CH3OH)](O2CCH3)]+ to adenine on a DNA 
AA12mer fragment, d(CTCTCAACTTCC).  Adapted with permission from ref. 16.  
Copyright 2006 © Wiley Science.  
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Photodynamic Therapy 
Photodynamic therapy (PDT) is a non-invasive treatment for endoscopically 
accessible tumors.63-64  The localized action of PDT allows for the successful treatment of 
lung, bladder, gastrointestinal, esophageal, prostate and gynecological tumors.63-65 This 
therapy uses photosensitizers and visible light (600-850 nm) in combination with 
molecular oxygen to cause damage to tumor cell membranes or tumor vasculature by the 
formation of 1O2 and other reactive oxygen species, which in turn causes cell death by 
apoptosis or necrosis (Figure 1.4).66-68  
One of the disadvantages of PDT is that it is dependent on the amount of oxygen 
present and the singlet oxygen generated can only diffuse by 0.02 µm therefore 
effectiveness of the treatment is restricted by 1O2 formation (concentration of O2 in the 
tumors) and its diffusion.63  To date the PDT market is dominated by organic molecules,  
but the population of the triplet excited states upon irradiation (3ES) is not efficient, thus 
limiting the generation of 1O2.
69 
Metal based photosensitizes exhibit long lived 3ES states that can generate 1O2 in 
high yields.  The literature is replete with examples of metal based photosensitizers that 
generate 1O2 in good yields:  Ru(II)
70-71, Os(II)72, Ir(III)73-74, Re(I)75 are some of them.  Our 
group has synthesized many dirhodium derivatives with the ability to act as PDT agents 
in both aerobic and anaerobic conditions with 3IL life times in the range of 2.40-4.10 µs 
which makes these types of compounds suitable for PDT applications.76   
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Figure 1.4  PDT mechanism of action in the cell.  Adapted with permission from ref. 45.  
Copyright 2006 © Nature Publishing Group. 
 
 
Oxygen Independent DNA Photocleavage of Dirhodium (II,II) Complexes 
Tailoring the coordination environment around the dirhodium core provides means 
for the exploration of their reactivity and cytotoxic properties in cancer cells.  One example 
of this is the photo-cisplatin analog [Rh2(O2CCH3)2(CH3CN)6][BF4]2 first synthesized by 
Garner and coworkers in 1986, it was found to be capable of binding to ds-DNA under 
visible light irradiation 20 years later by Turro and coworkers.77 This new cisplatin analog 
was studied for its anticancer activity against Hs-27 human skin cells and it exhibits very 
promising anticancer properties with a 34-fold increase in toxicity upon irradiation.  The 
activity of [Rh2(O2CCH3)2(CH3CN)6][BF4]2
 is a result of the exchange of two of the 
equatorial CH3CN ligands upon irradiation (λ = 355 nm and 509 nm), forming the active 
species [Rh2(O2CCH3)2(CH3CN)2(H2O)4]
2+ which upon irradiation can bind to 9-
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ethylguanine, and linearized PUC18 plasmid and also inhibits transcription by the T7-
RNA polymerazse.57,77  This is the first dirhodium partial paddlewheel compound that can 
act as a photochemotherapeutic (PCT) agent in an oxygen independent fashion.78  Ever 
since the discovery of the anticancer properties of [Rh2(O2CCH3)2(CH3CN)6][BF4]2  other 
derivatives have been pursued, such as: [Rh2(HNOCCH3)2(CH3CN)6]
2+, 
[Rh2(DTolF)2(CH3CN)6]
2+, [Rh2(DTolF)2(CH3CN)6]
2+
 , [Rh2(DTolF)2(CH3CN)6]
2+
 and 
[Rh2(Ph2P(C6H4)](CH3CN)6]
2+ ([F-form]-: p-difluorophenylformamidinate, [NNN]-: p-
ditolyltriazenide, [DTolF]-: p-ditolylformamidinate).79-81  
 
Oxygen Dependent DNA Photocleavage of Dirhodium (II,II) Complexes 
Another strategy being sought is the binding of electron acceptors to the dirhodium 
core.  In the early 2000’s Turro and coworkers studied the photophysical and 
photochemical properties of Rh2(µ-O2CCH3)4 and observed that upon irradiation with 
light  in the 395-600 nm region in the presence of an electron acceptor, the Rh2(µ-
O2CCH3)4 molecule is able to photocleave DNA by the formation of the mixed valence 
cation [Rh2(µ-O2CCH3)4·2H2O)]
+.82  This finding prompted the development of a new 
series of anticancer agents containing electron acceptors directly attached to the dirhodium 
core in order to study them for anticancer activity upon light activation.8,76 
 In this vein the monocationic series of compounds with formula 
[Rh2(O2CCH3)2(η1-O2CCH3)(N-N)1(CH3OH)]+ were N-N = bpy, phen, dpq, dppz and 
dppn, was investigated in the Dunbar and Turro labs.83-84  This family of compounds 
showed anticancer activity against HeLa cells, but COLO-316 cells are more susceptible 
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to the effects of these compounds.  The compounds that exhibited the most activity are 
[Rh2(O2CCH3)2(η1-O2CCH3)(dppz)1(CH3OH)]+ and [Rh2(O2CCH3)2(η1-
O2CCH3)(dppn)1(CH3OH)]
+ which are able to intercalate into DNA in vitro and cleave 
nuclear DNA as confirmed by the comet assay (a gel-electrophoresis method that 
measures DNA damage in individual cells).85-86 Glutathione (GSH) which protects cells 
from oxidative damage generated by reactive oxygen species (ROS)87 was modulated in 
the COLO-316 cells in order asses the effects of this tripeptide on the activity of the 
compounds. COLO-316 cells were incubated with the compounds in the presence of NAC 
(N-acetyl cysteine, increases cellular levels of GSH) and BSO (buthionine sulphoximine, 
depletes GSH levels in the cell) and their toxicity measured.85 The results indicate that 
increased levels of glutathione in the cells do not inhibit the anti-proliferative activity of 
the compounds.  This result is very important for the development of dirhodium based 
anticancer drugs, since the activity of these type of compounds is not hindered by the 
presence ROS scavengers in the cells. 
 Another series of compounds that was developed in our laboratories is the 
heteroleptic series of compounds of general formula [Rh2(O2CCH3)2(dppn)(N-N)]
2+.  The 
most active of the series are [Rh2(O2CCH3)2(dppn)(dppz)]
2+ and 
[Rh2(O2CCH3)2(dppn)2]
2+ which can generate 1O2 upon irradiation with good yields (Φ = 
0.4).88  The addition of extended π structures to the dirhodium compounds confers greater 
anticancer activity when the compounds are irradiated, mostly due to the long lived 3ππ 
states due to the formation of ROS through O2-dependent pathways.
88  It is worth noting 
that compounds [Rh2(O2CCH3)2(dppn)(dppz)]
2+ and [Rh2(O2CCH3)2(dppn)2]
2+ still elicits 
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DNA photo-cleavage in the absence of oxygen.78,88  These compounds exhibit toxicities 
in the lower micromolar range (Hs-27 cell line) upon irradiation, with phototoxicity 
indices (PI) of 21 and 24-fold respectively which is an improvement to current 
photodynamic therapy treatments (PDT) (Figure 1.5).88   
A more systematic study of the anticancer activities of these compounds against 
HeLa and COLO-316 cells was performed and in the new study it was found that the 
complexes do not reach the nucleus although they exhibit good anticancer activities.  It 
was also noted that changing the coordination environment around the dirhodium core 
triggers different responses in the cells; for example [Rh2(O2CCH3)2(dppn)(dppz)]
2+  
induces programmed cell death whereas [Rh2(O2CCH3)2(dppn)2]
2+ causes necrotic 
death.37  By tuning the ligand environment, DNA photocleavage, 1O2 or ROS generation 
can be enhanced, making these compounds attractive candidates for photodynamic 
therapy applications. 
 
Photoactivated Chemotherapy  
 Photoactivated chemotherapy or photochemothreapy (PCT) consists on the release 
of a biologically active drug upon light irradiation to induce cell death.78,89  The advantage 
of this type of therapy is that it is independent of the concentration of O2 present in the 
cell and light is used as a trigger for drug release to elicit a toxic response.  Ruthenium(II) 
compounds have been used for this application,  e. g. [Ru(tpy)(5-cyanouracyl)3]
2+ reported 
by Turro and coworkers.90  The prodrug upon irradiation with low energy light releases  
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Figure 1.5  Dirhodium compounds containing two different diimine ligands with 
sensitized 1O2 quantum yields, cytotoxicity LC
50 concentrations in the dark and upon 
irradiation against Hs-27 cells, and the phototoxicity index (ratio) obtained from ref. 88. 
 
 
the bioactive 5-cyanouracil molecule which has been known to inhibit pyrimidine 
catabolism in vivo.78,91  Studies in cellulo demonstrated that the toxicity of [Ru(tpy)(5-
cyanouracyl)3]
2+ is attributed by the release of the 5-cyanouracil molecules and not the 
formation of Ru-aquo adducts.78,90  A more recent report of  two Ru(II) polypyridyl 
compounds (RuL2(dppz-R) where R = CH2NH2 and L=bpy, phen or dipyridylamine) were 
conjugated to  a photolabile linker (PLPG = N-OH-succinimidylester) which is covalently 
bound to a targeting peptide (BBN, L-Gln-L-Trp-L-Ala-L-Lys-CONH2) or a nuclear 
localizing sequence (NLS,  L-Arg-D-Arg-L-Arg-L-Lys-CONH2) for PCT applications 
(Figure 1.6).92 The Ru(II) prodrug bound to the targeting peptide showed increased drug 
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uptake and the conjugate bound to the nuclear targeting sequence showed preferential 
nuclear accumulation.92  In addition light mediated release of the complexes induced a 
cytotoxic response against HeLa and MRC-5 cells.92   
Partially solvated dirhodium compounds of the form 
[Rh2(O2CCH3)2(CH3CN)6][BF4]2 are good candidates for PCT.  The substitution of the 
equatorial acetonitrile ligands for biologically active molecules poises 
[Rh2(O2CCH3)2(CH3CN)6][BF4]2 as a frontrunner in the PCT field.  Dirhodium (II,II) 
acetamide compounds of the form Rh2(NHOCCH3)2(dppz)(CH3CN)4][BF4]2  have been 
synthesized for this application.93  The compound shows dual DNA binding upon 
irradiation namely, intercalation and covalent binding which is the first example of Dual 
DNA binding.93  These are promising results that help further the understanding of 
dirhodium compounds and their interactions with DNA for better design of future drugs. 
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Figure 1.6  Schematic representation of Ru(II) prodrug for PCT applications, 
[Ru(bpy)2(dppz-PLGP-R)]
2+.  
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Dissertation Objectives and Outline 
Dirhodium compounds have shown interesting properties ranging from covalent 
binding to ss-DNA and ds-DNA, transcription inhibition and interactions with biologically 
relevant structure amongst others and activation by light.  These metal-metal bonded 
compounds can be easily tailored to improve their photochemical properties and their 
anticancer activity, which makes them excellent candidates for future anticancer therapy. 
In Chapter II the synthesis and characterization of a new class of dirhodium 
diimine compounds containing two bridging ligands will be discussed.  The effects of the 
bridging ligands on cytotoxicity were evaluated against drug resistant cell lines and 
fluorescent probes were used to elucidate mechanisms of action. 
Chapter III focuses on mixed-bridging ligand partially solvated dirhodium 
compounds and the rate of exchange of the equatorial CH3CN molecules and how it affects 
the cytotoxicity of these molecules against HeLa cells. 
Chapter IV describes the synthesis of a dirhodium partially solvated compounds 
with 2-pyrrolidinone as bridging ligands and their activity against HeLa cells for PCT 
applications.   
Conclusions and future directions in dirhodium anticancer therapy will be 
discussed in Chapter V.
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CHAPTER II  
DIRHODIUM (II,II) MIXED-BRIDGED LIGAND COMPOUNDS CONTAINING 
ELECTRON ACCEPTING DIIMINE LIGANDS AND THEIR ACTIVITY AGAINST 
OVARIAN CANCER CELLS 
 
Introduction 
The discovery of the anticancer properties of cisplatin shepherded in the current 
modern era of medicinal inorganic chemistry.94  Currently, many metal based compounds 
are being used as therapeutic and diagnostic agents.16,94-95  Despite the considerable 
efficacy that the platinum based drugs cisplatin, carboplatin and oxaliplatin exhibit against 
various tumor, it is imperative to explore new metal based drugs in order to circumvent 
drug resistance and severe side effects.96  Metal-metal bonded compounds constitute an 
excellent platform for new anticancer drugs due to their ease of tunability and 
functionalization.  One example is dirhodium tetraacetate [Rh2(O2CCH3)4], which was 
shown by Bear and coworkers to exhibit anti-tumor activity against Ehrlich ascites L1210, 
sarcoma 180 and P388 with increased survival rates in mice.55,97  Structure activity 
relationships have been established in order to understand mechanisms of action and 
possible targets.54,98 In the early 2000’s, NMR studies of Rh2(O2CCH3)4 reactions with 
DNA reported by Kang, Chifotides and Dunbar revealed that [Rh2(O2CCH3)4] can bind to 
double stranded DNA by generating DNA crosslinks at cytosine and adenine sites.99  The 
Turro group demonstrated that reactions of dirhodium tetraacetate with electron acceptors 
in the presence of light induce DNA photocleavage.82,100  Inspired by these results the 
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Dunbar and Turro groups initiated a collaboration to design dirhodium compounds with 
electron accepting ligands such as phen, dpq and dppz for therapeutic purposes.  One 
example is the family of compounds of general formula [Rh2(O2CCH3)2(η1-
O2CCH3)1(CH3OH)(L)]
+ (L = phen, dpq, dppz or dppn) which were shown to intercalate 
to DNA in vitro and also bind to nuclear DNA in cellulo 85  Another series of compounds 
showing significant increase in toxicity against skin cancer cells is the heteroleptic series 
of compounds [Rh2(O2CCH3)2(dppn)(L)]
2+ with the dppz and dppn compounds exhibiting 
21-fold and 24-fold increases in toxicity upon irradiation88   
 The ability of dirhodium compounds to induce a cytotoxic response upon 
irradiation poises them as good candidates for photodynamic therapy (PDT).  PDT is a 
non-invasive technique that relies on the use of light in the presence of a photosensitizer 
as treatment for superficial tumors.66 One of the limitations of current PDT agents is their 
dependence on oxygen concentration to be active which is a serious drawback for dense 
hypoxic tumors.101  Once the oxygen in the tumor cell has been depleted the PDT agent 
loses its activity.64  An important discovery for us is that the aforementioned dirhodium 
compounds do not require O2 to exert a toxic response against cancer cells.
88   
 Another aspect of the compounds that needs to be considered is that many 
anticancer drugs induce an apoptotic response (programmed cell death)  in the cells.102  In 
order to survive, cancer cells develop defense mechanisms and mutations against drug-
induced apoptosis.102-103 One of the advantages of PDT is that it induces a different cell 
death mechanism, namely necrosis.101  Necrosis can be identified by changes in 
morphology like swelling of organelles and loss of plasma membrane integrity.104  
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Inducing necrotic cell death can be a strategy to circumvent acquired drug resistance.103   
Tumor death by necrosis elicits a pro-inflammatory response that is beneficial to the 
organism.104  Recent reports suggest that in certain tumors the inflammatory response 
induced by necrotic death caused by an anticancer agent facilitates the production of 
cytokines that stimulates adaptive anti-tumor immunity.105-107  These findings suggest that 
therapies should not be limited to apoptotic inducers. 
 Mixed bridge dirhodium compounds of the type [Rh2(DTolF)2(O2CCF3)2(H2O)2] 
(DTolF = p-tolyl formamidinate) first studied by Piraino showed similar anticancer 
activity to that of cisplatin and [Rh2(O2CCH3)4] and exhibit increased survival rates in 
mice bearing Yoshida ascites and T8 sarcoma.97  In light of these results, a new series of 
mixed-bridging ligand dirhodium compounds with electron acceptors has been prepared.  
The combination of two different bridging ligands on the dirhodium core and the presence 
of the diimine ligands render these compounds very different than any others that have 
been studies.  The antineoplastic effects of these new family of compounds was 
investigated against cervical cancer cells (HeLa) and the ovarian carcinomas COLO-316, 
OVCAR-8 and multidrug resistant NCI-ADR/RES upon irradiation with visible light.  The 
synthesis, characterization and biological activities of these new compounds will be 
discussed herein.  
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Experimental Section 
Starting Materials 
The compound Rh2(µ-O2CCH3)4•2CH3OH was purchased from Pressure 
Chemicals or synthesized from RhCl3•xH2O from reported procedures.108  The compounds 
N,N’-bis(2,6-difluorophenyl)formamidine (o-HF2form) and 
Rh2((C6H5)2P(C6H4))(O2CCH3)3•2O2CCH3 were synthesized by slightly modified 
published procedures.109-110 Commercially available reagents, potassium tertbutoxide 
(KtBuO) (Sigma Aldrich), sodium tetrafluoroborate (NaBF4) (Sigma Aldrich) and 1,10-
phenanthroline (phen) (VWR) were used as purchased and used as received.  The ligands 
dpq (dipyrido[3,2-f:2’,3’-h]-quinoxaline, dppz (dipyrido[3,2-a:2’,3’-c]phenazine) and 
dppn (benzo[i]dipyrido[3,2-a:2’,3’-h]quinoxaline)111 were prepared according to 
published procedures.  Analytical thin layer chromatography was carried out on 
aluminum-backed sheets coated with silica gel (SiO2) 60 F254 adsorbent (0.20 mm 
thickness, EMD Chemicals).  Flash chromatography was performed with SiO2 60 (40-63 
µm, BDH Chemicals).  The solvents acetic acid (HOAc), acetone, hexanes (hex), 
tetrahydrofuran (THF), dichloromethane (CH2Cl2), diethyl ether (Et2O), were of ACS 
grade and used as received.  Acetonitrile (CH3CN) was of ACS grade and was dried with 
3Å molecular sieves and distilled under an inert atmosphere.  Standard Schlenk-line 
techniques under a N2 atmosphere were used, but work-up and isolation of products was 
performed in air unless otherwise stated. 
Cell culture reagents Dubelco’s modified Eagle medium (DMEM) (Invitrogen), 
fetal bovine serum (FBS) (Atlanta Biologicals), Leibovitz's L-15 Medium (L-15) without 
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phenol red (Life Technologies), Phosphate-Buffered Saline solution (DPBS) (Life 
Technologies), Resazurin (Sigma), Sytox Green® and Blue® (Invitrogen), Hoechst 33342 
(Invitrogen), mitoTracker green (Invitrogen), Annexin V-FITC and propidium iodide (PI) 
apoptosis assay (biotool.com) and MitoProbe® JC-1 assay (Life Technologies)  were used 
as received.  The HeLa cell line was obtained from the American Type Culture Collection, 
cell line CCL-2.  The COLO-316 cell line was kindly provided by Prof. Robert Burghardt 
(Texas A&M, Department of Veterinary Anatomy and Public Health) and the OVCAR-8 
and NCI/ADR-RES cell lines were provided by Prof. James Sacchettini (Texas A&M, 
Department of Chemistry). 
 
Preparation of Rh2(µ-o-F2form)(µ-O2CCH3)3•2O2CCH3 (1).  A Schlenk flask was 
charged with o-HF2form (72 mg, .26 mmol), K
tBuO (28 mg, 0.25 mmol) and THF (100 
mL) and the reaction mixture was allowed to stir at room temperature for 4h under inert 
atmosphere until the reaction changed to a tan color.  A purple solution of Rh2(µ-
O2CCH3)4•2CH3OH (123 mg, 0.24 mmol) in 100 mL of CH2Cl2:CH3CN (1:1 v/v) was 
treated with deprotonated o-HF2form in a dropwise form.  The reaction mixture was stirred 
for 24 h at room temperature.  The resulting maroon solution was filtered and the solvent 
was removed under reduced pressure to give a maroon solid which was washed with water 
and filtered to obtain a grey solid.  The grey solid was purified by flash chromatography 
(SiO2, hex/Acetone/HOAc 50:49:1) to afford 1 as a black solid which was recrystallized 
by slow diffusion of diethyl ether into a solution of 1 in acetonitrile from which X-ray 
quality crystals were obtained.  Yield: 67 mg (36%).  1H NMR (500 MHz, CD3CN-d3), δ 
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(ppm): 1.74 (s, 6H, O2CCH3), 1.85 (s, 3H, O2CCH3), 7.00 (t, 4H, o-2,6-difluorophenyl), 
7.20 (m, 2H, o-2,6-difluorophenyl).  Anal. Calcd. For C23H24F4N4O6Rh2 (4H2O): C 34.38, 
N 6.97, H 3.98 %.  Found C 35.31, N 6.00, H 3.12%. 
 
Preparation of [Rh2(µ-o-F2form)(µ-O2CCH3)1(phen)2](O2CCH3)2, (2).  An acetonitrile 
solution (20 mL) of 1 (50 mg, 0.07 mmol) was prepared and combined with 10 mL of a 
CH3CN suspension of the diimine ligand phen (29 mg, 0.16 mmol).  The reaction mixture 
gradually changed color from maroon to orange and finally brown and then was refluxed 
under an inert atmosphere for 20 h.  After stopping the reaction, the solvent was removed 
under reduced pressure and the brown solid that was recovered was dissolved in CH2Cl2 
(5 mL) and the sample was precipitated with hexanes and collected by filtration through a 
fine frit.  The product was washed with diethyl ether and dried under vacuum for 24 h.  
Yield: 30 mg (44%). 1H NMR (500 MHz, CD3OD-d4), δ (ppm): 1.89 (s, 6H, O2CCH3), 
2.68 (s, 3H, O2CCH3), 7.05 (t, 4H, o-2,6-difluorophenyl), 7.30 (m, 2H, o-2,6-
difluorophenyl), 7.67 (m, 4H, phen), 7.71 (s, 4H, phen), 8.26-8.33 (dd, 6H, phen), 8.65 (d, 
2H, phen), 9.19 (d, 2H, phen).  ESI-MS: [Rh2(µ-o-F2form)(µ-O2CCH3)1(phen)2]
2+, 
445.97.  X-ray quality crystals were obtained from slow diffusion of diethyl ether into a 
CH3CN solution of the compound. 
 
Preparation of [Rh2(µ-o-F2form)(µ-O2CCH3)1(dpq)2](O2CCH3)2 (3).  A Schlenk flask 
was charged with 1 (38 mg, 0.05 mmol) along with 20 mL of CH3CN to which was added 
a 5 mL of a suspension of dpq (23 mg, 0.10 mmol) in CH3CN.  The reaction mixture was 
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refluxed for 3 days under an inert atmosphere and the resulting brown solution was 
reduced to dryness under reduced pressure.  The brown solid was dissolved in CH3CN (~5 
mL) and treated with diethyl ether to afford a light brown solid.  The product was collected 
by filtration, washed with 3 x 10 mL of diethyl ether, and dried under vacuum for 24 h.  
Yield: 18 mg (32%).  ESI-MS: [Rh2(µ-o-F2form)(µ-O2CCH3)1(dpq)2]
2+, 498.02.  1H NMR 
(500 MHz, CD3OD-d4), δ (ppm): 1.87 (s, 6H, O2CCH3), 2.68 (s, 3H, O2CCH3), 7.07 (t, 
4H, o-2,6-difluorophenyl), 7.31 (m, 2H, o-2,6-difluorophenyl), 7.85 (m, dpq), 8.33 (m, 
dpq), 8.79 (d, dppz), 9.02 (s, dpq), 9.07 (m, dpq) 9.36 (d, dpq).  X-ray quality crystals 
were obtained by slow diffusion of hexanes into a CH2Cl2 solution of the compound.   
 
Preparation of [Rh2(µ-o-F2form)(µ-O2CCH3)1(dppz)2](O2CCH3)2 (4).  A CH3CN (5 
mL) suspension of dppz (30 mg, 0.10 mmol) was added to a flask containing 1 (36 mg, 
0.05 mmol).  The reaction was refluxed for 48 h after which time the reaction had turned 
colors from maroon to red-brown.  The reaction was stopped and a precipitate formed 
upon cooling to room temperature which was collected by filtration and dried under 
reduced pressure.  Yield: 32 mg (58%).  ESI-MS:  [Rh2(µ-o-F2form)(µ-
O2CCH3)1(dppz)2]
2+, 548.49.  1H NMR (500 MHz, CD3OD-d4), δ (ppm): 1.87 (s, 6H, 
O2CCH3), 2.72 (s, 3H, O2CCH3), 7.12 (t, 4H, o-2,6-difluorophenyl), 7.35 (m, 2H, o-2,6-
difluorophenyl), 7.93 (m, 4H, dppz), 7.95 (m, 5H, dppz), 8.40 (s, 1H, dppz), 8.84 (d, 2H, 
dppz), 9.29 (dd, 4H, dppz), 9.42 (d, 2H, dppz).  Crystals suitable for X-ray were obtained 
from slow diffusion of diethyl ether into a CH3CN solution of the compound.  Anal. Calcd. 
 27 
 
For C55H38F4N10O6Rh2 (2.95H2O): C 51.66, N 10.76, H 3.71%.  Found C 51.34, N 10.97, 
H 3.37%. 
 
Preparation of [Rh2(µ-o-F2form)(µ-O2CCH3)1(dppn)2](O2CCH3)2 (5).  A CH3CN (5 
mL) suspension of dppn (27 mg, 0.08 mmol) was added to a flask containing 1 (30 mg, 
0.04 mmol).  The reaction was refluxed for 4.5 days after which time the reaction color 
had turned from maroon to dark brown.  The reaction was stopped and a precipitate formed 
upon cooling to room temperature which was collected by filtration and dried under 
reduced pressure.  Yield: 34 mg (32%).  ESI-MS:  [Rh2(µ-o-F2form)(µ-
O2CCH3)1(dppn)2]
2+, 598.06.  Anal. Calcd. For C67H46F4N12O6Rh2 (6.65H2O): C 52.83, N 
10.9, H 4.08%.  Found C 52.26, N 10.32, H 3.5%. 
 
Instrumentation 
1H NMR spectra were collected on a 500 MHz Inova spectrometer.  The chemical 
shifts are reported in δ (ppm) and referenced relative to the residual proton impurities of 
the deuterated solvent (CD3CN, d3).  Electrospray ionization (ESI) mass spectra were 
collected on an Applied Biosystem PE SCIEX QSTAR mass spectrometer (MDS Sciex).  
Elemental analyses were performed by Atlantic Microlab, Inc.  X-ray data sets were 
collected for compounds 1, 2 and 4 were collected on a Bruker CCD APEX diffractometer 
with graphite monochromated Mo Kα radiation (λ = 0.71073 Å) and compounds 3 and 5 
X-ray data sets were collected at the Advanced Photon Source at Argonne National 
Laboratory using synchrotron radiation (λ = 0.41328 Å), beamline 15-ID-B.  Live-cell 
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imaging was performed on an inverted epifluorescence microscope (Model IX81, 
Olympus, Center Valley, PA) equipped with a heating stage maintained at 37ºC.  The 
images were collected using Rolera-MGI Plus back-illuminated EMCCD camera 
(Qimaging, Surrey, BC, Canada) mounted on the microscope with UplanFl 100x/ 1.3 NA 
oil, LCPlan 40x / 0.6 NA, or LCPlan 20x / 0.4 NA objectives. 
 
Methods 
Density functional theory.  Molecular electronic calculations were performed by Density 
Functional Theory (DFT) methods using Gaussian09 (G09) program.112 Correlation 
exchange functionals (MPW1PW91)113-115 were utilized with the Stuttgart RSC 1997 
Electron Core Potential (ECP)116  basis set for the Rh atoms and the 6-31G(d’) basis set 
for the C, N, O, F, H atoms117-118.  Atomic coordinates were taken from the crystal 
structures and used as starting points for the geometry optimization excluding the [BF4]
- 
counter ions and solvent molecules.  Time-Dependent Density Functional Theory (TD-
DFT)119-125 calculations were performed using the polarized continuum model (PCM) with 
CH3CN or H2O as the solvent
126-127.  The first twenty lowest singlet-state calculations were 
included for both CH3CN and H2O in the singlet state calculations.  The graphic software 
‘agui’128 was used to plot the molecular orbitals with iso-value of 0.04.  The molecular 
orbital compositions was analyzed with the Chemissian Visualization Computer 
Program.129  
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Cell culture and in vitro cytotoxicity.  Monolayers of HeLa cells were cultured in 
DMEM containing 10% FBS, 50 µg/mL of gentamicin, 4.5 mg/mL of glucose, and 4 mM 
of L-glutamine.  The cells were incubated in a humidified atmosphere containing 5% CO2 
at 37ºC.  The cells were allowed to grow to approximately 70% confluent for analysis.  
The viability of cervical cancer cells (HeLa) and the ovarian cancer cell lines COLO-316, 
OVCAR-8 and NCI/ADR-RES in the presence of compounds 4-5 was tested using the  7-
Hydroxy-3H-phenoxazin-3-one 10-oxide (resazurin) assay.  Cell monolayers at a 70% 
confluence 5000-1000 cell/mL were used, 100 µL of cells were seeded in 96-well sterile 
plates, and 100 µL of fresh medium was added to give a total volume of 200 µL. Cells 
were pre-incubated  at 37 °C in a humidified atmosphere containing  5% CO2.  After 24 
h, the medium was replaced by 100 µL of DMEM media containing different complex 
concentrations.  The plates were incubated for 2h after which time the cells were washed 
three times with PBS and the medium was replaced by 100 µL and incubated for another 
24 h.  At the end of the exposure time, the plates were washed with PBS and the medium 
replaced with 80 µL/well of L-15 medium along with 20 µL of fresh Resazurin solution 
(0.4 mg/mL) followed by incubation for 6 h.  After the 4 h incubation period the 
absorbance at 570 nm was measured using a Promega Glomax Multi microplate reader.  
Each experiment was performed in triplicate.  
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Sytox Green® assay.  HeLa cells, at a concentration of 5000-10000 cell/μL, were 
harvested, 20 μL of cells were seeded in an 8-well sterile plate, and 180 μL of fresh 
medium was added to give a total volume of 200 μL.  Cells were pre-incubated at 37 °C.  
After 48 h, cells were washed three times with sterile PBS and the medium was replaced 
by 200 μL/well of L-15 medium containing 5 at its LC50 concentration, 10 μM. 
Eight well sterile plates with 80% cell confluency in each well were placed on an 
inverted epifluorescence microscope.  Imaging was performed using the fluorescence 
filter set FITC (Ex=488 ± 10 nm/Em=520±20 nm).  The fluorescence intensities of HeLa 
cells were measured with the SlideBook 4.2 software (Olympus, Center Valley, PA).  The 
cells were irradiated for 2h inside a UV/vis photoreactor LZC-4 (LuzChem, Research, 
Inc.), equipped with 14 lamps (λirr>400 nm).  After irradiation the cells were washed three 
times with sterile PBS and the medium was replaced with 90 µL of L-15 medium and 
treated with 10 μL of a 20 µM SYTOX® Green solution and incubated for 10 minutes 
before imaging.  Cells were imaged with a 20X objective.  
 
MitoProbe JC-1 assay.  HeLa cells monolayers were cultured at a 70% confluence, 20 
µL of the cells were plated in two 8-well sterile plates to which 180 µL of fresh DMEM 
was added to give a total volume of 200 µL.  The cells were incubated for 24 h at 37 ºC 
after which time the cells were washed with DPBS and the medium was replaced by 200 
µL of compound 5 at its LC50
* concentration.  One plate was incubated for 2h in the dark 
and the other plate was placed inside the UV/vis photoreactor for 30 min.  The dark control 
was treated with 1 µL of a 2µg/mL JC-1® solution and incubated for 5 minutes before 
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imaging; the same procedure was followed with the irradiated sample.  The same 
procedure was followed for compounds 2-5 with NIC-ADR/RES cell line, however 
irradiation time was only 10 min. 
 
MitoTracker® green and Sytox Blue® staining.  HeLa cells at a 70% confluency were 
harvested, 20 µL of cells were plated in two 8-well sterile plates to which 180 µL of fresh 
DMEM was added for a total volume of 200 µL.  The 8-well dishes were pre-incubated 
for 24 h at 37 ºC, after 24 h they were washed with 200 µL of DPBS and the medium was 
replaced by 200 µL of L-15 medium containing compound 5 at its LC50
* concentration, 
MitoTracker Green (50 nM) and Sytox Blue® (1 µM).  The dark control was incubated 
for 2h in the dark and placed on an inverted epifluorescence microscope for imaging.  The 
second plate was incubated for 2h with compound 5 in the dark and then irradiated with 
the confocal microscope using a 488 nm laser for 8 min.  After irradiation, MitoTracker 
Green was added and allowed to incubate for 45 min and finally Sytox Blue® was added 
and incubated for 10 min before imaging.  Imaging was performed at different time periods 
over a course of 1 h. 
 
Annexing V-FITC and propidium iodide staining.  Monolayers of ADR-res cells were 
cultured at 5000-10000 cells/ µL concentrations, then 20 µL of cells were transferred to a 
sterile 8-well dish and 180 µL of fresh DMEM was added for a total volume of 200 µL.  
The plate was pre-incubated for 24 h at 37 ºC, then it was washed with DPBS and the 
medium was replaced with 100 µL of L-15 medium containing 2-5 at their LC50
* 
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concentration.  The dish was incubated for 2h in the dark and then irradiated in the UV-
vis photoreactor for 10 min.  After irradiation the cells were treated with Annexin V-FITC 
(5 µL of stock) and propidium iodide (PI) (5 µM) and placed on the microscope’s heating 
stage at 37 ºC for 15 min afterwards MES binding buffer was added (400 µL) and the cells 
were imaged. 
 
Results and Discussion 
Synthesis and Characterization 
 The compound [Rh2(F2form)(O2CCH3)(CH3CN)2] (1) was synthesized by first 
deprotonating HF2form with K
tBuO in THF for 4 h, the deprotonated HF2from was added 
dropwise to a CH3CN solution of [Rh2(O2CCH3)4(CH3OH)2].  The sample was filtered 
and the solvent removed.  To remove any excess ligand and unreacted dirhodium acetate, 
the sample was purified by flash chromatography.  X-ray quality crystals were obtained 
and the results will be discussed in more detail in the next section.  1H NMR spectroscopy 
was used to confirm the purity of 1 (Figure 2.1) with two singlet resonances at 1.74 ppm 
and 1.85 ppm being observed in a ratio of 1:2 respectively.  The singlet at 1.85 ppm 
corresponds to the acetate ligand located trans to the F2form and the 1.74 ppm singlet 
resonance is due to the in-plane acetates cis to the F2form.  There are also two other 
multiplets at 7.04 ppm and 7.25 ppm in the aromatic region that belong to the F2form 
ligand (Figure 2.1). 
Compound 1 was reacted with two equivalents of the diimine ligands phen, dpq, 
dppz and dppn to afford [Rh2(F2form)(O2CCH3)(phen)2]
2+ (2), 
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[Rh2(F2form)(O2CCH3)(dpq)2]
2+ (3), [Rh2(F2form)(O2CCH3)(dppz)2]
2+ (4), and 
[Rh2(F2form)(O2CCH3)(dppn)2]
2+ (5), as acetate salts.  A schematic representation of the 
syntheses of 2-5 is shown in (Figure 2.2).  Upon reaction of 1 with the respective diimine 
ligands, there is an obvious color change from maroon to orange and at the end of the 
reaction the color is orange brown.  The purity of compounds 2-4 was confirmed by 1H 
NMR spectroscopy in CD3OD; there is a characteristic triplet resonance of the protons on  
 
 
 
Figure 2.1  1H NMR spectrum of 1 in CD3CN. 
 
 
the [F2form]
- bridge at 7.04 ppm (J = 8.0 Hz), 7.07 (J = 8.9 Hz) and 7.12 ppm (J = 9.0 Hz) 
respectively.   This triplet is shifted to lower fields upon coordination to the diimine 
ligands as compared to the starting material.  In the solid state the axial positions of these 
compounds are occupied by acetate molecules, in solution they get replaced by the solvent 
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in this case CD3OD and the free acetate resonance shows up as a singlet at  1.87 ppm, 
while the coordinated acetate shifts downfield to 2.69 ppm, hence the 1:2 ratio between 
the two.  There is only one set of aromatic signals for the diimine ligands due to the C2h 
symmetry of the compounds which renders them magnetically equivalent (Figure 2.3a-
c). 
 
 
 
Figure 2.2  Schematic representation of the reaction of diimine ligands phen, dpq, dppz 
and dppn with 1 to form compounds 2-5.  Axial solvent molecules have been omitted for 
the sake of clarity. 
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Figure 2.3  1H NMR spectra of compounds a) 2 b) 3 and b) 4 in CD3OD. 
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In the case of compound 5 a 1H NMR spectrum could not be obtained due to the 
π-π stacking interactions in solution which renders the solubility very low, however ESI-
MS data show that the compound is pure.  Compound 5 exhibits two mass signals, one at 
m/z = 598 amu and a second one at m/z = 1255 amu;  the first peak corresponds to the 
[Rh2]
2+ cationic unit ([Rh2(µ-o-F2form)(µ-O2CCH3)1(dppn)2]
2+)  and the second one is the 
parent peak ([Rh2(µ-o-F2form)(µ-O2CCH3)1(dppn)2]
+) (Figure 2.4). 
 
 
 
Figure 2.4  ESI-MS spectra of compound 5. 
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X-ray Crystallographic Studies 
[Rh2(µ-o-F2form)(µ-O2CCH3)3(CH3CN)2], (1).  Compound 1 crystallizes in the 
monoclinic space group P21/c.  The cationic [Rh2]
4+ unit is supported by three acetate 
bridge groups and one [o-F2form]
- ligand with the axial positions being occupied by 
CH3CN ligands (Figure 2.5a).  The Rh-Rh bond length is 2.4217(7) which is in range of 
other dirhodium carboxylate (2.35-2.45 Å) and formamidinate (2.37-2.45 Å) 
derivatives.130  The average Rh-O (trans to [F2form]
-) bond distances is 2.070(4) Å, which 
is slightly longer than that of the acetates cis to the [F2form]
- which is not surprising since 
the formamidinate is a σ-donating ligand.  The Rh-N ([F2form]-) bond distances are in the 
range of 2.027(5)-2.035(5) Å.   
 
 
 
Figure 2.5  a) Thermal ellipsoid plot for compound 1 at the 50% probability level; 
interstitial solvent and hydrogen atoms have been omitted for the sake of clarity.  b) Table 
with important bond distances and dihedral angles for compound 1. 
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[Rh2(µ-o-F2form)(µ-O2CCH3)1(phen)2](O2CCH3)2, (2).  The mixed-bridging ligand 
compound 2 crystalizes in the P-1 space group.  The molecular structure of 2 consists of 
a bridging acetate and [F2form]
- ligand coordinated to the dirhodium (II,II) core along with 
two 1,10-phenantroline ligands in a syn configuration and two axial acetate molecules 
(Figure 2.6).  The Rh-Rh distance is 2.5650(9) Å which is similar to the values for 
[Rh2(O2CCH3)2(phen)2][BF4]2
131 and [Rh2(DTolF)2(phen)(CH3CN)3][BF4]2,
132 which are 
2.5808(2) Å and 2.5557(4) Å respectively.  The Rh-Ndpq bond distances are in the range 
of 2.004(7)-2.044(6) Å.  The complex adopts a twisted conformation which reduces 
repulsion between the two diimine ligands which adopt a dihedral angle of -18.3(3)° for 
N15-Rh1-Rh2-N19. 
 
 
 
Figure 2.6  Thermal ellipsoid plot for compound 2 at the 50% probability level; interstitial 
solvent and hydrogen atoms have been omitted for the sake of clarity. 
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[Rh2(µ-o-F2form)(µ-O2CCH3)1(dpq)2](Cl)2, (3).  The cationic structure of 3 is similar to 
that of 2 but the axial positions are occupied by Cl- ligands (Figure 2.7a).  The Rh-Clax 
bond distances are in the range of 2.5145(16)-2.5337(16) Å which is not unusual for other 
dirhodium compounds reported in literature.130,133  The Rh-Rh bond distance is 2.6086(6) 
Å which is ~ 0.04 Å longer than that of 2 and [Rh2(DTolF)(dpq)2][BF4]2.
134  The Rh-N 
(dpq trans to acetate) bond distances are 2.006(6) Å and 2.009(6) Å which are shorter than 
that of the Rh-N trans to the [F2form]
- which are 2.026(5) Å and 2.035(5) Å.  The 
asymmetric unit of compound 3 contains two independent dirhodium units that engage in 
π-π interactions when viewed along the a axis (Figure 2.7b).  The dirhodium metal unit 
causes the dpq ligands to come to close proximity, repulsions between the two dpq ligands 
causes splaying from the parallel alignment, therefore the planes between the two 
molecules cannot be determined.  In order to determine the π-π stacking interactions the 
distance between the centroids of C23-C20-C18-C19-C25-C24 from one dpq and N9-
C20-C23-N10-C22-C21 from the neighboring one was determined to be 3.52 Å (Figure 
2.7b). 
 
[Rh2(µ-o-F2form)(µ-O2CCH3)1(dppz)2](O2CCH3)2, (4). Compound 4 crystallizes in the 
monoclinic space group P21/n.  As in the case of compound 2, both axial positions are 
occupied by acetate ligands (Figure 2.8a).  The Rh-Rh bond distance is 2.6089(8), which 
is longer than that observed for [Rh2(O2CCH3)2(dppz)2][O2CCH3]2 (2.5519(6) Å) and 
within the range of those found in [Rh2(DTolF)2(dppz)2][BF4]2 and [Rh2(F-
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form)2(dppz)2][BF4]2 2.597(1) Å and 2.6190(9) Å, respectively.
84,134  There are two dppz 
ligands coordinated to the dirhodium core in a syn orientation that are distorted from an 
eclipsed conformation due to steric repulsion.  As in the case of 2 and 3 the Rh-Ndpq (trans 
to [F2form]
-) bond distances are longer than the Rh-Ndpq (trans to acetate) distances due 
to the σ-donating character of the formamidinate.  On the other hand, the bond distances 
for the Rh-O and Rh-Nform are comparable which is mainly attributed to the fact that the 
diimine ligands are electron acceptors.   
 
[Rh2(µ-o-F2form)(µ-O2CCH3)(dppn)2](Cl)2, (5).  The cationic structure of 5 is similar 
to that of 4, but with two Cl- ligands in the axial positions to complete the pseudo-
octahedral coordination sphere (Figure 2.8b).  The Rh-Rh bond distance is 2.582(11) Å, 
which is slightly shorter than those observed for 3 and 4.  There is a greater degree of 
distortion in the coordination sphere of the dirhodium (II,II) core due to a greater repulsion 
between the dppn ligands with dihedral angles defined by N14-Rh2-Rh1-N10 and N9-
Rh1-Rh2-N15 being 18(3)° and 19(3)°, respectively.  The Rh-Ndppn bond distances are in 
the range of 2.01(4)-2.05(4) Å.  As in the case of 4, compound 5 engages in π-π 
intermolecular interactions with neighboring molecules.  The Rh-N ([F2form]
-) distances 
are in the range of 2.09(6)-2.11(6) Å, which are significantly longer than those found in 
compounds 1-4.  The poor quality of the crystal in combination with the low resolution of 
the diffraction data (1.38 Å) accounts for the overestimated bond distances. in this 
compound.  
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Figure 2.7.  a) Thermal ellipsoid plot for compound 3 at the 50% probability level; 
interstitial solvent and hydrogen atoms have been omitted for the sake of clarity. b)  
Crystal packing of 3 showing intermolecular π-stacking. 
 
 
Crystal data and refinement parameters for compounds 1-5 can be found in Table 2.1.  
The detailed bond distances and dihedral angles for compounds 2-5 are compiled in Table 
2.2. 
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Figure 2.8.  a) Thermal ellipsoid plot for compound 4 at the 50% probability level; 
interstitial solvent and hydrogen atoms have been omitted for the sake of clarity.  b) 
Diamond generated representation of compound 5. 
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Table 2.1  Crystal structural parameters and refinement data for compounds 1-5. 
 
  1  6•H2O 3•CH2Cl2 4•H2O 5•H2O 
Formula C23H22F4N4O6Rh2  C43H32F4N6O9Rh2  C44.5H29Cl7F4N11O2Rh2  C55H36F4N10O8Rh2  C59H34.5N10O3.5F4Rh2Cl2  
Mol. Wt. 
(g/mol) 
732.26 1058.56 1279.76 1246.76 1257.43 
Space 
group  
P21/c  P-1  P-1  P21/n  P21/n  
a, b, c/ Å  15.425(3)  9.5800(15)  13.3576(7), 12.0611(18)  17.90(1)  
  10.138(2) 14.081(2)   14.5743(7) 13.413(2)  27.117(15)  
  17.663(4)  16.276(3)  14.6593(7)  31.013(5)  26.327(15)  
α, β, γ  /°  90  96.531(2)  67.0260(10)  90 90 
  103.23(3)  91.928(2)  66.4270(10)  98.064(2)  105.667(11)  
  90  100.763(2)  83.1490(10)  90 90 
Volume/
Å3  
2688.8(10)  2139.6(6)  2405.9(2)  4967.6(13)  12304(12)  
Z  4 2 2 4 8 
2Θ range 
for data 
collection 
52.822° 51.038° 54.968° 48.944° 29.74° 
Rint 0.0321 0.0582 0.0823 0.0597 0.2979 
Goodness
-of-fit (all 
data)a 
1.268 1.046 1.004 0.985 1.832 
R1,
b wR2
c 
[all data]  
R1 = 0.0462 R1 = 0.0858 R1 = 0.0925 R1 = 0.0696 R1 = 0.2921  
wR2 = 0.1175  wR2 = 0.2112  wR2 = 0.1753  wR2 = 0.1505  wR2 = 0.5609  
 aR = ∑Fo-Fc/∑Fo. bwR = {∑[w(Fo2 - Fc2)2]/∑w(Fo2)2]}1/2. cGoodness-of-fit = {∑[w(Fo2- Fc2)2]/(n-p)}1/2, where 
n is the number of reflections and p is the total number of parameters refined. 
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Table 2.2  Relevant bond distances and dihedral angles for compounds 1-5. 
Compound 2  Å Compound 3 Å 
Rh1-Rh2 2.5650(9) Rh1-Rh2 2.6086(6) 
Rh1-N10 2.004(7) Rh1-N7 2.009(6) 
Rh1-N15 2.028(7) Rh1-N8 2.026(5) 
Rh1-N12 2.044(6) Rh1-O1 2.051(5) 
Rh1-O62 2.061(5) Rh1-N2 2.069(5) 
Rh1-O1 2.207(5) Rh1-Cl2 2.5337(16) 
Rh2-N7 2.029(6) Rh2-N1 2.056(5) 
Rh2-N19 2.030(6) Rh2-N3 2.006(6) 
Rh2-O8 2.046(5) Rh2-N4 2.035(5) 
Rh2-N14 2.086(6) Rh2-O2 2.047(5) 
Rh2-O3 2.245(6) Rh2-Cl1 2.5145(16) 
Dihedral angles ° Dihedral angles ° 
N12-Rh1-Rh2-N14 -12.5(3) N2-Rh1-Rh2-N1 -11.6(3) 
O62-Rh1-Rh2-O8 -15.3(2) O1-Rh1-Rh2-O2 -13.98(18) 
N15-Rh1-Rh2-N19 -18.3(3) N8-Rh1-Rh2-N4 -15.9(3) 
N10-Rh1-Rh2-N7 -19.0(3) N7-Rh1-Rh2-N3 -16.6(3) 
Compound 4 Å Compound 5 Å 
Rh1-Rh2 2.6089(8) Rh1-Rh2 2.582(11) 
Rh1-N3 2.007(5) Rh1-N19 2.09(6) 
Rh1-N4 2.024(5) Rh1-N9 2.04(4) 
Rh1-O1 2.059(4) Rh1-N10 2.01(4) 
Rh1-N9 2.062(5) Rh1-O1 2.09(5) 
Rh1-O3 2.191(5) Rh1-Cl3 2.57(2) 
Rh2-N2 2.001(5) Rh2-N20 2.11(6) 
Rh2-N1 2.021(5) Rh2-N14 2.02(4) 
Rh2-O2 2.046(4) Rh2-N15 2.05(4) 
Rh2-N10 2.062(5) Rh2-O2 2.01(6) 
Rh2-O4 2.171(5) Rh2-Cl4 2.52(2) 
Dihedral angles ° Dihedral angles ° 
N9-Rh1-Rh2-N10 -7.6(2) O1-Rh1-Rh2-O2 12(2) 
O1-Rh1-Rh2-O2 -8.87(17) N19-Rh1-Rh2-N20 7(2) 
N4-Rh1-Rh2-N1 -9.7(2) N14-Rh2-Rh1-N10 18(3) 
N3-Rh1-Rh2-N2 -9.89(19) N9-Rh1-Rh2-N15 19(3) 
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Electronic Absorption Spectroscopy  
Electronic absorption spectroscopy data were obtained for compounds 1-5 in CH3CN and 
the results are summarized in Table 2.3. 
 
 
Table 2.3.  Electronic absorption data for compounds 1-5 in CH3CN collected at room 
temperature. 
  λ (nm), (ε x 103 (M-1•cm-1)) in CH3CN 
1 250 (15.9), 320 (2.6), 550 (0.22) 
2 225 (59.8), 273 (46.5), 290 (32), 350 (5.1), 410 (0.44) 
3 258 (10.6), 287 (59), 345 (14.0), 405 (6.6) 
4 216 (59.0), 278 (134.3), 380 (18.4), 440 (0.27) 
5 240 (71.2), 260 (61.3), 320 (107.3), 395 (18.4), 415 (19.8) 
 
 
Compound 1 exhibits a transition at 320 nm which corresponds to Rh(π*)Rh-
Leq(σ*) and a low energy transition at 550 nm ascribed to a metal centered transition 
originating from the Rh(π*) Rh(σ*) as in the case of other carboxylates (Figure 2.9).135-
136  The spectral characteristics of compounds 2-5 in the region between 280-420 nm are 
very distinct.  These bands in the higher energy range correspond to transitions originating 
from intramolecular ππ* transitions from the diimine ligands.88  Dirhodium compounds 
bearing 1,10-phenanthroline ligands have characteristic absorption bands around 260 nm 
and compound 2 has a distinctive band at 273 nm which is phen in origin (Figure 2.10a).88  
The free dpq ligand has an absorption maxima at 254 nm in chloroform which is in accord 
to that of 3 (287 nm, ε  =  58950 M-1cm-1) (Figure 2.10b).88  The ligands dppz and dppn 
in CHCl3 solutions have absorption maxima at 370 nm and 414 nm respectively; these 
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maxima are also present in compounds 4 and 5 (Figure 2.10c-d).  The electronic 
absorption spectrum characteristics from these series of compounds have also been 
observed in compounds previously synthesized in our laboratories; e. g. cis-
[Rh2(O2CCH3)2(L)(η1-O2CCH3)(CH3OH)]+(L= dpq, dppz, dppn), cis-[Rh2(F-
form)2(L)2]
2+ (L=dpq, dppz, dppn), cis-[Rh2(O2CCH3)2(dppz)2]
2+ and cis-
[Rh2(O2CCH3)2(dppn)2]
2+ also exhibit these bands.88,134 Formamidinate compounds like 
[Rh2(DTolF)4] and [Rh2(F-form)4] exhibit strong absorption features in the region between 
230-280 nm in acetonitrile, the same is observed with compounds 2-5.134  These intense 
absorption bands in the high energy range of the spectrum for compounds 2-5 arise 
between 240-280 nm, namely 290 nm for 2, 258 nm for 3, 278 nm for 4 and 260 nm for 5 
and are believed to be attributed to metal centered with the involvement of the diimine 
ligands.134Another important feature that can be observed for this new family of 
compounds is the presence of low energy absorption.  Compounds 2-5 exhibit low energy 
absorptions that tail off in the region between 600-800 nm.  This same feature has been 
observed for [Rh2(O2CCH3)2(L)2]
2+ (L = dpq, dppz and dppn)  and has been assigned as a 
charge-transfer transition originating from the [F2form]
- bridging ligand to the diimine 
ligand.88  
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Figure 2.9  Electronic absorption spectrum of 1 in CH3CN at room temperature. 
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Figure 2.10  Electronic absorption spectra of compounds 2-5 in CH3CN at room temperature.
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Computational Studies 
 Geometry optimization in the gas phase was performed on compounds 2-5.  The 
optimization of these compounds was performed using the crystal structures as a starting 
point.  Molecular orbital diagrams were constructed (Figure 2.11) and the contribution to 
the orbitals involved in the electronic transitions are listed in Error! Reference source 
ot found..  In compounds 2-4, the MO composition of the HOMO is mainly from the 
bridging ligand [F2form]
- (~70 %) with some metal character (~30 %) as well.  These 
findings are in accord with that of the analogous series of compounds cis-[Rh2(F-
form)(L)2]
2+ and cis-[Rh2(DTolF)(L)2]
2+ where L = dpq, dppz and dppn.134  On the other 
hand the HOMO as well as the HOMO-1-LUMO+1 orbitals of compound 5 are dppn 
based.  The orbitals HOMO-3 through HOMO-1 in compounds 2-4 are mostly metal in 
character (~70%).  The replacement of one [F2form]
- ligand does not seem to alter the 
electronic structure of this series of compounds as compared to that of cis-
[Rh2(DTolF)(L)2]
2+.134 In most of the molecular orbitals the contribution from the acetate 
is less than 5 %.   
 The LUMO to LUMO + 4 in compounds 3-5 are mostly diimine ligand centered 
as can be seen in Error! Reference source not found..  The LUMO of compound 5 lies 
.27 eV and 0.24 eV lower in energy than 3 and 4 respectively therefore compound 5 should 
be easier to reduce.  The Rh(σ*) orbital for compounds 3 and 4 has been predicted to be 
the LUMO+6, LUMO+5 for compound 5, while in compound 3 has been predicted to  be 
LUMO+3 with Rh(σ*) contributions in the range of ~50-75%.  
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Figure 2.11  Molecular orbital diagrams for compounds 2-5. 
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Table 2.4  Molecular orbital contributions for compounds 2-5 as predicted by DFT in 
CH3CN. 
  2 3 4 5 
H-4 
12 Rh               
83 F2form  
5 Rh           
 93 F2form 
5 Rh                       
90 dppz 
65 Rh               
20 dppn         
6 ax CH3CN 
H-3 
72 Rh             
 21 phen 
73 Rh          
 19 dpq 
69 Rh  
20 dppz 
76 Rh              
13 dppn 
H-2 
66 Rh             
22 phen                          
8 ax CH3CN 
68 Rh            
20 dpq                 
7 ax CH3CN 
68 Rh           
17 dppz          
6 ax CH3CN 
25 Rh           
71 F2form 
H-1 
73 Rh              
 17 F2form 
75 Rh             
14 dpq            
6 ax CH3CN 
77 Rh           
13 dppz 
99 dppn 
H 
28 Rh         
68 F2form         
24 Rh             
73 F2form 
26 Rh          
 71 F2form 
99 dppn 
L 95 phen  96 dpq 90 dppz  95 dppn 
L+1  99 phen 97 dpq 92 dppz 95 dppn 
L+2 97 phen 98 dpq 84 dppz 
4 Rh             
72 dppn 
L+3 
76 Rh             
5 F2form         
8 ax CH3CN 
99 dpq 87 dppz 
3 Rh             
74 dppn 
L+4 
51 Rh           
21 F2form       
22 phen         
99 dpq 86 dppz 
2 Rh            
 81 dppn 
L+5 89 phen 98 dpq 
27 Rh  
59 dppz  
58 Rh           
26 dppn 
L+6 
6 Rh            
 89 phen 
75 Rh              
5 F2form         
8 dpq            
10 ax CH3CN 
51 Rh  
33 dppz 
54 Rh           
20 F2form         
17 dppn          
6 OAc 
L+7 
45 Rh           
30 F2form   
19 phen 
55 Rh            
20 F2form      
19 dpq             
6 OAc 
55 Rh           
21 F2form     
17 dppz         
 6 OAc 
19 Rh           
63 dppn     
 
L+8 96 phen 
47 Rh            
30 F2form           
16 dpq            
6 Oac 
47 Rh           
29 F2form          
17 dppz          
6 OAc 
90 dppn 
a. H = HOMO, L = LUMO. 
b. Fragment contributions that account for less than 5% have been omitted.  
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 TD-DFT was also used to gain some insight into the composition of the electronic 
transitions observed for compounds 2-5.  The vertical energies and the orbitals that 
comprise the transitions are summarized in Table 2.5.  The lowest energy transition for 
compounds 2 and 3 at 480 nm (f = 0.001) and 477 nm (f = 0.002) respectively, were 
predicted to be metal centered (MC, Rh(π*) to Rh(σ*)), compound 5‘s MC transition was 
predicted at 475 nm with a very low oscillator strength (f = 0.002).  On the other hand 
compound 4  lowest energy transition corresponds to a ligand to ligand charge transfer 
band (1LLCT) from [F2form]
-(π)dppz(π*).  Compound 5 is the exception where the 
lowest energy transition is mostly attributed to the intraligand (IL) π to π* transition (~70 
%) centered at 518 nm, this has also been observed for the homoleptic compounds 
[Rh2(DTolF)(dppn)2]
2+ and [Rh2(F-form)(dppn)2]
2+.134  The HOMO in compounds 2-4 is 
~30 % Rh and ~70 % [F2form]
- character while the LUMO is localized on the diimine 
ligand is >90 % this explains the LLCT bands observed for compounds 2-4 at 418 nm, 
446 nm and 436 nm.  The LLCT on compound 5 is not centered on the HOMO and LUMO 
orbitals but on the HOMO-3 and LUMO+5 and it is predicted at 457 nm.   
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Table 2.5  First eight electronic transitions predicted for 2-5 by TD-DFT calculations in CH3CN as solvent.
a, b 
Excited State 2 3 4 5 
1 
480 nm, f = 0.001  
H-1--> L+3 (74 %) 
477 nm, f = 0.002  
H-1--> L+6 (62 %) 
478 nm, f = 0.001  
H-1--> L+6 (48 %)   
H-1--> L+5 (27 %) 
517 nm, f = 0.001  
H--> L (70 %)          
H-1--> L+1 (26 %) 
2 
432 nm, f = 0.003  
H--> L+3 (79 %) 
446 nm, f = 0.002  
H--> L (32 %)       
H-3--> L+6 (30 %) 
436 nm,  f = 0.002  
H--> L (63 %)       
H--> L+1 (30 %) 
516 nm, f = 0.03     
H-1--> L (67 %)     
H--> L+1 (29 %) 
3 
418 nm, f = 0.002 
H--> L (95 %) 
442 nm, f = 0.002 
 H--> L (58 %) 
431 nm, f = 0.004  
H--> L+6 (52 %)   
H--> L+5 (29 %) 
475 nm, f = 0.002  
H-3--> L+5 (56%) 
4 
387 nm, f = 0.002  
H-1--> L (35 %)    
H--> L+1 (22 %) 
430 nm, f = 0.002  
H-1--> L+6 (72%) 
409 nm, f = 0.001  
H--> L+2 (54 %)   
H-->L (32 %) 
473 nm, f = 0.002  
H--> L+1 (60 %)     
H-1--> L (26 %) 
5 
384 nm, f = 0.014  
H-1--> L (42 %) 
406 nm, f = 0.009  
H-1--> L (82 %) 
407 nm,  f = 0.002  
H--> L+1 (82 %) 
457 nm, f = 0.001  
H-2--> L (92 %) 
6 
380 nm, f = 0.002  
H--> L+1 (35 %) 
 H--> L+4 (23 %) 
389 nm, f = 0.018  
H-2--> L (58 %) 
395 nm, f = 0.017  
H-1--> L (44 %)     
H-1--> L+2 (44 %) 
443 nm, f = 0.001  
H-3--> L+5 (39 %)    
H-4--> L+5 (26 %) 
7 
376 nm, f = 0.004  
H--> L+2 (87 %) 
388 nm, f = 0.025  
H--> L+7 (37 %) 
383 nm, f = 0.02   
H--> L+7 (48 %) 
438 nm, f = 0.002  
H-2--> L+1 (95 %) 
8 
371 nm, f = 0.034  
H-2--> L (65 %) 
379 nm, f = 0.025  
H-3--> L (72 %) 
380 nm, f = 0.059  
H-2--> L (42 %)     
H-2--> L+2 (26 %) 
429 nm, f = 0.004  
H-2--> L+5 (63 %) 
a. H = HOMO, L = LUMO, f = oscillator strength. 
b. Only contributions greater than 20% have been listed. 
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In vitro Cytotoxicity Studies 
Compounds 2-5 were screened for their anti-proliferative activity against four 
human cancer cell lines, namely HeLa, COLO-316, OVCAR-8 and NCI/ADR-RES and 
compared to that of cisplatin.  The cell proliferation assay resazurin (7-Hydroxy-3H-
phenoxazin-3-one 10-oxide) was used to evaluate the toxicity of 2-5 as their [BF4]
- salts.  
Resazurin, also known as Alamar Blue, is a water-soluble fluorescent dye that forms 
resorufin upon reduction by NADH by the cells, turning colors from blue to pink.137-139  
The formation of resorufin (pink) is indicative of enzymatic reduction by living cells and 
direct correlations to cell viability can be established (Figure 2.12). 
 
 
 
 
 
Figure 2.12  Schematic representation of the reduction of resazurin to resorufin. 
 
 
The LC50 values (concentration required to kill 50 % of cell population) in the dark 
and upon irradiation (LC50
*) were calculated for compounds 2-5 by measuring the survival 
of the cells in the presence of complex relative to the untreated control.  The cells were 
incubated at different concentrations of complex for 2 h and then washed with phosphate 
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buffer, incubated for 24 h and their viability in the dark evaluated.  A similar procedure 
was followed for the irradiated experiment; after the incubation and washing steps, the 
cells were irradiated (λirr ≥ 400 nm) for 1 h.  The phototoxicity index (PI) in another 
chapter was determined by calculating the ratio between LC50
* and LC50.  The results of 
the cell proliferation assay for the different cell lines are summarized in Table 2.6.   
 Previous studies in our laboratories described the toxicity of a heteroleptic series 
of dirhodium compounds of the type [Rh2(O2CCH3)2(dppn)(N-N)][O2CCH3]2 (N-N is 
bpy, phen, dpq, dppz or dppn) in the dark and upon irradiation.  It was found that the 
compounds [Rh2(O2CCH3)2(dppn)(dppz)]
2+ and [Rh2(O2CCH3)2(dppn)2]
2+ exhibit the 
greatest PI, 21 and 24 respectively.88  The high toxicity of these compounds against human 
skin cancer cells (HS-27) is attributed to their ability to generate reactive oxygen species 
upon irradiation.  In light of these results the cytotoxicity of compounds 2-5 was 
determined in the dark and upon irradiation.  In these new series of compounds, 5 exhibits 
a 5.8-fold increase in toxicity upon irradiation unlike compounds 3 (PI = 1.8) and 4 (PI = 
1).  Although 2 also shows an estimated ~5-fold increase in toxicity upon irradiation, the 
LC50 values are very high for therapeutic purposes (LC50 >1 mM and LC50
* >200 µM).    
In addition the ovarian adenocarcinomas COLO-316, OVCAR-8 and NCI/ADR-RES 
were evaluated against compounds 2-5.  The ovarian carcinoma COLO-316 is an 
aneuploid cell line, meaning that it has multiple markers, deletions, additions and 
rearrangements of the chromosomes.140  The OVCAR-8 line is the parent cell line of 
NCI/ADR-RES and the latter is a drug resistant (carboplatin, Adriamycin and paclitaxel) 
cell line characterized by the up regulation of P-glycoprotein (P-gp) an ATP-  
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Table 2.6  Cell viability data of compounds 2-5 in the dark and upon irradiation as determined by the resazurin assay. 
  HeLa   COLO-316  OVCAR-8  NIC-ADR/res  
  LC50 µM
a LC50* µM
b PIc LC50 µM
a LC50* µM
b PIc LC50 µM
a LC50* µM
b PIc LC50 µM
a LC50* µM
b PIc 
cis-Ptd 56 ± 4 56 ± 9 1 71 ± 11 63 ± 12 1 241 ± 10 170 ± 24 1.4 199 ± 7 143 ± 6 1.4 
2 > 1mM > 200 µM 5 > 300 µm > 250 µM ~1.2 99 ± 18 44 ± 6 2.3 199 ± 5 192 ± 3 1 
3 81 ± 15  45 ± 6 1.8 > 1mM > 300 µM 3.3 86 ± 19 45 ± 20 1.9 149 ± 25 47 ± 10 3.2 
4 151 ± 22  142 ± 25 1 80 ± 12 59 ± 7 1.4 41 ± 11 5 ± 2 8.2 76 ± 18 71 ± 15 1 
5 64 ± 7  11 ± 4 5.8 246 ± 27 31 ± 6 7.9 353 ± 49 49 ± 8 7.2 336 ± 55 19 ± 4 17.7 
a.  Incubation time = 2 h.  The results in this table are means of three independent experiments. 
b. Irradiation time 1 h, λirr > 400 nm. 
c. PI = phototoxicity index. 
d. cis-Pt = cisplatin.
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independent efflux pump that controls the extrusion of toxins and substances like 
anticancer drugs out of the cells.141-143  As in the case of HeLa, 5 exhibits an LC50
* value 
in the low micromolar range (19 ± 4 µM) with an increase in phototoxicity for COLO-
316, OVCAR-8 and NCI/ADR-RES of 7.9, 7.2 and 17.7-fold respectively.  It is worth 
noting that compound 4 exhibits good toxicity upon irradiation under the experimental 
conditions (2 h incubation + 1 h irradiation, LC50
* = 5 ± 2 µM), with a PI of 8.2 which is 
even higher than that of compound 5.  The toxicity of compound 5 against the cell lines 
studied exceeds that of the FDA approved drug cisplatin and it also exhibits higher PI 
indices than Photofrin® (PI = 5.5)76 as observed in Table 2.6.  The greater toxicity of 5 in 
comparison to its congeners may be ascribed to the ability of the compound to generate 
reactive oxygen species upon irradiation as in the case of [Rh2(O2CCH3)2(dppn)2]
2+ (Φ1O2 
= 40 %) and subsequent photo-oxidation of membrane phospholipids as in the case of 
hematoporphyrin.144-146   
 
Sytox Green® Staining:  Effects of Light on Cell Health 
 In order to monitor the effects of compound 5 in cell morphology in the dark and 
upon irradiation confocal microscopy was utilized.  The fluorescent probe Sytox Green® 
was utilized to stain dead cells.  Sytox Green® is an impermeant fluorescent dye that 
translocates inside the cells once the plasma membrane has been compromised.147  Once 
inside the cell, Sytox Green® intercalates nuclear DNA and shows a fluorescent response.  
Two plates of HeLa cells were incubated with compound 5 (11 ± 4 µM) for 2 h in the dark 
and one of them was irradiated for 1 h (λ > 400 nm) after incubation with the compound 
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in the dark.  The experiment in the dark does not exhibit green fluorescent indicating that 
the cells were healthy under the experimental conditions as in the case of the dark control 
with no compound (Figure 2.13a-b).  In contrast, after irradiation, the Sytox Green® 
staining can be detected and also a dramatic change in morphology is observed.  Healthy 
cells show elongated structures, while cell membrane shrinkage and loss of membrane 
asymmetry is observed when 5 is followed by irradiation (Figure 2.13c).  The irradiation 
alone is not harming the cells as can be observed from the data in Figure 2.13d where the 
cells were incubated in the dark for 2 h in the absence of compound followed by 1 h 
irradiation.  The concentration (LC50
*), incubation time (2 h) in combination with 
irradiation poses 5 as an excellent prospect for photochemotherapeutic applications.   
 
Annexin V-FITC and Propidium Iodide Staining 
 Apoptosis or programmed cell death (PCD) is characterized by the activation of 
cysteine proteases (caspases), caspase mediated morphological changes (cell shrinkage, 
chromatin condensation, membrane blebbing, etc.) or caspase-independent pathways.148  
PCD is the best mechanism that the cell has to counteract tumor growth and most 
chemotherapeutic agents today work by triggering apoptosis via caspase dependent or 
independent pathways.42  One key aspect of the apoptotic mediated cell death is the 
molecular changes induced during this process, specifically the exposure of phosphatidyl 
serine (PS) on the surface of the plasma membrane.  The exposure of PS is used to detect 
apoptotic events, Annexin-V binds reversibly to the PS in the outer leaflet of the cell 
membrane and triggers a fluorescent response.  Annexin V-FITC is used in combination  
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Figure 2.13  Confocal microscopy images of HeLa cells treated with a) no compound in 
the dark, b) 11 µM solutions of 5 for 2 h in the dark, c) 11 µM solutions of 5 for 2 h in the 
dark followed by irradiation for 1 h and d) no compound incubated for 2 h in the dark 
followed by irradiation for 1 h.  The cells were treated with Sytox® Green and imaged.  
Left pane: phase contrast, middle pane: Sytox Green® fluorescence and right pane:  
overlay of phase contrast and Sytox Green® fluorescence, pseudo-colored green.  
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with the nuclear stain propidium iodide (PI).  PI is impermeable to live cells, but once the 
cell integrity has been compromised it binds to nuclear DNA and there is a 20-fold increase 
in fluorescence.149-150   
 In order to determine the type of cell death induced by compounds 2-5, NIC-
ADR/RES cells were incubated with the compounds at their LC50
* values in the dark for 
2 h followed by irradiation for 10 min (λ > 400 nm).  After treatment with the compounds, 
the cells were incubated with Annexin V-FITC and PI for 15 min.  A control experiment 
was also performed wherein the cells were incubated with no compound and with 
staurosporine (5 µM) an apoptosis inducer (Figure 2.14a and f).151  Compound 2 exhibits 
mostly green fluorescence and cell shrinkage can be observed, characteristic of an 
apoptotic death.  In the case of compounds 3-5 the mechanism of cell death is not as 
evident - symmetric cell shrinking or nuclear fragmentation is observed.  For compounds 
3 and 4, Annexin V and PI staining is observed but no cell symmetry is observed; this is 
most evident in 4.  Compound 5 exhibits membrane blebbing which is characteristic of an 
apoptotic mediated cell death, but the cell morphology is more characteristic of a necrotic 
type of cell death (Figure 2.14f).  The time scale of the death induced by these compounds 
is too short (~10 min) for it to be apoptosis.  Necrosis is characterized by the vacuolization 
of the cytoplasm, loss of membrane integrity and cellular swelling,102and  this processes 
is observed with 5 along with membrane blebbing.   These findings may suggest that the 
cell death mechanism may be a combination of apoptosis and a type of necrosis that has 
been recently identified in the literature as secondary necrosis.  In secondary necrosis, in 
late stages of apoptosis, the dead cells may present necrotic features.104 Another possibility 
 61 
 
is that these compounds are causing endosomal lysis induced by irradiation which releases 
Ca2+ into the cytosol which in turns causes cell death.  Porphyrin compounds have been 
widely used as PDT agents because upon light activation they can generate singlet oxygen.  
The generation of 1O2 in cells by the porphyrins causes the release of endocytic vesicle 
contents casing cell death.101 The compound [Rh2(O2CCH3)(dppn)2]
2+ had been 
previously studied in our laboratories for its anticancer activity upon irradiation and this 
compound can generate 1O2 (Φ = 0.4)88,  therefore it would be expected that 5 behaved in 
a similar fashion.   
 
JC-1 Mitochondrial Potential Assay  
 Positively charged lipophilic cations have the ability to localize in the 
mitochondria due to the negative charge that this organelle bears in its membrane.152-153  
High lipophilicity decreases the desolvation energy required to penetrate the membrane 
and makes it easier to penetrate the mitochondrial membrane.154-155  In this vein many 
efforts have been devoted to the development of organelle specific therapies against cancer 
and other malignancies and they are referred as “mitocans”.156-157   
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Figure 2.14 Confocal microscopy images of NCI-ADR/RES cells treated with a) no 
compound, b) 2, c) 3 d) 4 e) 5 f) staurosporine for 2 h in the dark followed by irradiation 
for 10 min.  The cells were treated with Annexin V-FITC and PI and imaged.  Left: red 
fluorescence.  Center: phase contrast.  Right: green fluorescence.  Far right: overlay of 
red and green fluorescence (pseudo-colored) images. 
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Recent studies indicate that fatty acid inhibitors (FAS-I) and vitamin E analogs exhibit 
excellent anticancer properties by preventing fatty acid synthesis or targeting the 
mitochondria in tumor cells.  One example of this type of compound is Orlistat a FAS-I 
which is an FDA approved drug that is highly lipophilic and inhibits tumor growth in 
different types of cancer.158  Another approach is the synthesis of metal complexes which 
are highly lipophilic and bear a positive charge in order to target this organelle, like the 
new family of dirhodium compounds 2-5.  
 Reports have shown that accumulation of foreign substances in the mitochondria 
induces changes in the mitochondrial potential and the same observation has been made 
about some cancer drugs.153  In order to monitor the changes in mitochondrial potential 
induced by compounds 2-5, JC-1 (carbonyl cyanide 3-chlorophenylhydrazone) dye was 
utilized.  The cationic dye JC-1, is a lipophilic compound that changes fluorescence 
emission from red to green, when there mitochondrial potential (ΔΨ) is depleted (Figure 
2.15).159   In healthy cells the fluorescence emission of JC-1 would be red (J-aggregates), 
cells whose mitochondria has been compromised show green fluorescence (J-monomers) 
which is an indication of decreased ΔΨ. 
 
 
 
Figure 2.15  Schematic representation of mitochondrial depolarization and changes in 
fluorescence by JC-1. 
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 Two independent experiments were performed with HeLa cells; the cells were 
incubated with compound 5 (11 µM) for 2 h in the dark and then stained with JC-1.  The 
second experiment involved irradiation for 1 h after incubation with 5.  The cells incubated 
in the dark exhibit both red and green fluorescence after incubation with 5 in the dark.  On 
the other hand, a significant decrease in red fluorescence and increase in green 
fluorescence is observed indicating depolarization of the mitochondria (Figure 2.16). 
 
 
 
Figure 2.16  Confocal microscopy images of HeLa cells treated with 11 µM solutions of  
5 for 2h in the dark followed by JC-1 staining (top panel) and irradiation experiment 
(bottom panel).  a) Red fluorescence, b) phase contrast, c) green fluorescence and d) 
overlay of red and green fluorescence (pseudo-colored) images. 
 
 
 65 
 
The same experiment was repeated with the drug resistant cells NIC-ADR/RES for 
compounds 2-5, but the irradiation step was carried out for just 10 minutes.  In addition, a 
positive control was performed with CCCP (carbonyl cyanide m-chlorophenylhydrazone) 
which is an inhibitor of oxidative phosphorylation that causes mitochondrial potential 
depletion (Figure 2.17f).160 Compounds 2-5 show different degrees of mitochondrial 
depolarization as in the case of the positive control and most of the fluorescence observed 
for these compounds is green.  Compound 2, being the least cytotoxic one, shows 
mitochondrial potential depletion to a lesser extent while in 5 is more evident (Figure 
2.17b and e).  Even though the mitochondrial potential is depleted in each case, it is 
possible that the depletion in mitochondrial potential is triggered by the endosomal release 
of Ca2+ caused by our compounds upon irradiation which causes Ca2+ overload in the 
mitochondria.  In order to prove this hypothesis more experiments need to be carried out, 
such as inhibiting PARP-1 or depleting the cell from Ca2+ in order to study its effect on 
cell viability and death mechanisms.102-104,161 
 
Mitotracker Green & Sytox Blue® 
The mitochondria are responsible for cell respiration and energy production in the 
cell and it is susceptible to oxidative damage.  The accumulation of oxidative damage by 
the mitochondria is a contributing factor to mitochondrial dysfunction, disease and cell 
death.162-163  The mitochondria are characterized by elongated tubules that form dynamic 
interconnecting networks; when mitochondrial health is compromised so is the morpho- 
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Figure 2.17  Confocal microscopy images of NCI-ADR/RES cells treated with a) no 
compound, b) 2, c) 3 d) 4 e) 5 f) CCCP for 2 h in the dark followed by irradiation for 10 
min.  The cells were treated with JC-1 and imaged.  Left: red fluorescence.  Center: green 
fluorescence.  Right: overlay of red and green fluorescence (pseudo-colored) images. 
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logy.164  Monitoring the morphology of the mitochondria after the treatment of cells with 
anticancer agents can provide another piece of evidence about the effects of compound 5 
on the cell.  Mitotracker selectively binds to the mitochondria providing an easy avenue 
to monitor the morphology of the mitochondria after incubation with compound 5.  HeLa 
cells were treated with compound 5 for 2 h in the dark followed by treatment with 
Mitotracker green and Sytox Blue®.  After incubation with 5, the mitochondria still look 
healthy with the characteristic filamentous extended network as seen for the control 
(Figure 2.18).  The cells were then irradiated for 8 min with the microscope and after this 
time the mitochondria had fragmented which was not observed with the negative control 
that had been irradiated.  Also Sytox Blue® staining did not show up until 45 min after 
the cells were irradiated and cell shrinkage and chromatin condensation can be observed.  
These findings in combination with the JC-1 assay suggest that compound 5 may disrupt 
mitochondrial function thus triggering cell death.  
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Figure 2.18  Confocal microscopy images of HeLa cells treated with 11µM solutions of 
5.  a) 5 in the dark , b) 5 after 8 min irradiation, c) 5 after 45 min of treatment d) no 
compound after irradiation for 8 min.  The cells were treated with Mytotracker and Sytox 
Blue® and imaged.  Left: phase contrast.  Center: blue fluorescence.  Right: green 
fluorescence Far right: overlay of red and green fluorescence (pseudo-colored) images. 
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Concluding Remarks 
 A new family of dirhodium mixed bridging ligand compounds bearing electron 
accepting ligands phen, dpq, dppz and dppn was successfully synthesized and 
characterized and their anticancer activities against HeLa and ovarian cancer cell lines 
were evaluated.  The DFT studies showed that the HOMO for compounds 2-4 is mostly 
[F2form]
- and the LUMO is diimine ligand in character, for which LLCT bands are 
observed between 415-440 nm in their electronic absorption spectra.  The cell viability 
data show that compound 5 is most active against HeLa and NCI-ADR/RES, while 4 is 
most active against OVCAR-8 upon irradiation.  The mechanism of cell death for this new 
series of compounds is not conclusive but it appears that compound 2 induces apoptotic 
cell death whereas compounds 3-5 trigger two different responses, namely dramatic cell 
morphology changes and Annexin V staining.  These findings suggest that a combination 
apoptotic and necrotic cell death mechanisms are being triggered.  The studies performed 
in this project provide insight into how changing the bridging ligand dramatically changes 
their anticancer activity and mechanisms of cell death and can help guide us in our quest 
to modulate the structure of dirhodium compounds in order to target preferential 
mechanisms of cell death. 
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CHAPTER III  
MIXED-BRIDGING LIGAND PARTIALLY SOLVATED DIRHODIUM 
COMPOUNDS AS POTENTIAL ANTICANCER DRUGS 
 
Introduction 
The discovery of cisplatin as an anticancer drug by Barnett Rosenberg in the mid 
1960’s unveiled a new area of metal based treatments against cancer and other 
malignancies.165   Although cisplatin is still widely used as a chemotherapeutic agent, new 
derivatives have been prepared and approved by the FDA to treat drug resistant tumors 
including oxaliplatin and carboplatin.166  Other compounds are currently in the pipeline 
for approval; these include the Ru(III) based NAMI-A compound ([H2im][trans-RuCl4(S-
dmso)-(Him)]; Him = imidazole, dmso = dimethyl sulfoxide) and KP1019 ([H2ind][trans-
RuCl4(Hind)2]; Hind = indazole) both of which are in phase II clinical trials with the latter 
being studied as a colorectal anticancer drug.167  These metal complexes are just a handful 
of examples that mark the progress of the bioinorganic medicinal chemistry field in 
therapeutic applications.  Among the known anticancer active compounds are dirhodium 
(II,II) based compounds including Rh2(O2CCH3)4,  the mixed-bridging ligand compound 
cis-[Rh2(DTolF)2(O2CCF3)2•2H2O (DTolF= p-ditolylformamidinate), and 
[Rh2(O2CCH3)3[(C6H3-2-O)P(C6H3-2-OMe)2](HOAc)] which exhibit carcinostatic 
activity against mice bearing Ehrlich ascites tumors,  Yoshida ascites sarcoma and oral 
carcinoma, bladder cancer, colon adenocarcinoma and breast cancer, respectively.97,168-169 
The mixed-bridging ligand compounds cis-[Rh2(DTolF)2(O2CCF3)2•2H2O  and 
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[Rh2(O2CCH3)3[(C6H3-2-O)P(C6H3-2-OMe)2](HOAc)] have shown the most promise 
with anticancer activities similar to that of cisplatin but with an increased average life span 
in mice being treated with the drug.   
In our laboratories, we are striving to develop dirhodium based anticancer agents 
that can be activated with low energy light for photodynamic therapy (PDT) applications.  
One avenue for this is the development of partially solvated compounds as example of 
which is [Rh2(µ-O2CCH3)2(CH3CN)6]
+2
, reported by Turro et al.
77 which covalently binds 
to biologically relevant molecules upon irradiation and loss of some of the acetonitrile 
ligands.  Additional examples of this type of compound have been studied in our 
laboratories over the past decade.77,79-81,170  Modifying the ligands around the rhodium 
centers at axial and equatorial positions offers a variety of possible binding sites for 
reactions with biomolecules in order to enhance the anticancer properties.  Considering 
the anticancer activity exhibited by the mixed-bridge carboxylate compounds it is our aim 
to prepare partially solvated dirhodium mixed-bridging ligand compounds that combine 
the anticancer activity of the mixed-bridge carboxylates with that of the photocisplatin 
analog [Rh2(µ-O2CCH3)2(CH3CN)6]
+2.   
The present work focuses on the synthesis, characterization and anticancer 
evaluation of  a new family of dirhodium mixed-bridging ligand partially solvated 
compounds of the type [Rh2(µ-o-F2form)(µ-O2CCH3)(CH3CN)6](BF4)2 and [Rh2(µ-
Ph2P(C6H4))(µ-O2CCH3)(CH3CN)6](BF4)2.  The full characterization and the anticancer 
properties of these compounds will be discussed in the following sections. 
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Experimental Section 
Starting Materials 
The compound Rh2(µ-O2CCH3)4•2CH3OH was either purchased from Pressure 
Chemicals or synthesized from RhCl3•xH2O from a reported procedure.108  The 
compounds N,N’-bis(2,6-difluorophenyl)formamidine (HF2form) and 
Rh2((C6H5)2P(C6H4))(O2CCH3)3•2O2CCH3 were synthesized by slightly modified 
published procedures.109,171 The commercially available reagents potassium tertbutoxide 
(KtBuO) (Sigma Aldrich), triphenylphosphine (PPh3) (Sigma Aldrich), triethyloxonium 
tetrafluoroborate (Et3OBF4), 1M in CH2Cl2 (TCI America) were used as purchased.  The 
solvents acetonitrile (CH3CN), acetone, hexanes (hex), dichloromethane (CH2Cl2), and 
diethyl ether (Et2O) were of ACS grade and used as received.  Standard Schlenk-line 
techniques under a N2 atmosphere were used but work-up and isolation of products was 
performed in air unless otherwise stated. 
Cell culture reagents Dubelco’s modified Eagle medium (DMEM) (Invitrogen), 
fetal bovine serum (FBS) (Atlanta Biologicals), Leibovitz's L-15 Medium (L-15) without 
phenol red (Life Technologies), Phosphate-Buffered Saline solution (DPBS) (Life 
Technologies), Sytox Green® (Invitrogen) and Hoechst 33342 (Invitrogen) were used as 
received.  The HeLa cell line was obtained from the American Type Culture Collection, 
cell line CCL-2. 
 
Preparation of [Rh2(µ-o-F2form)(µ-O2CCH3)(CH3CN)6](BF4)2 (6).  An aliquot of 2 mL 
of Et3OBF4 (1M CH2Cl2) was added to 30 mL of an acetonitrile solution of Rh2(µ-o-
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F2form)(µ-O2CCH3)3 (60 mg, 0.08 mmol) and the mixture was stirred at room temperature 
for 18 h.  The maroon solution turned orange upon addition of the Et3OBF4.  The reaction 
mixture was concentrated to ~3 mL and 30 mL of Et2O was added which resulted in 
precipitation of the sample as an orange oil.  The oil was washed three times with Et2O 
and then recrystallized by slow diffusion of diethyl ether into a CH3CN solution of the 
product from which X-ray quality crystals were obtained.  Yield: 64 mg (84%). 1H NMR 
(500 MHz, CD3CN-d3), δ (ppm): 2.02 (s, 3H, O2CCH3), 2.49 (s, 6H, eqCH3CN), 2.53 (s, 
6H, eqCH3CN), 7.05 (t, 4H, o-2,6-difluorophenyl), 7.33(m, 2H, o-2,6-difluorophenyl).  
C25H25B2F12N7O2Rh2•3H2O: C, 3.43; N, 9.26; H, 3.11 %.  Found: C, 3.42; N, 10.82; H, 
2.71 %.   
 
Preparation of [Rh2(µ-Ph2P(C6H4))(µ-O2CCH3)(CH3CN)6](BF4)2 (7).  A 2 mL solution 
of Et3OBF4 (1M in CH2Cl2) was added to a brown solution of 
Rh2(Ph2P(C6H4))(O2CCH3)3•2O2CCH3 (36 mg, 0.05 mmol) in CH3CN (20 mL) which 
produced a color change from brown to orange.  The reaction mixture was stirred for 1h 
at room temperature after which time the solvent was removed under reduced pressure to 
afford an orange oil.  The orange oil was washed with copious amounts of Et2O and the 
product was recovered as an orange solid.  X-ray quality crystals were obtained by slow 
diffusion of diethyl ether into an CH3CN solution of the product.  Yield: 25 mg (51%).  
1H 
NMR (500 MHz, CD3CN-d3), δ (ppm): 1.64 (s, 3H, eqCH3CN), 1.70 (s, 3H, eqCH3CN), 
1.88 (s, 3H, O2CCH3), 6.67 (m, 1H, bridging C6H4), 7.01 (m, 1H, bridging C6H4), 7.26 
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(m, 1H, bridging C6H4), 7.38-7.45 (m, 5H, PPh2), 7.52-7.63 (m, 5H, PPh2), 7.85 (q, 1H, 
bridging C6H4). 
 
Instrumentation and Methods 
Electrochemical data were collected using a HCH Electrochemical Analyzer 
model CH 1620A in dry CH3CN.  A BAS Pt disk working electrode, Pt wire auxiliary 
electrode, Ag/AgCl (3M KCl(aq)) reference electrode and 0.1 M tetra-n-butylammonium 
hexafluorophosphate ([nBu4N][PF6]) as supporting electrolyte were utilized to carry out 
the measurements.  X-ray data sets were collected for compounds 6 and 7 on a Bruker 
CCD APEX diffractometer with a graphite monochromated Mo Kα radiation (λ = 0.71073 
Å), while 6b X-ray data sets were collected from the APS-Argonne National Lab, 
beamline 15-ID-B.   
 
Electrochemistry.  The electrochemical studies were carried out at room temperature 
(298 K) in CH3CN.  The E1/2 values were referenced against the Ag/AgCl electrode 
without correction for the junction potentials [E1/2 = (Ep,a + Ep,c)/2].  Ferrocene was used 
as an internal standard in CH3CN under the same experimental conditions as the 
compounds under study, E1/2= 0.44 V vs Ag/AgCl for the Fc
+/Fc couple. 
 
In vitro cytotoxicity.  The cell viability of HeLa cells in the presence of compounds 7 and 
8 was tested using the fluorescent probe Sytox Green®.  Multichannel sterile dishes were 
cultured with HeLa cells at a concentration of 5000-10000 cells/µL, each channel was 
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washed with DBPS and the medium was replaced with 200 µL of L-15 containing different 
concentrations of the compounds under study followed by incubation for 2h in the dark.  
After incubation of the compounds the second batch was irradiated inside a UV-visible 
photoreactor for 1 h.  For each of the conditions both Hoechst (0.5 µg/mL) and Sytox 
Green® (1 µM) were added and incubated for 10 min in the dark on the confocal 
microscope’s warming stage, 37 ºC before imaging. 
 
Results and Discussion 
Synthesis and Characterization  
The synthesis of 6 involves the alkylation of the bridging acetate ligands of 1 with 
Et3OBF4 in dry acetonitrile, (Figure 3.1a).  The trans influence that the [F2form]
-
 exerts 
on the  trans acetate, ensures that the this is the second ligand to be alkylated to form the 
mixed bridging ligand compound and not the already known cis-
[Rh2(O2CCH3)2(CH3CN)6](BF4)2.
77 The reaction mixture was stirred for 18 h at room 
temperature and was protected from the ambient light.  The solvent was then removed in 
vacuo ~2 mL of acetonitrile was added to the red oil followed by 10 mL of diethyl ether 
to precipitate the product.  The sample was filtered, washed with three 10 mL portions of 
Et2O and dried overnight to afford 6 as a purple solid.  
1H NMR spectroscopy in CD3CN 
was used to confirm the formation of 6 as a pure compound (Figure 3.1b).  The 1H NMR 
spectrum contains 4 singlet resonances in the aliphatic region at 1.98 ppm, 2.02 ppm, 2.49 
ppm and 2.53 ppm which are assigned to the free CH3CN, bridging acetate, eq CH3CN
N 
trans to [F2form]
- and eq CH3CN
O trans to the bridging acetate, respectively.  In the 
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aromatic region the characteristic triplet resonance corresponding to the H atoms from the 
bridging [F2form]
- is observed at 7.05 ppm with a coupling constant of 8.4 Hz, which is 
slightly larger than for other dirhodium formamidinate compounds.81,172  There is also a 
multiplet at δ = 7.33 ppm, which is attributed to the protons from the phenyl rings of the 
[F2form]
- ligand. 
 Compound 7 was synthesized in a similar manner as 6 (Figure 3.2a).  The 
[Rh2(Ph2P(C6H4))(O2CCH3)3(CH3CN)2)] was dissolved in dry acetonitrile to afford a 
brown solution and treated with the alkylating which led to a color change from brown to 
orange.  After 24 h of stirring the solvent was removed and the product was recovered 
from precipitation with diethyl ether and dried in vacuo.  The purple solid recovered was 
characterized by 1H NMR spectroscopy in D2O (Figure 3.2b).  Upon dissolution of 7 in 
D2O the colors changes to purple which is attributed to the exchange of the axial 
acetonitrile ligands for the deuterated water which appears a singlet resonance at 2.06 
ppm.  There are three other singlet resonances at 1.72 ppm, 1.95 ppm and 2.17 ppm 
attributed to bridging acetate, eq CH3CN
C trans to the orthometallated phenyl group of the 
phosphine, and the eq CH3CN
P trans to the phosphorous atom from the phosphine.  In the 
aromatic region there are four triplet resonances at 6.81 ppm, 7.06 ppm, 7.33 ppm and 
7.81 ppm all of which that integrate to one proton which are due to the protons from the 
orthometallated phenyl ring of the phosphine.  The remaining multiplet at 7.57 ppm 
integrates to twelve protons and has been assigned to the remaining phenyl rings of the 
phosphine. 
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Figure 3.1  a) Synthetic scheme for the formation of 6 and b) 1H NMR spectrum of 6 in 
CD3CN. 
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Figure 3.2  a) Synthetic scheme for the formation of 7 and b) 1H NMR spectrum of 7 in 
D2O. 
 
 
X-ray Crystallography 
Crystal data and structure refinement for compounds 6, 6b and 7 are summarized in 
Table 3.1. 
 
[Rh2(µ-o-F2form)(µ-O2CCH3)(CH3CN)6](BF4)2 (6).  The mixed bridging compound 6 
crystalizes in the monoclinic space group P21/c.  The cation in 6 contains one acetate and 
one [F2form]
- bridging the dirhodium core.  There are six acetonitrile ligands completing 
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the pseudo-octahedral coordination sphere around the dirhodium (II,II) core (Figure 3.3).  
The Rh-Rh bond distance is 2.5575(2) Å, which is comparable to other dirhodium partially 
solvated formamidinate complexes such as [Rh2[DTolF]2(CH3CN)6]
2+, [Rh2[F-
form]2(CH3CN)6]
2+, and the lantern compound Rh2[DTolF]]2(O2CCF3)2.
81,173 The Rh-N 
from the eq CH3CN trans to the [F2form]
- bond distances are in the range of 1.840(2)-
1.875(1) Å and are comparable to similar complexes (Table 3.2).  On the other hand the 
Rh-N bond distances for the eq CH3CN ligands trans to the acetate are between 2.408(2) 
Å and 2.436(2) Å, which is ~0.44 Å longer than that of the Rh2(O2CCH3)2(CH3CN)6]
2+.174       
 
[Rh2(µ-o-F2form)(µ-O2CCH3)(CH3CN)6](BF4)2 (6b).  The formation of this complex 
results from the poor stability of 6 in solution, crystals of 6b were obtained from the slow 
diffusion of ether into an acetonitrile solution of 6 at room temperature.  The cationic unit 
for compound 6b crystalizes in a P-1 triclinic space group with two independent 
dirhodium units in the asymmetric unit and four outer-sphere [BF4]
- (Figure 3.4).  The 
dirhodium (II,II) core is supported by one [F2form]
- and there are eight CH3CN ligands 
occupying the remaining coordination sites.  The Rh-Rh bond length is 2.58 Å, slightly 
longer than that of 6, the [F2form]
- is twisted by 30.2(6)º from the eclipsed conformation.  
The eq CH3CN ligands are also twisted from the ideal eclipsed conformation by 33.3(7)º, 
the splaying of the eq CH3CN ligands has also been observed in other formamidinate 
compounds like [Ir2(DTolF)2(CH3CN)6][BF4]2
175
,  [Rh2(DTolF)2(CH3CN)6][BF4]2 and 
[Rh2(F-form)2(CH3CN)6][BF4]2,
81
 but to a lesser extent.   The Rh-N (eq CH3CN) bond 
distances are in the range of  1.971-2.038 Å, which are in agreement with those of 6 and 
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[Rh2(F-form)2(CH3CN)6][BF4]2.
81
    The crystal structure of 6 showed that the Rh-O bond 
distances were 2.424(1) Å and 2.468(1) Å, remarkably long, the acetate group becomes 
labile to form 6b. 
 
 
 
Figure 3.3  Thermal ellipsoid plot for the cationic unit 6 at the 50% probability level.  The 
hydrogen atoms and counter ions have been omitted for the sake of clarity. 
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Table 3.1  Crystal and structural refinement data for 6 and 7. 
  6 6b 7 • 2CH3CN 
Empirical formula C29H30B2ClF12N9O2Rh2  C29H31B4F16N10Rh2  C35.5H38.75B2F8N6.25O2PRh2 
Formula weight (g/mol) 992.06 1072.7 995.39 
Crystal system monoclinic  triclinic  monoclinic 
Crystal description, color orange needle red needle orange plate 
Space group P21/c  P-1  P21/n 
a, b, c/Å 15.204(3), 13.329(3), 22.242(4) 12.3599(18), 17.283(3), 19.791(3) 14.359(6), 13.513(5), 21.968(8) 
α, β, γ  /° 90, 90.98(3), 90 100.345(3), 95.826(3), 100.300(3) 90,707(5), 90 
Volume/Å3 4506.6(16)  4052.8(10)  4262(3) 
Z 4 4 4 
ρcalcg/cm3 1.462 1.74 1.551 
2Θ range for data collection/° 2.68 to 52.602  1.228 to 20.186  3.37 to 50.776 
Independent reflections 
6119 [Rint = 0.2261,  
Rσ = 0.1468]  
4922 [Rint = 0.1527,  
Rσ = 0.0803]  
7796 [Rint = 0.0567,  
Rσ = 0.0424] 
Data/restraints/parameters 6119/3/256  4922/40/533  7796/3/527 
Goodness-of-fit on F2 1.148 1.035 1.041 
Final R indexes [I>=2σ (I)] R1 = 0.1245, wR2 = 0.3165  R1 = 0.0678, wR2 = 0.1345  R1 = 0.0484, wR2 = 0.1235 
Final R indexes [all data] R1 = 0.1950, wR2 = 0.3558  R1 = 0.1086, wR2 = 0.1550  R1 = 0.0642, wR2 = 0.1348 
aR = ∑Fo-Fc/∑Fo. bwR = {∑[w(Fo2 - Fc2)2]/∑w(Fo2)2]}1/2. cGoodness-of-fit = {∑[w(Fo2- Fc2)2]/(n-p)}1/2, where n 
is the number of reflections and p is the total number of parameters refined. 
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Table 3.2  Summary of important bond distances in 6. 
Compound Rh-Rh (Å) Rh-Lax (Å) Rh-Leq (Å)
a,c Rh-N (Å) Rh-O (Å) 
6 2.5575(2) 2.244(2), 2.164(2)a 
1.840(2), 
1.875(1), 
2.408(2), 
2.436(2) 
1.852(2), 1.864(2) 
2.424(1), 
2.468(1) 
[Rh2[DTolF]2(CH3CN)6]
2+  (d) 2.5594(8) 2.208(7), 2.235(7)a 
2.020(6), 
2.029(7) 
2.026(6), 2.037(6) - 
[Rh2[F-form]2(CH3CN)6]
2+  (d) 2.571(1) 2.195(4), 2.251(4)a 
2.032(5), 
2.040(5) 
2.038(5), 2.046(5) - 
Rh2[DTolF]]2(O2CCF3)2 
(e) 2.425(1) 2.311(3), 2.319(3)b - 
1.996(4), 1.998(4), 
1.987(3), 1.990(3) 
2.087(3), 
2.079(3), 
2.073(3), 
2.092(4) 
a  L is CH3CN.  
b  Axial H2O.  
c  Axial and equatorial ligands are the same.  d  Ref.  125.  e  Ref. 126.
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Figure 3.4  Thermal ellipsoid plot for the cationic unit 6b at the 50% probability level.  
The hydrogen atoms and counter ions have been omitted for the sake of clarity. 
 
 
[Rh2(µ-Ph2P(C6H4))(µ-O2CCH3)(CH3CN)6](BF4)2 (7).  The cationic unit in 7 also 
crystallizes in the centrosymmetric monoclinic space group P21/n.  The thermal ellipsoid 
plot shows that the dirhodium (II,II) core is bridged by one acetate and one orthometallated 
phosphine in a similar fashion to that of 6 (Figure 3.5).  The Rh-Rh bond distance is 
2.5591(9) Å, which is ~0.10 Å shorter than the [Rh2(µ-Ph2P(C6H4))2(µ-
O2CCH3)(CH3CN)6](BF4)2
81
 and its isocyanide analogues and other dirhodium 
orthometallated phosphine compounds.171 The phosphine is considerably twisted from an 
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eclipsed conformation, 28.88 º as the absence of a second phosphine on the dirhodium unit 
provides it with more flexibility which results in an increase in the Rh-Rh bond length.   
 
 
 
Figure 3.5  Thermal ellipsoid plot for the cationic unit 7 at the 50% probability level.  
The hydrogen atoms and counter ions have been omitted for the sake of clarity. 
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The Rh-N bond distances of the eq CH3CN ligands that are trans to the acetate group are 
1.980(4) Å and 1.985(4) Å which are similar to those of the [Rh2(O2CCH3)2(CH3CN)6]
2+ 
precursor (Table 3.3).  The other two eq CH3CN ligands trans to the phosphine exhibit 
more elongated Rh-N bond distances, 2.153(4)-2.127(4) Å which is attributed mainly to 
the trans influence from the phosphine since it is a good -donor.  The Rh-C and Rh-P 
bond distances are comparable to those of the bis-cyclometallated compound [Rh2(µ-
PPh2(C6H4))(µ-O2CCH3)(CH3CN)6](BF4)2.
81
  The four eq CH3CN ligands are splayed as 
one can see from the dihedral angles, 31.11(16)º and 30.43(18)º and are far from the ideal 
eclipsed conformation.  Detailed bond distances and dihedral angles for compounds 6-7 
are compiled in Table 3.3.  
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Table 3.3  Summary of important bond distances in 7. 
Compound Rh-Rh (Å) Rh-Lax (Å) 
Rh-Leq 
(Å)a,b 
Rh-Cc (Å) Rh-P (Å) Rh-Od (Å) 
7 2.5591(9) 
2.184(5), 
2.226(4)a 
2.153(4), 
2.127(4), 
1.985(4), 
1.980(4) 
2.011(6) 2.2333(2) 
2.035(4), 
2.042 (3) 
R-[Rh2[Ph2P(C6H4)]2(CH3CN)6]
2+  (e) 2.656(1) 2.196(6)a 
2.104(6), 
2.142(6) 
2.01(2) 2.232(7) - 
S-[Rh2[Ph2P(C6H4)]2(CH3CN)6]
2+  (e) 2.655(1) 2.202(6)a 
2.127(5), 
2.131(5) 
2.024(5) 2.228(2) - 
Rh2[Ph2P(C6H4)]2(O2CCH3)2
 (f) 2.508(1) 2.342(5) - 1.996(6) 2.210(2) 
2.136(4), 
2.190(4) 
Rh2[Ph2P(C6H4)]1(O2CCH3)3 
(g) 2.430(2) 
2.336(4), 
2.301(4) 
- 1.999(5) 2.206(2) 
2.025(4), 
2.034(4), 
2.218(4), 
2.163(3) 
Rh2(O2CCH3)2(CH3CN)6  
(h) 2.534(1) 2.232(4)a 
1.985(4), 
1.980(3) 
- - 
2.017(3), 
2.012(3) 
a  L is CH3CN.  
b  Axial and equatorial ligands are the same.  c  C atoms from the orthometallated phosphine.  d  O atoms from 
the bridging acetate groups.  e  Ref. 81.  f  Ref. 171.  g  Ref. 109.  h  Ref. 174.
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Table 3.4  Relevant bond distances and dihedral angles for compounds 6-7. 
 
6 6b 7 
Bond Distances Length/Å Bond Distances Length/Å Bond Distances Length/Å 
Rh1-Rh2 2.5575(2) Rh1-Rh2 2.581(2) Rh1-Rh2 2.5591(9) 
Rh1-O1 2.424(1) Rh1-N1 2.021(14) Rh1-O1 2.035(4) 
Rh2-O2 2.468(1) Rh1-N3 2.169(17) Rh2-O2 2.042(3) 
Rh1-N1 1.852(2) Rh1-N4 2.038(17) Rh2-C3 2.011(6) 
Rh2-N2 1.864(2) Rh1-N5 1.971(17) Rh1-P3 2.2333(2) 
Rh1-N3 1.840(2) Rh1-N8 2.013(19) Rh2-N6 2.153(4) 
Rh2-N4 1.875(1)   Rh1-N9 2.127(4) 
Rh1-N5 2.408(2)   Rh2-N5 1.985(4) 
Rh2-N6 2.436(2)   Rh1-N7 1.980(4) 
Rh1-N7 2.244(2)   Rh2-N4 2.184(5) 
Rh2-N8 2.164(2)   Rh1-N8 2.226(4) 
Dihedral angles ₒ Dihedral angles ₒ Dihedral angles ₒ 
N1-Rh1-Rh2-N2 -9.6(7) N1-Rh1-Rh2-N2 27.2(6) C3-Rh2-Rh1-P3 28.88(12) 
O1-Rh1-Rh2-O2 -3.7(4) N6-Rh2-Rh1-N4 33.3(7) O1-Rh1-Rh2-O2 23.18(12) 
N7-Rh1-Rh2-N8 -2.4(7) N19-Rh2-Rh1-N5 37.9(6) N6-Rh2-Rh1-N9 31.11(16) 
N9-Rh1-Rh2-N10 -4.9(5) N8-Rh1-Rh2-N9 36.2(7) N7-Rh1-Rh2-N5 30.43(18) 
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Time Lapse 1H NMR Spectroscopic Studies  
 The 1H NMR spectra of compound 6 were measured in D2O at different time 
intervals in the dark in order to monitor its stability in water.  There are four singlet 
resonances in the spectrum of 6 in the aliphatic region, namely at 2.05 ppm, 2.13 ppm, 
2.56 ppm and 2.58 ppm which are assigned as free CH3CN, bridging acetate, eq CH3CN
N 
and eq CH3CNO respectively.  In the aromatic region one can observe the characteristic 
triplet resonance from the [F2form]
- bridging ligand (3JH-Rh = 8.4 Hz) and the multiplet at 
7.33 ppm.  The time lapse experiment reveals how the eq CH3CNN singlet resonance at 
2.56 ppm and that of the bridging acetate at 2.13 ppm decrease in intensity with time.  
There is also the appearance of new resonances at 2.15 ppm, 2.46 ppm and 2.63 ppm 
which are attributed to side products from the exchange of eq CH3CN for D2O which 
occurs upon dissolution and become more pronounced as time progresses (Figure 3.6).     
 The time lapse experiment was also performed on 7 and, in this case, the strong 
donating ability of the orthometallated phosphine promotes fast exchange of the trans eq 
CH3CN ligands with D2O in the dark.  This process is monitored by the 2.06 ppm singlet 
resonance which integrates to twelve H with the other six H nuclei corresponding to the 
axial CH3CN ligands which exchange readily in the dark with the solvent.  The spectra 
taken over a period of 4 h indicate that the eq CH3CN trans to the acetate are very stable 
and do not exchange during the time frame of the experiment (Figure 3.7). 
 Irradiation experiments were performed in an NMR tube located 18 inches away 
from a Vivitek D508 projector and spectra were collected at different time intervals.  
Compound 6 was irradiated for a period of 4 h and the 1H NMR spectra look similar to 
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the time lapse experiment performed in the dark.  Clearly irradiation of the sample does 
not aid in the exchange of the eq CH3CN ligands for the D2O solvent (Figure 3.8).  The 
low stability of the eq CH3CN in the dark makes this compound a poor candidate for PDT 
applications but it could be used as a scaffold for further functionalization due to the 
lability of the eq CH3CN ligands trans to the [F2form]
-. 
 
 
 
Figure 3.6  Changes in 1H NMR spectra of 6 in D2O as a function of time in the dark; 
only the region involving the changes in the spectra are shown.  The labels R and * 
represent reagents and products, respectively. 
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Figure 3.7  Changes in 1H NMR spectra of 7 in D2O as a function of time in the dark; 
only the region involving the changes in the spectra are shown.  The labels R and F 
represent reagents and free CH3CN, respectively. 
 
 
 
 The time lapse experiment for 7 was conducted for 4 h under irradiation with the 
projector.  As in the case of 6, the eq CH3CN ligands do not exchange in the dark after 
photolysis for 4 h with white light (Figure 3.9).  The eq CH3CN ligands  trans to the  
cyclometallated phosphine exhibit fast exchange in the dark upon dissolution in D2O;  this 
behavior is also observed in the case of [Rh2[Ph2P(C6H4)]2(CH3CN)6][BF4]2 due to the 
strong σ-donating ability of the  bridging phosphine ligand.81    
 91 
 
 
Figure 3.8  Changes in 1H NMR spectra of 6 in D2O as a function of irradiation time (λirr 
> 400-700 nm); only the region involving the changes in the spectra are shown.  The labels 
R and * represent reagents and products, respectively. 
 
 
 
Figure 3.9  Changes in 1H NMR spectra of 7 in D2O as a function of irradiation time (λirr 
> 400-700 nm); only the region involving the changes in the spectra are shown.  The labels 
R and F represent reagents and free CH3CN, respectively. 
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Electronic Absorption Spectral and Electrochemical Studies 
Electronic absorption spectra were obtained for compounds 6 and 7 in CH3CN and H2O; 
the data are summarized in Table 3.5. 
 
 
Table 3.5  Electronic absorption data for complexes 6 and 7 in CH3CN and H2O at room 
temperature. 
  λ (nm), (ε x 103 (M-1•cm-1)) in CH3CN λ (nm), (ε x 103 (M-1•cm-1)) in H2O 
6 220 (7.5), 260 (20.4), 360 (0.51), 500 (0.18) 250 (110), 360 (1.80), 510 (0.43) 
7 243 (35.0), 290 (27.5), 485 (0.26) 234 (20.2), 290 (11.2), 535 (0.20) 
 
 
The electronic absorption spectrum of 6 (Figure 3.10a) shows a strong absorption 
at ~ 260 nm (ε = 2.0 x 104 M-1•cm-1) which is attributed to a metal-centered transition with 
some contributions from the [F2form]
- bridging ligand and the eq CH3CN ligands.  The 
spectrum in CH3CN also displays a shoulder of moderate intensity at 360 nm (ε = 5.1 x 
102 M-1•cm-1) which becomes more prominent in H2O.  The lowest energy transition for 
6 is observed at 500 nm with a bathochromic effect being observed in water at 510 nm.  
This transition is assigned as Rh(π*)-Rh(σ*).  It is worth noting that in 6, the lowest energy 
band is shifted to higher energies as compared to [Rh2(DTolF)2(CH3CN)6][BF4]2 and 
[Rh2(F-form)2(CH3CN)6][BF4]2 whose transitions occur at 521 nm and 534 nm 
respectively.
81
  The hypsochromic shift exhibited by 6 underscores the effect on the 
electronic structure of the partial paddlewheel of merely substituting one formamidinate 
bridge for acetate. 
 93 
 
 In the case of 7 there is a shoulder of moderate intensity located at 243 nm (ε = 3.5 
x 105 M-1•cm-1) which originates from the Rh(π*) to Rh-CH3CN(eq)(σ*).  There is also a 
band at 290 nm (ε = 2.7 x 105 M-1•cm-1) that does not shift with changes in solvent.  The 
lowest energy transition is observed at 485 nm which is shifted to lower energies by ~ 10 
nm as compared to [Rh2[Ph2P(C6H4)]2(CH3CN)6]
2+ (478 nm).81 
 
 
 
Figure 3.10  Electronic absorption spectra of compounds a) 6 and b) 7 in CH3CN and 
H2O at room temperature. 
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 Dirhodium compounds are characterized by the facile exchange of the axial 
ligands with the solvent in which they are dissolved which causes the lowest energy 
transition to shift depending on their interaction with the Rh(σ*) orbital.  Upon irradiation 
the compound [Rh2[O2CCH3)2(CH3CN)6][BF4]2 labilizes two of its eq CH3CN ligands a 
process that is readily monitored by electronic absorption spectroscopy.77  The lowest 
energy transition for 6 at 500 nm decreases in intensity over time and a slight shift to 515 
nm was observed (Figure 3.11a).  There is also a decrease in intensity in the band at 360 
nm, which is Rh(π*) to Rh-CH3CN(eq) (σ*) in character (Figure 3.11b).  The thermal 
population of the Rh-CH3CN(eq)(σ*) level promotes the labilization of the eq CH3CN 
which is mainly due to the strong σ-donation of the [F2form]- bridging ligand.   
 
 
 
Figure 3.11  a) Electronic absorption spectra of 6 at room temperature in H2O at different 
time intervals.  b)  Inset: absorbance values for the 500 nm and 360 nm absorption bands 
as a function of time. 
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 The electronic absorption spectrum of 7 was also studied at different time intervals 
in H2O.  A slight decrease in intensity was observed in the lowest energy transition at 530 
nm but no bathochromic shift was observed (Figure 3.12a-b).  The behavior observed for 
7 is mainly due to the trans influence that the [PPh3]
- exerts on the eq CH3CN trans to it.  
Upon dissolution in H2O the eq CH3CN ligands trans to [PPh3]
- dissociate, thus the 
spectrum obtained in water corresponds to 
[Rh2[Ph2P(C6H4)](O2CCH3)(H2O)(CH3CN)2][BF4]2 (Figure 3.12c). 
 
 
 
Figure 3.12  a) Electronic absorption spectra of 7 at room temperature in H2O at different 
time intervals.  b)  Inset: absorbance values for the 530 nm absorption band as a function 
of time.  c) Schematic representation of ligand exchange upon dissolution in water in the 
dark and at room temperature for compound 7. 
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The redox potential for compounds 6 and 7 were measured and the results are summarized 
in Table 3.6. 
 
 
Table 3.6 Electrochemical reduction potentials for compounds 6 and 7 and the free 
ligands. 
Potential, V Epc,(red)1 Epc,(red)2 E1/2(ox) Epa,(ox) 
[Rh2(O2CCH3)1(F2form)(MeCN)6](BF4)2 -0.84  -1.07  +1.75   
[Rh2(O2CCH3)1[Ph2P(C6H4)](MeCN)6](BF4)2 -0.87  -1.11  +1.51   
N,N’-2,6-difluoroformamidinea    +1.60 
Triphenylphosphinea    +1.35 
a. Irreversible  
 
 
 
The mixed bridge dirhodium compounds supported by [F2form]
- and [PPh3]
- 
ligands exhibit a reversible oxidation at +1.75 V and +1.51 V respectively attributed to 
the Rh(II)-Rh(II)Rh(II)-Rh(III) couple.  Ren et al. reported that the presence of electron 
donating groups on the formamidinates under study render the oxidation event more 
accessible and the opposite is true for electron withdrawing groups which can be observed 
in the reversible oxidation of compound 6 (+1.75 V).176 The oxidation of compound 7 is 
in agreement with [Rh2[Ph2P(C6H4)]2(CH3CN)6][BF4]2 (+1.54 V).
81  
[Rh2[O2CCH3)2(CH3CN)6][BF4]2 displays two irreversible reduction waves at -0.56 V and 
-0.99 V vs SCE79 and compounds 6 and 7 exhibit similar behavior.  Compound 6 also 
displays two reductions at -0.84 V and -1.07 V, and 7 at -0.87 V and -1.11 V; in both cases 
the  reduction waves are comparable to those of [Rh2[O2CCH3)2(CH3CN)6][BF4]2.
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Computational Studies 
  
A summary of important bond distances and molecular orbital contributions for 6 and 7 from the optimized structures are listed 
in Table 3.7and Table 3.8. 
 
 
Table 3.7  Experimental bond distances obtained from X-ray diffraction data and the calculated ones derived from DFT gas 
phase optimization of the cationic structures of compounds 6 and 7. 
Compound 6 
Bond  
Experimental Calculated Compound 7          
Bond  
Experimental Calculated 
Length/Å Length/Å Length/Å Length/Å 
Rh1-Rh2 2.5575(2) 2.5565(5) Rh1-Rh2 2.5591(9) 2.5791(0) 
Rh1-O1 2.424(1) 2.0363(7) Rh1-O1 2.035(4) 2.0509(9) 
Rh2-O2 2.468(1) 2.0331(2) Rh2-O2 2.042(3) 2.0455(4) 
Rh1-N1 1.852(2) 2.0310(6) Rh2-C3 2.011(6) 2.0158(5) 
Rh2-N2 1.864(2) 2.0332(4) Rh1-P3 2.2333(2) 2.2782(6) 
Rh1-N3 1.840(2) 2.0448(7) Rh2-N6 2.153(4) 2.2033(9) 
Rh2-N4 1.875(1) 2.0455(5) Rh1-N9 2.127(4) 2.1372(5) 
Rh1-N5 2.408(2) 1.9955(1) Rh2-N5 1.985(4) 1.9879(5) 
Rh2-N6 2.436(2) 1.9957(0) Rh1-N7 1.980(4) 1.9846(2) 
Rh1-N7 2.244(2) 2.2231(5) Rh2-N4 2.184(5) 2.1798(4) 
Rh2-N8 2.164(2) 2.2199(8) Rh1-N8 2.226(4) 2.2585(0) 
Dihedral  ₒ Dihedral  ₒ 
N1-Rh1-Rh2-N2 -9.6(7) 16.76(8) C3-Rh2-Rh1-P3 28.88(12) 27.12(5) 
O1-Rh1-Rh2-O1 -3.7(4) 16.597 O1-Rh1-Rh2-O2 23.18(12) 22.65(5) 
N7-Rh1-Rh2-N8 -2.4(7) 20.78(2) N6-Rh2-Rh1-N9 31.11(16) 31.64(7) 
N9-Rh1-Rh2-N10 -4.9(5) 21.42(9) N7-Rh1-Rh2-N5 30.43(18) 30.83(6) 
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Table 3.8  Orbital contribution of selected molecular orbitals for compound 6 in CH3CN and H2O derived from TD-DFT. 
6 in CH3CN 6  in H2O 7 in CH3CN 7  in H2O 
HOMO-2 
13 Rh 1 eq CH3CN 
HOMO-2 
77 Rh 7 eq CH3CN 
HOMO-2 
80 Rh 7 eq CH3CN 
HOMO-2 
84 Rh 8 eq CH3CN 
84 F2form 1 ax CH3CN 11 F2form 3 ax H2O 4 PPh3 3 ax CH3CN 2 PPh3 1 ax H2O 
1 OAc   2 OAc   6 OAc   5 OAc   
HOMO-1 
63 Rh 6 eq CH3CN 
HOMO -1 
85 Rh 8 eq CH3CN 
HOMO-1 
69 Rh 5 eq CH3CN 
HOMO-1 
76 Rh 5 eq CH3CN 
23 F2form 3 ax CH3CN 4 OAc 3 ax H2O 17 PPh3 7 ax CH3CN 2 PPh3 3 ax H2O 
5 OAc       2 OAc   5 OAc   
HOMO 
67 Rh 2 OAc 
HOMO 
28 Rh 2 OAc 
HOMO 
46 Rh 3 eq CH3CN 
HOMO 
47 Rh 3 eq CH3CN 
28 F2form 3 eq CH3CN 67 F2form 3 eq CH3CN 48 PPh3 2 ax CH3CN 47 PPh3 1 ax H2O 
        2 OAc   2 OAc   
LUMO 
78 Rh 5 eq CH3CN 
LUMO 
80 Rh 4 eq CH3CN 
LUMO 
72 Rh 5 eq CH3CN 
LUMO 
75 Rh 4 eq CH3CN 
5 F2form 9 ax CH3CN 5 F2form 8 ax H2O 11 PPh3 8 ax CH3CN 11 PPh3 7 ax H2O 
3 OAc   3 OAc   4 OAc   3 OAc   
LUMO+1 
56 Rh 7 OAc 
LUMO+1 
53 Rh 7 OAc 
LUMO+1 
44 Rh 7 OAc 
LUMO+1 
42 Rh 6 OAc 
21 F2form 15 eq CH3CN 26 F2form 14 eq CH3CN 37 PPh3 11 eq CH3CN 41 PPh3 10 eq CH3CN 
LUMO+2 
50 Rh 7 OAc 
LUMO+2 
50 Rh 7 OAc 
LUMO+2 
4 Rh 
LUMO+2 
3 Rh 
26 F2form 16 eq CH3CN 28 F2form 15 eq CH3CN 92 PPh3 93 PPh3 
        3 eq CH3CN 3 eq CH3CN 
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In order to gain more insight into the structural and electronic absorption 
characteristics of compounds 6 and 7, DFT calculations were conducted.  The geometry 
optimization results for both compounds are comparable to that of the experimental 
findings.  The Rh-Rh bond distance in 6 is in close agreement with that of the crystal 
structure and in the case of 7 it is slightly longer than the experimental value, ca. ~0.02 Å.  
The crystal structure of 6 exhibits remarkably long Rh-O bond distances, differing by 
~0.43 Å from the calculated structure.  Dirhodium partially solvated compounds bearing 
acetate and acetamides typically exhibit bond distances in the range of 1.98-2.02 Å,79,174 
however 6 has unusually long Rh-Neq CH3CN
O from the X-ray diffraction data, 2.408(2) 
Å.  The optimization of 6 provides a Rh-Neq CH3CN
O bond distance that resembles more 
that of the reported values, 1.875(1) Å.  Also the dihedral angles for the optimized cationic 
structure of 6, shows big distortions and splaying of the four eq CH3CN molecules which 
is not observed on the crystallographic structure.  The geometry optimization results for 
compound 7 confirmed that the Rh-Neq (trans to P) and Rh-Neq (trans to C) are longer 
than that of the Rh-Neq trans to the acetate groups which is not surprising since the 
orthometallated phosphine exerts a stronger trans effect than the acetate group on the eq 
CH3CN monodentate ligands.  Also the dihedral angles for 7 defined by the eq CH3CN 
and the dirhodium core are in good agreement with the X-ray diffraction data.  The 
dihedral angles from the bridging ligands, [PPh3]
- and [O2CCH3]
- and the dirhodium core 
calculated by DFT are ~1.5º and ~0.5º shorter than the X-ray structure, but are still in good 
agreement with the experimental results.   
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Figure 3.13  MO diagram involving the dirhodium core unit in 6 obtained by DFT 
calculations (iso-value=0.04). 
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Figure 3.14  MO diagram involving the dirhodium core unit in 7 obtained by DFT 
calculations (iso-value=0.04).
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DFT calculations were performed on the optimized cationic structures of 6 and 7 
in CH3CN and H2O.  The results from this study indicate that the molecular orbital 
contributions are very similar in both solvents (Table 3.8).  The HOMO in 6 is mostly 
[F2form]
- (pπ bridging) based (71%) with some contribution from the acetate bridge 
(~2%).  The LUMO is a rhodium based orbital corresponding to the Rh(σ*) orbital, 
whereas the LUMO+1 and LUMO+2 have considerable antibonding character between 
the Rh and eq CH3CN ligands, with equal contributions to the eq CH3CN trans to the 
acetate and to the [F2form]
-.  The Rh(σ) level is higher in energy by 0.68 eV that the Rh(δ) 
level which is lower in energy than the Rh(π*).  The stabilization of the Rh(π*) is mainly 
due to the bonding interactions of the rhodium with the [F2form]
- bridging ligand (Figure 
3.13). 
The metal-based orbitals for 7 exhibit the configuration π4δ2δ*2 σ2π*4σ*0 (Figure 
3.14).  The HOMO for 7 has a 1:1 contribution from Rh and [PPh3]
- (π Phenyl).  The Rh(δ) 
and Rh(δ*) are stabilized due to its interaction with the bridging phosphine ligand, while 
the Rh(σ) lies at higher energies due to the antibonding interactions with the axial CH3CN 
ligands.  The LUMO is mostly a rhodium based orbital with 72% contributions and 
visualization of this orbital indicates that it corresponds to the Rh(σ*).  The LUMO+1 and 
LUMO+2 have significant Rh-CH3CNeq character which corresponds to the Rh-Leq(σ*) 
orbitals responsible for the labilization of the equatorial acetonitrile ligands. 
To gain more insight into the origin of the electronic transitions of compounds 6 
and 7, TD-DFT/PCM calculations were conducted.  The lowest energy band (λ = 465 nm, 
f = 0.001) for 6 corresponds to the HOMO-1 to LUMO ligand-to-metal charge-transfer 
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(LMCT) transition (Table 3.9) from the [F2form]
- (pπ) to the Rh(σ*) orbital.  The 
absorption band at 435 nm involves the transition from HOMO-6 to LUMO which have 
been ascribed to the Rh(π*) to Rh(σ*) transition due to the rhodium contribution which 
makes this a metal centered transition (MC).  The transition at 326 nm has orbital 
contributions from the HOMO-1 to the LUMO+1 and is ascribed as the transition from 
Rh(π*) to Rh-Leq (σ*).  This transition is responsible for the labilization of the eq CH3CN 
monodentate ligands upon irradiation.  The strong absorptions from 311-318 nm are a 
combination of MC and LMCT and originate from the HOMO-5 and HOMO-8 levels with 
a 1:3 Rh:F2form character and major contributions from the Rh(δ) orbitals respectively.   
Compound 7 displays a low energy band at 463 nm (f = 0.001) that corresponds to 
transitions originating from the HOMO-2 to LUMO orbitals.  This electronic transition is 
a metal centered transition composed mainly of Rh(π*) and Rh(σ*) character and it 
correlates well with the experimental results.  The absorptions between 290-310 nm are 
charge transfer bands (LMCT) that have been attributed to transitions involving the 
phosphine bridging ligand and the metal center, HOMO-12 to LUMO and HOMO-2 to 
LUMO+2 and are LMCT/MC in character.  The transitions in the region between 340-360 
nm have contributions from the HOMO-2 to L+1 orbitals, which have Rh(π*) and Rh-
LMeCN (σ*) in character, this is the band that decreases in intensity due to the labilization 
of the equatorial ligands as shown in the time lapse experiments.  Visualization of the 
frontier orbitals for 6 and 7 are depicted in Figure 3.15 and Figure 3.16.  
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Table 3.9  First ten electronic transitions predicted for 6 and 7 by TD-DFT calculations in 
CH3CN and H2O as solvent.  H = HOMO, L = LUMO and f = oscillator strength. 
6 in CH3CN 6 in H2O 
E/ 
(nm) 
f Excitations 
E/ 
(nm) 
f Excitations 
465 0.001 H-1 -->L 58% 509 0.001 H-1 -->L 82% 
454 0.002 H-->L 79% 495 0.001 H --> L, H-2 --> L 
34%, 
48% 
435 0.002 H-6-->L 50% 477 0.002 H --> L, H-2 --> L 
42%, 
30% 
392 0.002 H-->L 65% 386 0.005 H --> L+1 61% 
378 0.002 H-->L+2 56% 374 0.002 H -->L 52% 
347 0.010 H-10-->L 22% 346 0.002 H-8-->L 30% 
331 0.010 H-1-->L+1 29% 335 0.004 H-8 --> L 54% 
326 0.003 H-1-->L+1 23% 329 0.002 H-1 --> L+1 63% 
318 0.013 H-8-->L 52% 319 0.013 H-2 --> L+2 27% 
311 0.013 H-5-->L 30% 308 0.015 H-1 -->L+2, H-6 -->L 
25%, 
22% 
7 in CH3CN 7 in H2O 
E/ 
(nm) 
f Excitations 
E/ 
(nm) 
f Excitations 
463 0.001 H-2 -->L   77% 520 0.001 H-2 -->L 79% 
444 0.008 H-1-->L, H-->L 
35%, 
22% 
502 0.003 H-1 --> L, H->-L 
41%, 
34% 
390 0.001 H-->L, H-1-->L 
39%, 
37% 
423 0.001 H --> L, H-1-->L 
48%, 
34% 
361 0.001 H-2 --> L+1 39% 373 0.001 H-2 --> L+1 25% 
349 0.004 
H-1-->L+1,       
H-->L+1 
46%, 
20% 
350 0.006 
H-1 -->L+1,       
H-->L+1 
37%, 
20% 
338 0.003 
H-7-->L+1,       
H-10-->L+1 
29%, 
25% 
339 0.003 
H-7-->L+1,         
H-10-->L+1 
23%, 
20% 
321 0.006 H-11-->L 30% 336 0.004 
H-2 --> L+1,       
H-9-->L 
29%, 
23% 
314 0.019 H-4-->L+1 26% 328 0.024 
H-10 --> L,        
H-7-->L 
23%, 
20% 
311 0.030 H-->L+2 29% 306 
0.005
3 
H-3 --> L 37% 
301 0.030 H-12-->L 34% 298 0.006 H-3 --> L+1 20% 
*2|coefficient|2 > 0.2 
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Figure 3.15  MO depiction of 6 generated by TD-DFT calculations in solvation model 
(CH3CN) generated by agui with iso-value = 0.04; H = HOMO, L = LUMO. 
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Figure 3.16  MO depiction of 7 generated by TD-DFT calculations in solvation model 
(CH3CN) generated by agui with iso-value = 0.04; H = HOMO, L = LUMO. 
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In-vitro Cytotoxicity Studies 
The cytotoxicities of compounds 6 and 7 were determined against HeLa cells with 
the aid of fluorescent probes, Sytox Green® and Hoechst 33342.  The blue fluorescent 
dye, Hoechst 33342 indiscriminately binds to DNA in both dead and live cells, while 
Sytox Green® selectively stains dead or dying cells, exhibiting green fluorescence.147,177 
The cells were incubated with compounds 6 and 7 for 4 h in the dark at different 
concentrations, followed by treatment with Sytox Green® and Hoechst for 10 min.  The 
dark experiments showed that for both compounds, mostly blue fluorescence was 
observed, meaning that the cells were still alive (Figure 3.17 and Figure 3.18).  Since no 
green fluorescence was observed under the experimental conditions, the LC50 values could 
not be determined but have been estimated to be >>200 µM.   
 
 
 
Figure 3.17  Cell viability plot for compound 6 in the dark (red) and upon irradiation 
(blue). 
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Figure 3.18  Confocal microscopy images of HeLa cells treated with 50 µM solutions of 
6 and 9 for 4 h in the dark followed by treatment with Sytox® Green and Hoechst.  Top 
control in the dark, middle pane compound 6 and bottom compound 7.  a) Hoechst 33342, 
blue fluorescence, b) phase contrast, c) SYTOX® Green fluorescence, and d) overlay of 
blue and green fluorescence. 
 
 
The photocytotoxicities of 6 and 7 were also studied.  These cells were incubated 
in the dark for 2 h followed by irradiation with white light (λ = 400-700 nm) for a period 
of 1 h.  After staining with Sytox Green® and Hoechst it was observed that, as in the case 
of the dark experiment and the control with no compound, only blue fluorescence was 
observed (Figure 3.19).  Clearly the mixed bridge partially solvated compounds are not 
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toxic against HeLa cells.  These results are not surprising considering the low stability of 
6 in aqueous soliton; moreover the compound may not be entering the cell or it could be 
decomposing before reaching its target.  Compound 7 exhibits rapid exchange of the eq 
CH3CN (trans to PPh3) for H2O in the dark but the eq CH3CN ligands trans to acetate are 
not released upon irradiation which may be a contributing factor to the lack of toxicity 
upon irradiation. 
 
 
 
Figure 3.19  Confocal microscopy images of HeLa cells treated with 50 µM solutions of 
6 and 7 for 4 h in the dark, irradiated for 30 min, and followed by treatment with Sytox® 
Green and Hoechst.  Top control after irradiation, middle pane compound 6 and bottom 
compound 7.  a) Hoechst 33342, blue fluorescence, b) phase contrast, c) SYTOX® Green 
fluorescence, and d) overlay of blue and green fluorescence. 
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Concluding Remarks 
 The partial paddlewheel dirhodium compounds bearing mixed-bridging ligands 
[Rh2(µ-o-F2form)(µ-O2CCH3)(CH3CN)6](BF4)2 and [Rh2(µ-Ph2P(C6H4))(µ-
O2CCH3)(CH3CN)6](BF4)2 were successfully prepared and characterized and their anti-
proliferative activity tested against HeLa cells.  Compounds 6 and 7 have strong sigma 
donating bridges along with one acetate group.  The eq CH3CN ligands trans to the σ-
donating bridgeheads exchange readily with the H2O molecules upon dissolution with the 
opposite being observed for the eq CH3CN trans to the acetate group.  The time lapse 
1H 
NMR spectra of compound 6 shows that the eq CH3CN ligands exchange at the same rate 
in the dark and upon light irradiation, this may be due to the light source utilized for this 
experiments.  Also 6 is not stable for long periods of time as evidence by the isolation of 
the by-product 6b and subsequent X-ray analysis that shows that the acetate bridge has 
been lost which may be due to the remarkably long Rh-O (bridging acetate) bond 
distances.  In the case of 7, the orthometallated phosphine group causes strains in the 
dirhodium unit with a 29 º torsion angles which had also been observed for 
[Rh2(C6H4(Ph2))2(CH3CN)6]
2+. 
The DFT calculations helped in the interpretation of the transitions in the electronic 
absorption spectrum.  Compound 6 has a low energy transition that is [F2form](pπ) to 
Rh(σ*) in character while in 7 it is Rh(π*) to Rh(σ*).  The presence of only one strong σ-
donor bridging ligand does not improve the lability of the eq CH3CN ligands trans to the 
acetate.  The time lapse 1H NMR studies indicate that the eq CH3CN ligands trans to the 
acetate do not exchange upon light irradiation over a period of 5 h.  The cell viability data 
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indicate that the compounds studied in this chapter do not show anti-proliferative 
properties under the experimental conditions.  To our knowledge this is the first report of 
partial paddlewheel dirhodium compounds bearing mixed bridging ligands.  Additional 
bridging ligands should be pursued in order to improve the dark stability of these 
compounds and render the photolability of the eq CH3CN ligands trans to acetate more 
facile.   
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CHAPTER IV  
DIRHODIUM (II,II) PYRROLIDINATO COMPOUNDS AND THEIR 
APPLICATIONS AS ANTICANCER AGENTS 
Introduction 
Despite the great success of cisplatin in battling various forms of cancer, its 
efficacy has been compromised by drug resistance mechanisms and a plethora of side 
effects.15,178  This situation has prompted the development of new and improved drugs that 
interact with targets other than DNA, including proteins,98 enzymes,179  histones,95 and 
which induce a cascade of events that ultimately leads to cell death.180-181 Although 
cisplatin and other platinum complexes are widely viewed as the gold standards for metal 
chemotherapeutic agents, other transition metal compounds exhibit impressive anti-
carcinostatic properties and deserve to be explored.   
One major drawback of current traditional therapies is the lack of targeted action.  
A much more effective alternative approach is photodynamic therapy (PDT).  PDT is a 
non-invasive treatment for endoscopically accessible tumors63-64 which involves the use 
of photosensitizers and visible light in combination with molecular oxygen to cause 
damage to tumor cell membranes by generation of singlet oxygen and other reactive 
oxygen species (ROS).66-67  The fact that the photosensitizer relies on the oxygen present 
in the cell, however, is disadvantageous because once the oxygen is depleted in dense 
tumor tissue, the drug becomes ineffective.63  To circumvent this problem, “photo-
cisplatin” analogs that do not rely on oxygen are being studied in our laboratories and 
others.  Turro and co-workers studied the photophysical properties of [Rh2(µ-
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O2CCH3)2(CH3CN)6]
+2 and, upon irradiation with low energy light, two equatorial CH3CN 
monodentate ligands are labilized and exchanged for H2O molecules.
77  The photo-
aquation product [Rh2(µ-O2CCH3)2(H2O)4(CH3CN)2]
+2 becomes the active species and 
induces a 34-fold increase in toxicity when tested against skin cancer cells.  A number of 
related compounds have been synthesized and their photophysical properties investigated 
examples of which are the H,H and H,T isomers of [Rh2(HNOCCH3)2(CH3CN)6](BF4)2
79, 
[Rh2(6-chloro-oxo-pyridinate)(CH3CN)6](BF4)2
170 that photocleave DNA in vitro and 
exhibit an increase in toxicity against HeLa cells upon irradiation with low energy light 
respectively. In order to improve antiproliferative activity of these type of compounds we 
set out to tune the properties by studying different bridging ligands. 
Dirhodium tetrakis-pyrrolidinato and valerolactamate complexes were reported in 
the late 1980’s but their biological applications were not investigated until 2012.182-184  Che 
and coworkers reported the antiproliferative properties of a series of dirhodium 
tetracarboxylates and Rh2(3-butyl-2-pyrrolidinato)4 and their studies revealed that it 
exhibits anticancer activity with LC50 values in the range of 0.5-1.60 µM on the different 
cancer cell lines tested.  The compound 2-pyrrolidinone is known for a wide range of 
applications ranging from tablet binders, and as a food additive, our interest in the 
molecule lies in the fact that it shows antioxidant and anticancer activities.185-186  The aim 
of the work in this chapter is the synthesis and characterization of a new family of 
dirhodium (II,II) partially solvated compounds equipped with 2-pyrrolidinate bridging 
ligands and the study of their anticancer activity upon white light irradiation. 
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Experimental Section 
Starting Materials 
The compound Rh2(µ-O2CCH3)4•2CH3OH was purchased from Pressure 
Chemicals or synthesized from RhCl3•xH2O from reported procedures.108  The compound 
Rh2(µ-NOC4H6)4(CH3CN)2 was prepared following reported procedures.
183 The 
commercially available reagents 2-pyrrolidinone (pyrro) and ferrocenium 
hexafluorophosphate were purchased from Sigma Aldrich and triethyloxonium 
tetrafluoroborate (Et3OBF4), 1M in CH2Cl2 was purchased from TCI America; all of them 
were used as purchased.  Analytical thin layer chromatography was carried out on 
aluminum-backed sheets coated with aluminum oxide (Al2O3) neutral 60 F254 adsorbent 
(0.20 mm thickness, EMD Chemicals).  Flash chromatography was performed with Al2O3 
(activated, basic, Brockmann I, Sigma Aldrich).  The solvents acetonitrile (CH3CN), 
toluene and diethyl ether (Et2O) were of ACS grade quality and used as received.  Standard 
Schlenk-line techniques (under N2 atmosphere) were used and work-up and isolation of 
products was performed in air unless otherwise stated. 
Cell culture reagents Dubelco’s modified Eagle medium (DMEM) (Invitrogen), 
fetal bovine serum (FBS) (Atlanta Biologicals), Leibovitz's L-15 Medium (L-15) without 
phenol red (Life Technologies), Phosphate-Buffered Saline solution (DPBS) (Life 
Technologies) and Sytox Green® (Invitrogen), Hoechst 33342 (Invitrogen) were used as 
received.  The HeLa cell line was obtained from the American Type Culture Collection, 
cell line CCL-2. 
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Preparation of cis-2,2-[Rh2(µ-NOC4H6)2(NOC4H7)(CH3CN)5](BF4)2 (8).  The reagent 
Et3OBF4 (1 mL, 1 mmol) was added to a CH3CN:CH3OH (1:1 v/v) solution of Rh2(µ-
NOC4H6)4(CH3CN)2 (28.2 mg, 0.045 mmol) and the mixture was stirred for 18 h in the 
absence of light.  The reddish/purple colored solution was concentrated to ~3 mL and 
diethyl ether was added to precipitate a purple solid which was collected by filtration.  The 
solid was purified by flash chromatography (Al2O3, toluene:CH3CN 70:30) to afford 9 as 
a light purple solid.  X-ray quality crystals were obtained from slow diffusion of diethyl 
ether into a solution of the product in acetonitrile.  Yield 15 mg (40%).  1H NMR (500 
MHz, CD3CN-d3), δ (ppm): 1.96 (s, 6H axCH3CN), 2.40 (m, pyrro), 2.46 (s, eqCH3CNN), 
2.49 (s, 6H, eqCH3CN
O), 3.29 (m, pyrro), 3.40 (m, pyrro), 3.48 (m, pyrro), 5.93 (s, 
Hpyrro).  ESI-MS: m/z = 665.97 ([Rh2(µ-NOC4H6)2(NOC4H7)(CH3CN)5]
+), 533.86 
([Rh2(µ-NOC4H6)2(CH3CN)4]
+), 498.96 ([Rh2(µ-NOC4H6)2(CH3CN)3]
+),  490.93 
([Rh2(µ-NOC4H6)2(CH3CN)1]
+), 449.88 ([Rh2(µ-NOC4H6)2(NOC4H7)]
+).   
 
Preparation of cis-2,2-[Rh2(µ-NOC4H6)2(NOHC4H6)(CH3CN)5](BF4)2 (9).  A solution 
of 2 (20 mg, .030 mmol) in acetonitrile was stirred at room temperature in the absence of 
light for 18 h.  The pink solution was reduced in volume to ~5 mL and the product was 
precipitated by adding diethyl ether to afford a reddish solid.  The solid was purified by 
flash chromatography (Al2O3, toluene:CH3CN 50:50) to afford 10 as a light red-purple 
solid.  X-ray quality crystals were obtained from slow diffusion of diethyl ether into a 
solution of the product in acetonitrile.  Yield: 12 mg (48 %). 1H NMR (500 MHz, CD3CN-
d3), δ (ppm): 1.96 (s, 6H axCH3CN), 2.05 (m, pyrro), 2.34 (s, eqCH3CN), 2.42 (s, pyrro), 
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2.45 (t, 2H, eq OH-pyrro), 2.49 (s, 3H, eqCH3CN), 3.32 (m, pyrro), 3.43 (m, pyrro), 3.53 
(m, pyrro), 3.72 (m, pyrro), 10.87 (s, 3,4-dihydro-2H-pyrrol-5-ol).  ESI-MS: m/z = 539.90 
([Rh2(µ-NOC4H6)2(CH3CN)4]
+2),  498.88  ([Rh2(µ-NOC4H6)2(CH3CN)3]
+2),  457.89  
([Rh2(µ-NOC4H6)2(CH3CN)2]
+2).  Anal. Calcd. for C20H34B2F8N7O4Rh2•1.15H2O:  C, 
28.78; N, 11.75; H, 4.14%.  Found:  C, 28.19; N, 12.33; H, 3.65%.   
 
Preparation of cis-2,2-[Rh2(µ-NOC4H6)4(CH3CN)2](PF6)1 (10).  A solution of Rh2(µ-
NOC4H6)4(CH3CN)2 (17 mg, .027 mmol) in acetonitrile was treated with [FeCp2](PF6) 
(8.8 mg, .027 mmol) and the mixture was stirred for 1 h.  After this time the solvent was 
removed under reduced pressure and the resulting dark purple solid was washed with 
diethyl ether and warm toluene and collected by filtration.  X-ray quality crystals were 
obtained from slow diffusion of diethyl ether into a solution of the product in acetonitrile.  
Yield: 18 mg (84%).  The compound is NMR silent.  (ESI-MS: m/z = 541.97 ([Rh2(µ-
NOC4H6)4]
+), 583.02 ([Rh2(µ-NOC4H6)4(MeCN)]
+). 
 
Instrumentation and Methods 
X-ray data sets were collected for compounds 8 and 9 on a Bruker CCD APEX 
diffractometer with graphite monochromated Mo Kα radiation (λ = 0.71073 Å).  X-ray 
data for 10 was collected at beamline 15-ID-B at the Advanced Photon Source at Argonne 
National Laboratory using synchrotron radiation (λ= 0.41328 Å).   
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Results and Discussion 
Synthesis and Characterization of the Dirhodium Pyrrolidinato Complexes 
The synthesis of 8 involves the reaction of neutral cis-2,2-Rh2(µ-
NOC4H6)4(CH3CN)2 with a slight excess of alkylating agent Et3OBF4 in order to replace 
two 2-pyrrolidinato ligands for CH3CN molecules according to a published procedure by 
Turro et al79 (Figure 4.1).  A similar procedure was followed for compound 9 by using 
the starting material cis-2,2-Rh2(µ-NOC4H6)4(CH3CN)2.  In both reactions, compounds 8 
and 9 turned color from reddish-pink to magenta upon contact with the alkylating agent.  
Both compounds were purified by flash chromatography using Al2O3 as the solid phase 
and a mixture of toluene:CH3CN as the mobile phase; in both cases a dark purple band 
was recovered.  The dark purple fraction was reduced in volume and recrystallized.  The 
purity of 8 and 9 was confirmed by 1H-NMR spectroscopy and ESI mass spectrometry.  
Compounds 8 and 9 adopt H-H conformations and only one isomer was observed.  
Compound 8 contains an axial 2-pyrrolidonone whereas 9 has an equatorial pyrrol ligand 
trans to the O which is a result of the alkylation of one of the 2-pyrrolidinone bridging 
ligands followed by protonation in situ.  X-Ray analysis of the dark purple fraction 
recovered from the flash chromatography of 8 and 9 indicated that it was the oxidized 
starting material crystallized as the tetrafluoroborate salt.  Bear and coworkers183 reported 
the electrochemical generation of the Rh2(II,III) compound in bulk via controlled potential 
electrolysis of Rh2(µ-NOC4H6)4(CH3CN)2.  We prepared compound 10 by chemical 
oxidation of cis-2,2-Rh2(µ-NOC4H6)4(CH3CN)2 with [FeCp](PF6) in acetonitrile to afford 
a dark purple solution which was purified by TLC (toluene: CH3CN, 1:1) and whose 
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identity was confirmed by ESI-MS; no 1H NMR spectrum was obtained for this compound 
due to its paramagnetic nature.   
 
 
 
Figure 4.1  Schematic representation of the synthesis of compounds 8-10. 
 
 
X-ray Crystallographic Studies  
Crystal data and structure refinement for compounds 8 and 9 are summarized in Table 
4.1. 
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Table 4.1  Crystal and structural refinement data for 8-10.  
 8 9 10 
Formula C22H34N8O3Rh2B2F8 C26H40B2F8N10O3Rh2 C20H30N6O4F6PRh2 
Mol. Wt. (g/mol) 838.01 920.12 769.29 
Space group P212121 P-1 C2/c 
a, b, c/ Å 11.6660(17) 11.931(10) 19.720(3) 
 14.141(2) 12.430(10) 8.1009(10) 
 18.853(3) 12.489(10) 16.911(2) 
α, β, γ  /° 90 93.696(11) 90 
 90 97.323(12) 98.055(4) 
 90 98.120(11) 90 
Volume/Å3 3110.1(8) 1812(3) 2674.8(6) 
Z 4 2 4 
2Θ range for data collection/° 54.204 46.502 29.558 
Rint 0.061 0.0346 0.0397 
Goodness-of-fit  
(all data)a 
1.105 1.037 1.048 
R1,
b wR2
c 
 [all data] 
R1 = o.0453 R1 = 0.0876 R1 = 0.0748 
wR2 = 0.1308 wR2 = 1601 wR2 = 0.1890 
aR = ∑Fo-Fc/∑Fo. bwR = {∑[w(Fo2 - Fc2)2]/∑w(Fo2)2]}1/2. cGoodness-of-fit = {∑[w(Fo2- Fc2)2]/(n-p)}1/2, where n 
is the number of reflections and p is the total number of parameters refined. 
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cis-2,2-[Rh2(µ-NOC4H6)2(NOC4H7)(CH3CN)5](BF4)2 (8).  A pink needle was selected 
for the X-ray crystallographic analysis which was grown from slow diffusion of diethyl 
ether into a solution of 8 in CH3CN.  Compound 8 crystallizes in the chiral space group 
P212121 and the cationic unit contains a dinuclear Rh2(II,II) core coordinated to two 
bridging [2-pyrrolidinato]- ligands in a cis-2,2 arrangement with four CH3CN ligands 
occupying the equatorial positions with another CH3CN molecule in the axial position 
proximal to the N bridge head.  There is a 2-pyrrolidinone molecule in the axial position 
of the Rh center coordinated to the O atom from the bridgehead with H-bonding 
interactions involving the NH group of the axial 2-pyrrolidione and the O atom of the 
bridge (N-H•••O = 1.98 Å, 145.72(6)º) are observed (Figure 4.2).  The Rh-Rh bond 
distance is 2.5752(4) Å which is longer than that of dirhodium paddlewheel complexes 
with four bridging ligands such as cis-2,2-[Rh2(µ-NOC4H6)4]
183 but comparable to the 
partially solvated cis-[Rh2(OC(O)CH3)2(CH3CN)6][BF4]2.
77 The Rh-N [2-pyrro]-  
distances are in the range of  2.0014(2)-2.0190(2) Å which is longer than that of the cis-
2,2-[Rh2(µ-NOC4H6)4]
183; the Rh-O [2-pyrro]- distances range between 2.0105(2)-
2.0114(2) Å which is longer than for the parent compound.  The Rh-NN (eq CH3CN) and 
Rh-NO (eq CH3CN) bond distances are in the range of Å and 2.0260(2)-2.0494(2) Å and 
1.9763(2)-1.99414(2) respectively which are comparable to the corresponding parameters 
for the acetamide H,H and H,T isomers of cis-[Rh2(HNOCCH3)2(CH3CN)6][BF4]2
79.  The 
Rh-N (ax CH3CN) distance is ~0.20 Å longer than that of the eq CH3CN ligands and the 
Rh-O (ax Hpyrro) has a bond distance of 2.2460(3) Å which is ~0.40 Å longer than that 
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of the bridging ligands.  Compound 8 adopts an eclipsed configuration of the eq CH3CN 
with very minor distortions to the octahedral coordination sphere of the rhodium atoms. 
 
 
 
 
Figure 4.2  Thermal ellipsoid plot for the cationic unit 8 at the 50% probability level.  The 
hydrogen atoms and counter ions have been omitted for the sake of clarity.  
 
 
 
cis-2,2-[Rh2(µ-NOC4H6)2(η1-NOHC4H7)(CH3CN)5](BF4)2 •2CH3CN (9).  Compound 9 
crystallizes in the space group P-1.  The thermal ellipsoid plot in Figure 4.3 shows that 
the cationic unit consists of a dirhodium core with two cisoid bridging 2-pyrrolidionato 
ligands in a H-H fashion and unlike the other partially solvated compounds, 9 bears four 
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eq CH3CN monodentate ligands and one 3,4-dihydro-2H-pyrrol-5-ol in the equatorial 
position trans to the O from the bridge head and two axial CH3CN molecules.  The Rh-
Rh bond distance is 2.547(2) Å, slightly shorter than that in 8.  The Rh-N (ax CH3CN) 
bond distance are in the range of 2.198(9)-2.209(9) Å which is shorter than 8.  The Rh-NN 
(eq CH3CN) bond distances fall in the range of 2.018(8)-2.033(8) Å, similar to those of 8 
and [Rh2(HNOCCH3)2(CH3CN)6][BF4]2.
79  The Rh-NO bond distance is 1.973(9) Å, also 
comparable to the acetate and acetamide analogs.  The 3,4-dihydro-2H-pyrrol-5-ol in the 
equatorial position is engaged in H-bonding with the O from the bridge (O-H•••O = 
1.781(6) Å, 160.2(6)º).  Small distortions form the eclipsed configuration of the 2-pyrro 
bridging ligands, with the dihedral angle defined by O4-Rh2-Rh1-N2 being 6.2(3)º which 
is not observed in 8.  The equatorial 3,4-dihydro-2H-pyrrol-5-ol is positioned outside of 
the eq CH3CN plane by 10.2(7)º; this displacement is mostly due to its ability to H-bond 
with the O6 from the bridgehead. 
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Figure 4.3  Thermal ellipsoid plot for the cationic unit 9 at the 50% probability level.  The 
hydrogen atoms and counter ions have been omitted for the sake of clarity. 
 
 
 
cis-2,2-[Rh2(µ-NOC4H6)4(CH3CN)2](PF6)1 (10).  The oxidized compound [Rh2(µ-
NOC4H6)4 crystallizes in the space group C2c.  The thermal ellipsoid plot shows that the 
cationic unit consists of a dirhodium core which lies on an inversion center and is bound 
to two cis N and two cis O atoms as in the case of [Rh2(µ-NOC4H6)4 reported by Bear 
(Figure 4.4).183 The dirhodium compound contains two acetonitrile molecules occupying 
the axial positions instead of the 2-pyrrolidinone molecules.  The Rh-Nax distances are 
2.214(6) Å which are in agreement with other structures of the same type.  The Rh-Rh 
bond distance is 2.4436(10) Å which is comparable to the neutral analog.  Important bond 
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distances for this unit have been summarized in Table 4.2.  The counter ion [PF6]
- lies on 
a C2 axis and is disordered.  The presence of the counter ion taken together with 
spectroscopic data confirms that the dirhodium compound is positively charged and that 
the Rh units are mixed-valence with a Rh2(II,III) oxidation state.   
 
 
 
 
Figure 4.4  Thermal ellipsoid plot of the cationic unit 10 at the 50% probability level.  The 
hydrogen atoms have been omitted for the sake of clarity. 
 
 
 
 
Detailed bond distances and dihedral angles for compounds 8-10 are compiled in Table 
4.2. 
. 
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Table 4.2  Relevant bond distances and dihedral angles for compounds 8-10. 
 
8 9 10 
Bond Distances Length/Å Bond Distances Length/Å Bond Distances Length/Å 
Rh1-Rh2 2.5752(8) Rh1-Rh2 2.547(2) Rh1-Rh1' 2.4436(10) 
Rh1-N1 2.019(7) Rh1-N3 1.995(7) Rh1-O1 2.033(5) 
Rh1-N2 2.001(6) Rh1-N2 2.000(7) Rh1-N1 2.214(6) 
Rh1-N5 2.049(7) Rh1-N6 2.018(8) Rh1-O2 2.033(5) 
Rh1-N8 2.206(7) Rh1-N7 2.033(8) Rh1-N2 1.983(6) 
Rh1-N4 2.026(7) Rh1-N5 2.208(8) Rh1-N3 1.978(6) 
Rh2-O2 2.010(6) Rh2-N1 2.011(8)   
Rh2-O2 2.011(5) Rh2-N8 1.973(8)   
Rh2-N7 1.976(6) Rh2-O11 2.020(7)   
Rh2-N6 1.994(7) Rh2-O4 2.020(6)   
Rh2-O3 2.246(7) Rh2-N4 2.198(9)   
O1-H3 1.951(6) O4-H6 1.7803(12)   
Dihedral  ₒ Dihedral  ₒ Dihedral  ₒ 
N2-Rh1-Rh2-O2 -1.4(2) O4-Rh2-Rh1-N2 6.168(5) N2-Rh1-Rh1'-O2 1.15 
O1-Rh2-Rh1-N1 -3.6(3) O11-Rh2-Rh1-N3 8.385(7) N3-Rh1'-Rh1-O1 0.48 
N7-Rh2-Rh1-N5 -0.1(3) N7-Rh1-Rh2-N8 6.467(5)   
N4-Rh1-Rh2-N6 -1.5(3) N6-Rh1-Rh2-N1 6.811(5)   
Rh2-O3-C12-N3 -12.3(11) N1-C1-O6-Rh2 -5.197(5)   
O1-C4-N1-C1 176.6(8) C6-C5-N2-C8 0.7801(7)   
C5-N2-C8-O2 -179.5(6) O11-C9-N3-C12 -176.851(3)   
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NMR Spectroscopic Studies of Compounds 8 and 9 
The 1H NMR spectrum of 8 shows two multiplets at δ = 2.02 ppm and δ = 2.39 
ppm corresponding to the protons from the 2-pyrrolidinato bridging ligands and that of 
the axially bound 2-pyrrolidionone (Figure 4.5).  There are two unique multiplets at δ = 
3.39 ppm and 3.47 ppm corresponding to the 2-pyrrolidinato ligands, each integrating to 
4 protons.  The triplet resonance at δ = 3.29 ppm integrates to two protons and is assigned 
as the axially bound 2-pyrrolidione molecule.  The two singlet resonances at δ = 2.46 ppm 
and δ = 2.49 ppm correspond to the equatorial CH3CN molecules.  The eq CH3CN 
molecules were integrated against the bridging 2-pyrrolidinate ligand resonance at δ = 
3.39 ppm, the δ = 2.46 ppm but does not integrate to six protons which indicates fast 
exchange of the monodentate ligand with the NMR solvent CD3CN in the dark.  
Compound 9 also has four multiplets which are not as resolved as in the case of 8 located 
at δ = 2.02 ppm, δ = 3.32 ppm, δ = 3.43 ppm and δ = 3.53 ppm that correspond to the 2-
pyrrolidinato bridging ligand (Figure 4.6).  There are three singlet resonances at δ = 2.34 
ppm, δ = 2.42 ppm and δ = 2.49 ppm and a triplet at δ = 2.45 ppm.  Also there three 
multiplets at δ = 2.66 ppm, δ = 2.81 ppm and δ = 3.69 ppm that are ascribed as the 
equatorial 3,4-dihydro-2H-pyrrol-5-ol ligand and a singlet at δ = 10.87 ppm corresponding 
to the hydroxyl proton which is not observed in 8.   
The X-Ray crystallographic data for these compounds shows that the Rh centers 
are supported by two cis [NOC4H6]
- groups in a head-to-head conformation and that the 
third 2-pyrrolidinone in 8 resides in the axial position.  Unlike 8, compound 9 bears a 3,4-
dihydro-2H-pyrrol-5-ol in an equatorial position trans to the O atom from the bridging 
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group which explains the triplet resonance at δ = 2.45 ppm.  The fast exchange of the eq 
CH3CN ligands for 8 and 9 prompted the 
1H NMR study of these in D2O in the dark and 
after irradiation with white light at different time intervals the results of which will be 
discussed in the following section.  
 
 
 
Figure 4.5  a) 1H NMR spectrum of compound 8 in CD3CN, bridging 2-pyrrolidinate 
signals b) 1H NMR spectrum of eq CH3CN signals of compound 8. 
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Figure 4.6  a) 1H NMR spectrum of compound 9 in CD3CN, bridging 2-pyrrolidinate 
signals b) 1H NMR spectrum of eq CH3CN signals of compound 9. 
 
 
 
Time Lapse 1H-NMR Studies of 8 and 9 
 
 In order to study the exchange of the equatorial CH3CN ligands in 8 and 9, 
1H-
NMR spectroscopy was utilized.  The 1H NMR spectrum of compound 8 in D2O  exhibits 
two singlets of equal intensity at δ = 2.50 ppm and δ = 2.57 ppm and a triplet at δ = 2.34 
ppm assigned to the eq CH3CN
N, eq CH3CN
O and 2-pyrrolidinate ligands respectively 
(Figure 4.7).  The 1H NMR resonances were assigned by comparison with the cis-2,2-
[Rh2(HNOCCH3)2(CH3CN)6] compound.
79  The eq CH3CN ligands were integrated 
against the 2.34 ppm resonance since it does not change with time.  After 30 min in the 
dark, a decrease in intensity for the 2.50 ppm and 2.57 ppm resonances is observed which 
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is due to the exchange of the eq CH3CNN  and eq CH3CNO ligands respectively.  The 
lability of eq CH3CN with D2O was also studied for compound 9 in the dark (Figure 4.8).  
There are three singlet resonances at 2.39 ppm, 2.53 ppm and 2.56 ppm.  The features at 
2.39 ppm and 2.53 ppm correspond to the eq CH3CN molecules trans to N.  The resonance 
at 2.53 ppm decreases in intensity as the reaction progresses whereas the one at 2.39 ppm 
does not change during the time investigated.  The resonance at 2.56 ppm is assigned as 
the eq CH3CN trans to O by comparison to 8 which has a resonance at 2.56 ppm as well 
and exchanges slowly in the dark as in the case of 9.  There are two multiplet resonances 
at 2.51 ppm and 3.49 ppm that are assigned as the eq pyrrol; these two resonances decrease 
in intensity after 3 h which indicates that the ligand is labile in the dark. 
 
 
 
Figure 4.7  Changes in 1H NMR spectra of 8 in D2O as a function of time in the dark; 
only the region involving the changes in the spectra are shown. 
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Figure 4.8  Changes in 1H NMR spectra of 9 in D2O as a function of time in the dark; 
only the region involving the changes in the spectra are shown. 
 
 
 
A time lapse experiment was also performed for compounds 8 and 9 after 
irradiation.  This experiment reveals that the eq CH3CN
O exchange takes more than 1 h of 
irradiation to take place and that release of eq CH3CN
N is very slow.  There is also an 
increase in intensity in the resonance at δ = 2.06 ppm which corresponds to free CH3CN.  
Both exchange processes are much slower as compared to the acetamide compounds 
reported by Turro et al.79 which could be due to the power dependence of the 
photoaquation process (Figure 4.9).77   As in the case of 8, compound 9 was irradiated 
with white light (>400-700 nm) and a 1H NMR spectrum was taken at different time 
intervals in order to determine the lability of the eq CH3CN ligands and that of the eq 
pyrrole molecule.  The eq pyrrole resonance is observed at 2.10 ppm and 3.49 ppm and 
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these signals decrease in intensity with increasing irradiation times (Figure 4.10).  The eq 
CH3CN
O resonance at 2.39 ppm disappears upon irradiation and the eq CH3CN
N 
resonances at 2.53 ppm and 2.56 ppm also decrease in intensity with time.  The 2.06 ppm 
resonance increases in intensity which corresponds to free CH3CN.  Several new singlet 
resonances can be observed after 5 h of irradiation, namely 2.16 ppm, 2.46 ppm and 2.61 
ppm, which correspond to various photoaquation products as in the case of other 
compounds of this type such as the dirhodium acetamides and oxopyridinates, cis- 
[Rh2(HNOCCH3)2(CH3CN)6][BF4]2 and cis-[Rh2(mhp)2(CH3CN)6][BF4]2 
respectively.79,170 
 
 
 
Figure 4.9  Changes in 1H NMR spectra of 8 in D2O as a function of irradiation time (λirr 
> 400-700 nm); only the region involving the changes in the spectra are shown.
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Figure 4.10  Changes to the 1H NMR spectra of 9 in D2O as a function of irradiation time 
(λirr >400-700 nm), where * denotes product; only the region involving the changes in the 
spectra are shown. 
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Electronic Absorption and Electrochemical Studies 
Electronic absorption spectra were obtained for compounds 8-10 in CH3CN and H2O; the 
data is summarized in Table 4.3.   
 
 
Table 4.3  Electronic absorption data for complexes 8-10 in CH3CN and H2O at room 
temperature. 
  λ (nm), (ε x 103 (M-1•cm-1)) in CH3CN λ (nm), (ε x 103 (M-1•cm-1)) in H2O 
8 277 (5.8), 330 (0.75), 515 (0.33) 273 (1.0), 370 (0.76), 555 (0.51)  
9 275 (13.2), 359 (0.42), 525 (0.25) 275 (36.3), 380 (0.25), 550 (0.17) 
10 
245 (12.4), 335 (0.82), 490 (3.86), 530 
(3.63), 1033 (2.05), ~1410 (0.03) 
250(7.53), 330 (0.22), 475 (4.05), 
520 (3.87), 1050 (1.62) 
 
 
 The electronic absorption spectra of 8 and 9 exhibit similar behavior in CH3CN.  
There is a transition at 515 nm for 8 and 525 nm for 9, which are ascribed as metal center 
transitions of the type Rh2(π*)Rh(σ*) with some bridging ligand character (Figure 
4.11a).  Both compounds exhibit absorptions between 330-360 nm; these features have 
been observed for the partially solvated compounds [Rh2(HNCOCH3)2(CH3CN)6]
2+(~350 
nm),170 [Rh2(6-R-oxo-pyridinate)2(CH3CN)6]
2+ (~380 nm)170 and 
[Rh2(OOCCH3)2(CH3CN)6]
2+ (~363 nm).77 The transitions in this region are characterized 
by contributions from the Rh(π*) to Rh-CH3CNeq(σ*) and Rh(σ*) molecular orbitals and 
are weak as indicated by molar absorptivity coefficients (Table 4.3).  The bands at 275 
nm for both 8 and 9 correspond to metal-centered transitions with contributions from both 
bridging ligands and the equatorial ligands.  Electronic absorption spectra were obtained 
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in water for both 8 and 9 and, as expected, there is a bathochromic shift of the lowest 
energy transition in accordance with the behavior of analogous compounds under the same 
experimental conditions (Figure 4.11b).   
 
 
 
Figure 4.11  Electronic absorption spectra of compounds 8 and 9 in (a) CH3CN and (b) 
H2O at room temperature. 
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The electronic absorption spectrum of compound 10 had been reported in the late 
1980’s by Bear et al. and it was noted that the compound has a weak band at 490 nm and 
530 nm that do exhibit a bathochromic shift when the solvent is changed unlike previous 
compounds (Figure 4.12).109  There are also two other transitions in the low energy region 
of the UV and NIR area of the spectrum in acetonitrile, at 1033 nm and 1410 nm (Figure 
4.12a, inset) which were not reported by Bear  
 
 
 
Figure 4.12  Electronic absorption spectra of compounds 10 in (a) CH3CN and (b) H2O 
at room temperature. 
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 The stability of compounds 8 and 9 in H2O was assessed by measuring the 
electronic absorption spectra in the dark at different time intervals over a period of 24 h.  
The lowest energy transition for partially solvated compounds as 8 and 9 are characterized 
by a decrease in intensity over time when eq CH3CN molecules are being labilized, with 
a concomitant increase in intensity and a bathochromic shift of this band.  This is not the 
case for 8 over the course of the experiment; there is a decrease in intensity (Figure 4.13a) 
in the band at 555 nm and a small bathochromic shift is observed which is not as prominent 
as in the case of the model compound [Rh2(OOCCH3)2(CH3CN)6]
2+]77 (Figure 4.13b).  
This experiment supports the time lapse 1H NMR studies in the dark for this compound in 
that 8 is stable in the dark as evidenced by the minimal decrease in intensity of the 555 nm 
band. 
 Compound 9 has its lowest energy transition at 550 nm.  The time lapse experiment 
showed a decrease in the absorption and, unlike 8, a bathochromic shift is observed to 575 
nm as the time progresses and the band increases in intensity.  An isobestic point is 
observed at 565 nm at t = 5 h.  The inset in Figure 4.14 shows the decrease in absorbance 
of the band at 550 nm and the increase in absorbance of the band at 575 nm.  These results 
are in agreement with the 1H NMR data obtained during the time lapse experiments in the 
dark, namely that 9 exchanges the eq CH3CN ligands in the dark.  
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Figure 4.13  a) Electronic absorption spectra of 8 at room temperature in H2O at different 
time intervals.  b) Inset absorbance values for the 555 nm absorption band as a function 
of time. 
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Figure 4.14  a) Electronic absorption spectra of 9 at room temperature in H2O at different 
time intervals.  b)  Inset absorbance values for the 550 nm and 575 nm absorption bands 
as a function of time. 
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The redox potentials of 8-10, [Rh2(pyrro)4] and 2-pyrrolidinone were obtained by 
cyclic voltammetry measurements in acetonitrile and are listed in Table 4.4.  The free 
ligand 2-pyrrolidinone ligand does not exhibit any electrochemical reactions within the 
limits of the solvent stability.  Compounds 8 and 9 exhibit similar electrochemical 
behavior in that both exhibit a reversible oxidation event at +1.58 V which is consistent 
with the Rh2(II,II) Rh2(II,III) couple as in the case of the acetamide partial paddlewheel 
complexes and the cis-2,2-[Rh2(pyrro)4] compound of Bear et al. and cis-
[Rh2(HNCOCH3)(CH3CN)6](BF4)2.
79,109,182  There is an irreversible reduction for 8 and 9 
located at -1.23 V and -1.44 V, an event that is also observed for the partially solvated 
acetamide compounds reported by Turro, but which is absent for cis-
[Rh2(OCOCH3)3(CH3CN)6][BF4]2.  There is an additional reduction for 8 and 9 at -1.02 V 
and -0.92 V respectively.  In the case of 8 there is an additional oxidation at +0.20 V that 
is not present in 9 and by comparing it to the starting material it appears to be metal based 
as well.  With regards to the irreversible oxidation at ~0.89 V, this is a chemical reaction 
that occurs after the compound has been oxidized from Rh2(II,II) to Rh2(II,III) as in the 
case of [Rh2(pyrro)4].  Compound 10 had been previously reported by Bear et. al.,
109 and 
once the compound oxidizes to the Rh2(II,III) analog, an irreversible chemical reaction 
occurs which is also observed for compounds 8 and 9.  It is important to note that 10 
decomposes after several scans and the same is observed if the compound is left in solution 
for prolonged periods of time.  
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Table 4.4  Electrochemical reduction potentials for compounds 8-10as well as the free 
ligands. 
Potential, V 
E1/2 
ox(1) 
E1/2    
ox(2) 
Epc   
red(1) 
Epc   
red(2) 
Epc 
red(3) 
Rh2(µ-pyrro)2(MeCN)5(Hpyrro)1](BF4)2 1.58 0.20 0.87a -1.02a -1.28a 
Rh2(µ-
pyrro)2(MeCN)5(NOHC4H6)1](BF4)2 
1.58 - 0.87a -0.92a -1.24a 
[Rh2(pyrro)4(MeCN)2](PF6)1 1.37 0.17 0.89a - - 
[Rh2(pyrro)4(MeCN)2] 1.38 0.18 0.89a - - 
2-pyrrolidinone b 
a  Irreversible  b  Not active within the limits of the solvent. 
 
 
Computational Studies 
Density functional theory calculations were conducted on compounds 8 and 9 in 
order to aid in the assignment of the electronic transitions in the UV spectra and to 
augment the electrochemistry results.  The optimizations of 8 and 9 were performed based 
on the crystal structures as a starting point for the geometry optimization.  The results of 
these optimizations are in close agreement with the X-ray structures (Table 4.5).  The 
bond distances from the calculated cationic structures of 8 and 9 are comparable to that of 
the crystal structures, although the dihedral angles vary slightly from the experimental 
data which may result from the splaying of the eq CH3CN ligands upon optimization of 
the cationic structures under the solvation model.  The TD-DFT calculations were 
conducted on the optimized structures of compounds 8 and 9 in both CH3CN and H2O. 
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Table 4.5  Experimental bond distances obtained from X-ray crystallography data and the calculated distances derived from   
DFT gas phase optimization of the cationic structures of compounds 8 and 9. 
8 9 
Bond 
Experimental Calculated 
Bond 
Experimental Calculated 
Length/Å Length/Å Length/Å Length/Å 
Rh1-Rh2 2.5752(8) 2.5900(3) Rh1-Rh2 2.547(2) 2.5774(3) 
Rh1-N1 2.019(7) 2.0162(8) Rh1-N3 1.995(7) 2.0151(6) 
Rh1-N2 2.001(6) 2.0170(1) Rh1-N2 2.000(7) 2.0232(9) 
Rh1-N5 2.049(7) 2.0452(4) Rh1-N6 2.018(8) 2.0471(7) 
Rh1-N8 2.206(7) 2.2761(5) Rh1-N7 2.033(8) 2.0399(1) 
Rh1-N4 2.026(7) 2.0426(3) Rh1-N5 2.208(8) 2.22716(8) 
Rh2-O1 2.010(6) 2.0328(4) Rh2-N1 2.011(8) 2.0575(2) 
Rh2-O2 2.011(5) 2.0144(2) Rh2-N8 1.973(8) 1.9923(2) 
Rh2-N7 1.976(6) 2.0044(1) Rh2-O11 2.020(7) 2.0514(2) 
Rh2-N6 1.994(7) 1.9969(1) Rh2-O4 2.020(6) 2.0387(9) 
Rh2-O3 2.246(7) 2.2259(4) Rh2-N4 2.198(9) 2.1952(1) 
O1-H3 1.951(6) 1.9633(1) O4-H6 1.7803(12) 1.6394(1) 
Dihedral  ₒ ₒ Dihedral  ₒ ₒ 
N2-Rh1-Rh2-O2 -1.4(2) -5.7(1) O4-Rh2-Rh1-N2 6.168(5) 16.183(6) 
O1-Rh2-Rh1-N1 -3.6(3) -4.9(8) O11-Rh2-Rh1-N3 8.385(7) 16.723(8) 
N7-Rh2-Rh1-N5 -0.1(3) -6.2(5) N7-Rh1-Rh2-N8 6.467(5) 21.035(4) 
N4-Rh1-Rh2-N6 -1.5(3) -7.2(9) N6-Rh1-Rh2-N1 6.811(5) 19.615(1) 
Rh2-O3-C12-N3 -12.0(2) -10.7(4) N1-C1-O6-Rh2 -5.197(5) -10.782(3) 
O1-C4-N1-C1 176.6(8) 178.3(2) C6-C5-N2-C8 0.7801(7) 1.549(9) 
C5-N2-C8-O2 -179.5(6) -177.4(1) O11-C9-N3-C12 -176.851(3) -175.439(9) 
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The electronic configuration of Rh2(O2CCH3)4(L)2 in the ground state is σ2 
π4δ2π*4δ*2σ* with the HOMO being the Rh-Rh(δ*) orbital.187-188  Coordination of the 
donating ligand 2-pyrrolidinate to the dirhodium core causes a destabilization of the 
Rh(δ*) by antibonding interactions of the 2-pyrrolidinate ligands with the metal based 
orbital,  raising it in energy and making it the HOMO, as observed for other compounds 
such as Rh2(DTolF)4.
189  The electronic configuration for this new family of dirhodium 
compounds is π4δ2π*4 σ2δ*2σ* for compounds 8 and 9.  On the other hand, the LUMOs for 
8 and 9 have Rh(σ*) character which is consistent with the well-studied compounds 
Rh(O2CCH3)4(L)2 and Rh2(O2CCH3)2(CH3CN)6]
2+.  The LUMO+1 orbitals have Rh-
Leq(σ*) antibonding character with electron density concentrated on the acetonitrile 
ligand positioned trans to the oxygen atom from the 2-pyrrolidinato bridging ligand as in 
the case of the [Rh2(HNOCCH3)2(CH3CN)6]
2+
 reported by Turro.  The MO diagram 
involving the Rh2(II,II) unit for compounds 8 and 9 was constructed and the visualization 
of the frontier orbitals depicted with Agui (Figure 4.15 and Figure 4.16 ); energy and 
orbital contributions have been summarized in Table 4.6.  In the case of the oxidized 
compound 10 the electronic configuration becomes π4 σ2π*4δ2δ*1σ*.  The HOMO and 
SOMO orbitals of [Rh2(NOC4H6)4]+ are the Rh(δ) and Rh(δ*) orbitals, respectively.  The 
LUMO as in the case of other dirhodium carboxylates and 8 and 9 is the metal based 
orbital Rh(σ*).  The δ orbital is higher in energy than that of the π* orbitals, this may be 
attributed to the destabilization of the δ orbital through interactions with the Nπ that raises 
the energy of both δ and δ* orbitals.   
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Figure 4.15  MO diagram involving the dirhodium core unit in 8 obtained by DFT calculations (iso-value=0.04). 
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Figure 4.16  MO diagram involving the dirhodium core unit in 9 obtained by DFT calculations (iso-value=0.04). 
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Table 4.6  Orbital contributions, energy levels and bond characters for the dirhodium 
units in 8 and 9. 
  8 9 
  
Orbital and 
Energy 
Contribution 
(%) 
Orbital and Energy 
Contribution 
(%) 
π 
HOMO-8,             
-8.358 eV 
66  Rh 
HOMO-7,                
-8.308 eV 
70  Rh 
10  Pyrro 
Bridge 
11  Pyrro 
Bridge 
11  ax Pyrro 6  eq Pyrro 
10 eq CH3CN 9 eq CH3CN 
π 
HOMO-7,             
-8.308 eV 
75 Rh 
HOMO-6,                
-8.082 eV 
56 Rh 
10 eq CH3CN 
11  Pyrro 
Bridge 
9 Pyrro Bridge 26 eq Pyrro 
δ 
HOMO-6,             
-7.835 eV 
57 Rh 
HOMO-5,                 
-7.806 eV 
71Rh 
10 Pyrro Bridge 10 Pyrro Bridge 
12 eq CH3CN 8 eq CH3CN 
20 ax Pyrro 10 eq Pyrro 
π* 
HOMO-3,             
-7.192 eV 
81 Rh 
HOMO-4,                 
-7.412 eV 
37 Rh 
10 Pyrro Bridge 53 Pyrro Bridge 
7 eq CH3CN   
π* 
HOMO-2,             
-7.102 eV 
75 Rh 
HOMO-3,                
-7.187 eV 
65 Rh 
6 Pyrro Bridge 27 Pyrro Bridge 
6 eq CH3CN 5 eq CH3CN 
11 ax Pyrro   
σ 
HOMO-1,             
-6.987 eV 
63 Rh 
HOMO-1,                
-7.146 eV 
78 Rh 
7 Pyrro Bridge 9 ax CH3CN 
21 ax Pyrro 6 Pyrro Bridge 
5 ax CH3CN 6 eq CH3CN 
δ* 
HOMO,                 
-6.574 eV 
43 Rh 
HOMO,                    
-6.595 eV 
41 Rh 
51 Pyrro Bridge 54 Pyrro Bridge 
4eq CH3CN   
σ* 
LUMO,                           
-2.216 eV 
80 Rh 
LUMO,                           
-2.137 eV 
79 Rh 
7 Pyrro Bridge 7 Pyrro Bridge 
5 ax Pyrro 9 ax Pyrro 
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The MO diagram involving the Rh2(II,II) unit for compound 10 was constructed and the 
visualization of the frontier orbitals depicted with Agui (Figure 4.17); energy and orbital 
contributions have been summarized in Table 4.7. 
 
 
 
Figure 4.17  MO diagram involving the dirhodium core unit in 10 obtained by DFT 
calculations (iso-value=0.04). 
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Table 4.7  Orbital contributions, energy levels and bond characters for the dirhodium 
units in 10. 
10 
  
Orbital 
Energy 
(eV) 
Orbital Contribution (%) 
π 
HOMO-
10 
-8.391 
52  Rh 
46  Pyrro Bridge 
5 ax CH3CN 
π HOMO-9 -8.979 
48 Rh 
46  Pyrro Bridge 
6 ax CH3CN 
σ HOMO-5 -7.681 
76 Rh 
7 Pyrro Bridge 
16 ax CH3CN 
π* HOMO-3 -7.052 
25 Rh 
74 Pyrro Bridge 
1 ax CH3CN 
π* HOMO-2 -7.023 
78 Rh 
4 ax CH3CN 
18 Pyrro Bridge 
δ HOMO -6.774 
76 Rh 
20 Pyrro Bridge 
4 ax CH3CN 
δ* SOMO -6.444 
58 Rh 
42 Pyrro Bridge 
σ* LUMO -1.961 
77 Rh 
13 Pyrro Bridge 
ax CH3CN 
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The MO compositions related to the electronic transitions for compounds 8-10 in 
CH3CN are listed in Table 4.8 orbital contributions for compounds 8 and 9 in water are 
listed in Error! Reference source not found..  The orbital contributions for 8 and 9 in 
oth solvents are very similar so only the results from the CH3CN experiment will be 
discussed.  The Rh based orbitals span from HOMO-8 to HOMO-1 with minor 
contributions from the 2-pyrrolidinate bridging ligand.  The HOMO is evenly distributed 
between bridging ligand character in 8 (~51% HOMO, 4% eq CH3CN) and Rh, whereas 
in 9 it is composed of 2-pyrrolidinate, pyrrol and the eq CH3CN ligand in nature 
accounting for 59% of the HOMO with the remaining being Rh based; in both cases the 
HOMO corresponds to the Rh(δ*) orbital and 2-pyrrolidinato (π*) character.  The LUMO 
for both compounds is mostly Rh in character, which has been assigned as the Rh(σ*) 
level.  The orbitals LUMO+1 and LUMO+2 engage in significant antibonding interactions 
between the Rh core and the eq CH3CN ligands and have been ascribed to Rh-Leq(σ*); the 
same has been observed for the analogous compound cis-H-H-
[Rh2(HNOCCH3)2(CH3CN)6]
2+
 and cis-2,2-[Rh2(O2CCH3)2(CH3CN)6]
2+
.
79
  Compound 
10’s HOMO is Rh(δ) in character, the SOMO corresponds to the Rh(δ*) and the LUMO 
is Rh(σ*) in character.  
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Table 4.8  Orbital contribution of selected molecular orbitals for compounds 8-10 in 
CH3CN derived from TD-DFT. 
8 in CH3CN 9 in CH3CN 10 in CH3CN 
HOMO-6 
57 Rh 
HOMO-6 
56 Rh 
HOMO-6 
75 Rh 
10 Pyrro Bridge 11 Pyrro Bridge 9 Pyrro Bridge 
12 eq CH3CN 26 eq Pyrrol 16 ax CH3CN 
20 ax Pyrro     
HOMO -4 
13 Rh 
HOMO-4 
37 Rh 
HOMO -5 
7 Rh 
82 Pyrro Bridge 53 Pyrro Bridge 93 Pyrro Bridge 
     
HOMO-3 
81 Rh 
HOMO-3 
65 Rh 
HOMO-3 
25 Rh 
74 Pyrro Bridge 
10 Pyrro Bridge 27 Pyrro Bridge 
7 eq CH3CN 5 eq CH3CN 
HOMO-2 
75 Rh 
HOMO-2 
78 Rh 
HOMO-2 
80 Rh 
6 Pyrro Bridge 6 Pyrro Bridge  
6 eq CH3CN 6 eq CH3CN 17 Pyrro Bridge 
11 ax Pyrro 9 ax CH3CN  
HOMO-1 
63 Rh 
HOMO-1 
67 Rh 
HOMO-1 
76 Rh 
7 Pyrro Bridge 7 Pyrro Bridge  
21 ax Pyrro 20 eq Pyrrol 20 Pyrro Bridge 
5 ax CH3CN 5 ax CH3CN   
HOMO 
43 Rh 
HOMO 
41 Rh 
HOMO 
78 Rh 
51 Pyrro Bridge 54 Pyrro Bridge 20 Pyrro Bridge 
    4 ax CH3CN 
LUMO 
80 Rh 
LUMO 
79 Rh 
SOMO 
58 Rh 
42 Pyrro Bridge 
7 Pyrro Bridge 7 Pyrro Bridge 
5 ax Pyrro 9 ax CH3CN 
LUMO+1 
62 Rh 
LUMO+1 
62 Rh 
LUMO 
77 Rh 
21 eq CH3CN 17 Pyrro Bridge 9 ax CH3CN 
17 Pyrro Bridge 12 eq Pyrrol 13 Pyrro Bridge 
  9 eq CH3CN   
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Table 4.9  Orbital contribution of selected molecular orbitals for compounds 8 and 9 in 
H2O derived from TD-DFT. 
8  in H2O 9 in H2O 
HOMO-6 
69 Rh 
HOMO-6 
57 Rh 
14 eq CH3CN 
10 Pyrro 
Bridge 
12 Pyrro 
Bridge 
28 eq Pyrrol 
5 ax Pyrro 5 eq CH3CN 
HOMO-4 
16 Rh 
HOMO-4 
57 Rh 
77 Pyrro 
Bridge 
31 Pyrro 
Bridge 
  5 eq CH3CN 
  5 ax H2O 
HOMO-3 
80 Rh 
HOMO-3 
36 Rh 
10 Pyrro 
Bridge 
56 Pyrro 
Bridge 
6 eq CH3CN 6 ax H2O 
HOMO-2 
66 Rh 
HOMO-2 
85 Rh  
21 ax Pyrro 6 Pyrro Bridge 
5 Pyrro Bridge 7 eq CH3CN 
    
HOMO-1 
75 Rh 
HOMO-1 
71 Rh 
21 ax Pyrro 5 Pyrro Bridge 
5 Pyrro Bridge 20 eq Pyrrol 
    
HOMO 
44 Rh 
HOMO 
45 Rh 
51 Pyrro 
Bridge 
50 Pyrro 
Bridge 
LUMO 
80 Rh 
LUMO 
81 Rh  
7 Pyrro Bridge 7 pyrro Bridge 
6 ax Pyrro 7 ax H2O 
LUMO+1 
63 Rh 
LUMO+1 
63 Rh 
17 Pyrro 
Bridge 
16 Pyrro 
Bridge 
20 eq CH3CN 11 eq Pyrrol 
  9 eq CH3CN 
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The TD-DFT calculations were as a tool to assign the origin of the electronic 
transitions in the UV-visible spectrum.  The lowest energy transition at λ = 474 nm and 
471 nm have been assigned as charge-transfer transitions with a minor contribution from 
the Rh(δ*)Rh(σ*) originating from the HOMO, HOMO-3 to LUMO for 8 and HOMO-
1, HOMO-2 and HOMO-3 to LUMO for 9 respectively (Error! Reference source not 
found. and Table 4.11).  Population of the Rh-Leq(σ*) orbital (namely LUMO+1 and 
LUMO+2) upon irradiation promotes labilization of the eq CH3CN ligands whose 
signature is observed in the region of 320-420 nm.  There is a very distinct feature at 275 
nm which corresponds to the HOMO-6 and HOMO to the LUMO+1 which is mostly metal 
centered and has been ascribed to Rh(π*)Rh-Leq(σ*).  The electronic transitions 
derived from the TD-DFT calculations in CH3CN and H2O and the frontier orbitals 
involved in the electronic transitions are summarized in Error! Reference source not 
ound. and Table 4.11, Figure 4.18 and Figure 4.19 show the visualization of the orbitals 
involved in the electronic transitions for compounds 8 and 9.   
Compound 10’s electronic absorption spectrum shows a band with two distinct 
absorptions comprised of two peaks at 490 and 530 nm originating from the HOMO-5 and 
HOMO to LUMO and HOMO-6 to LUMO, respectively.  These two absorptions have 
been assigned as a combination of pyrro(π*)Rh(σ*) and Rh(π*) Rh(σ*).  The low 
energy absorption at 1033 nm is a charge transfer band originating from the HOMO-4 
(pyrro(π*)) to the SOMO (Rh(δ*)) which corresponds to ta LMCT transition.  The 
transition at 1410 nm has been assigned as a metal centered transition, Rh(π*)Rh(δ*), 
with contributions from the HOMO-2 and SOMO which explains the low absorptivity 
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coefficient of this transition (ε = 0.3 x 102 M-1•cm-1).  The first ten electronic transitions 
for 10 have been summarized in Table 4.12 and the depiction of orbitals involved in the 
electronic transitions in Figure 4.20. 
 
 
Table 4.10  First ten electronic transitions predicted for 8 by TD-DFT calculations in 
CH3CN and H2O as solvent.  H = HOMO, L = LUMO. 
8 in CH3CN 8  in H2O 
E (nm) f Excitations Contribution E (nm) f Excitations Contribution 
474 0.001 
H-3 -->L   48% 507 0.001 H-1 --> L 56% 
H-->L   26% 
497 0.001 
H-3 --> L 36% 
351 0.004 H-2-->L+1 30% H-2--> L 23% 
347 0.005 H-->L+2 52% 
362 0.004 
H-4 --> L 25% 
345 0.005 H-3 -->L +1 25% H-1 --> L+1 25% 
317 0.029 H-7-->L 42% 
353 0.008 
H-7 --> L 29% 
314 0.049 
H-8-->L 25% H-3 --> L+1 20% 
H-4-->L 22% 
340 0.001 
H-4 --> L 27% 
289 0.356 
H-2-->L 35% H-1 --> L+1 27% 
H-3-->L+2 22% H-6 --> L 22% 
284 0.013 H-3-->L+2 46% 
304 0.001 
H-2--> L+1 61% 
281 0.176 H-2-->L+2 27% H-3 --> L+1 27% 
273 0.015 
H-->L+1 37% 
290 0.141 H-1 --> L+2 42% 
288 0.162 H-3 --> L+2 27% 
H-6-->L+1 35% 
281 0.105 H-3 --> L+1 41% 
279 0.079 H --> L+1 34% 
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Table 4.11  First ten electronic transitions predicted for 9 by TD-DFT calculations in 
CH3CN and H2O as solvent.  H = HOMO, L = LUMO. 
9 in CH3CN 9 in H2O 
E (nm) f Excitations Contribution E (nm) f Excitations Contribution 
471 0.001 H-1 -->L   69% 539 0.001 H-1 -->L 85% 
456 0.001 
H-3-->L   50% 517 0.001 H-2 --> L 81% 
H-2-->L 23% 380 0.001 H --> L+1 48% 
354 0.001 H-1-->L +1 54% 365 0.002 H-4 --> L 35% 
347 0.001 H-->L+2 69% 
353 0.001 
H-7 --> L 25% 
341 0.005 H-4-->L 42% H-1 -->L+1 23% 
323 0.002 H-5-->L 84% H-5 --> L 20% 
311 0.002 H-6-->L 24% 349 0.001 H-5 --> L 50% 
304 0.082 
H-2-->L 20% 346 0.001 H --> L+2 25% 
H-3-->L 20% 
322 0.025 
H-3 --> L 44% 
300 0.009 
H-2-->L+1 38% H-5 --> L+1 23% 
H-3-->L+1 27% 313 0.009 H-2 --> L+1 48% 
289 0.018 H-1-->L+2 35% 292 0.005 H-1 --> L+2 52% 
 
 
Table 4.12  First ten electronic transitions predicted for 10 by TD-DFT calculations in 
CH3CN and H2O as solvent.  H = HOMO, L = LUMO. 
10 in CH3CN 
E (nm) f Excitations Contribution 
1556 0.001 H-2-->S  87% 
1126 0.018 H-4-->S 24% 
626 0.061 H-4-->S 100% 
546 0.037 H-6-->S 100% 
504  0.005 
H-5-->L 39% 
H -->L 32% 
501  0.001 
H-5 -->L 60% 
H-->L 14% 
425 0.001 H -->L 100% 
417 0.004 H -->L 72% 
416 0.003 H-1-->L 76% 
353 0.004 H-11-->S 100% 
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Figure 4.18  MO depiction of 8 generated by TD-DFT calculations in the solvation 
model (CH3CN) generated by agui with iso-value = 0.04; H = HOMO, L = LUMO. 
 
 
 
 
 
 
Figure 4.19  MO depiction of 9 generated by TD-DFT calculations in the solvation 
model (CH3CN) generated by agui with iso-value = 0.04; H = HOMO, L = LUMO. 
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Figure 4.20  MO depiction of 10 generated by TD-DFT calculations in the solvation 
model (CH3CN) generated by agui with iso-value = 0.04; H = HOMO, L = LUMO. 
 
 
 
In Vitro Cytotoxicity Studies 
Cell viability studies were performed on compounds 8 and 9 and their toxicities 
were evaluated in the dark and upon irradiation with visible light using SYTOX® Green 
and Hoechst 33342 fluorescent staining performed on HeLa cells, whereas 10  was 
evaluated by the resazurin assay.  Sytox Green® is a cell impermeable dye that increases 
its fluorescence signal by 100-fold when the cells have been compromised or are dead.147 
Hoechst 33342 is a permeable blue fluorescence probe that stains both live and dead cells 
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by binding to the minor groove of double-stranded DNA rich in adenine and thymine.177 
On the other hand resazurin is a fluorescent cell viability assay analogous to the formazan-
based assays (MTT/XTT) as it measures cell viability via the irreversible reduction of 
resazurin to resorufin which is directly proportional to aerobic respiration.138-139 For the 
dark experiments, the cells were incubated with different concentrations of compounds 8-
10 for 2 h followed by treatment with Sytox® Green and Hoechst 33342 staining for 10 
min or resazurin in the case of 10.  The cells incubated with 8 and 9 in the dark exhibited 
mostly blue fluorescence (Figure 4.21).  Compound 10, like 8 and 9, exhibits no toxicity 
in the dark with an LC50 value >> 1mM.  The absence of green fluorescence indicates that 
the cells are not dying upon exposure to 8 and 9 up to concentrations in the mM range.  
The LC50 in the dark for 8 is 913 ± 51 µM; this result is comparable to the dark control 
experiments where no compound is present thus indicating the low toxicity of 8 in the 
dark.  The toxicity of compounds 8-10 is significantly lower than that of cisplatin under 
the same conditions, results which have been summarized in Table 4.13.  
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Figure 4.21 Confocal microscopy images of HeLa cells treated with 50 µM solutions of 
8 and 100 µM solutions of 9 for 2 h in the dark followed by treatment with Sytox® Green 
and Hoechst.  Top control in the dark, middle pane compound 8 and bottom compound 9.  
a) Hoechst 33342, blue fluorescence, b) phase contrast, c) SYTOX® Green fluorescence, 
and d) overlay of blue and green fluorescence. 
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Table 4.13 Cytotoxicity and phototoxicity data for compounds 8-10, cisplatin and 
Hematoporphyrin in the dark and upon irradiation. 
  LC50 µM LC50
* µM Phototoxicity Index 
cisplatin 58 ± 4 47 ± 3 1.2a 
Hematoporphyrin 21 ± 1 3.8 ± 0.2 5.5b 
8 913 ± 51  483 ± 41  2 
9 4115± 72  186 ± 30  22 
10c >>1 mM 868 ± 99  NA 
a. Ref 170 
b. Ref 190 
c. Measured with resazurin assay. 
 
 
 
The toxicities of 8-10 were evaluated after irradiation for 1 h (Figure 4.22 and 
Table 4.13).  Compounds 8 and 10 do not show increase activity upon light activation.  
The low toxicity of 8 is ascribed to the relative stability of the eq CH3CN ligands in 
aqueous solution as it takes more than 4 h for these to exchange as demonstrated by 1H 
NMR studies.  The mixed-valence compound 10 does not exhibit cell toxicity in the dark 
or upon irradiation; the LC50
* is 868 ± 99 µM.  The most active of this new family of 
dirhodium compounds is 9 with an LC50
* of 186 ± 30 µM with an increase in phototoxicity 
index (PI) of LC50/LC50
* = 22.  The toxicity of this compound is still lower than that of 
cisplatin, but it’s PI is superior than that of hematoporphyrin the main ingredient in the 
FDA approved PDT agent Photofrin®, PI = 5.5.  Dirhodium aqua species can bind to 
biomolecules and other cellular targets in an analogous way to cisplatin therefore the 
increased toxicity of 9 may be due to the generation of the active aqua species and the 
release of the eq pyrrole molecule upon light irradiation as evidenced by the 1H NMR 
studies.77,79,170 
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Figure 4.22  Confocal microscopy images of HeLa cells treated with 50 µM solutions of 
8 and 100 µM solutions of 9 for 2 h in the dark, irradiated for 1h, followed by treatment 
with Sytox® Green and Hoechst.  Top control after irradiation, middle pane compound 8 
and bottom compound 9.  a) Hoechst 33342, blue fluorescence, b) phase contrast, c) 
SYTOX® Green fluorescence, and d) overlay of blue and green fluorescence. 
 
 
Mitochondrial Trans-membrane Potential Disruption: JC-1 Assay 
The mitochondrial respiratory chain in the inner mitochondrial membrane is 
responsible for the generation of ROS, which, in the absence of antioxidants, can cause 
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damage to lipids, proteins and DNA and eventually trigger cell death.191  It is well 
understood by the scientific community that accumulation of cationic species inside the 
mitochondria induces changes in mitochondrial potential (ΔΨ)192  which promote the 
release of pro-apoptogenic factors, which in turn induce cell death.153 In order to study the 
changes in mitochondrial potential induced by 9, the commercially available JC-1 dye was 
used.  JC-1 targets the mitochondria and exhibits two types of fluorescent responses when 
the ΔΨ changes.193-194 Healthy cells have high ΔΨ and in this type of environment JC-1 is 
in its aggregated form (J-aggregates) which fluoresces red.  Conversely when ΔΨ is low, 
the dye adopts a monomeric form which has a green fluorescence. 
 In order to study the cell death mechanism of compound 9, HeLa cells were 
incubated with JC-1 and the ratio of green to red florescence was measured as a function 
of time (Figure 4.23).  The changes in mitochondrial potential were monitored for a period 
of 5 h and it was found that compound 9 induces a decrease in mitochondrial potential 
with time which plateaus after 4 h.  It is possible that the decrease in mitochondrial 
potential observed in 9 is triggered by an apoptotic response. 
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Figure 4.23  Mitochondrial potential changes in HeLa cells as a function of time for 
compound 9. 
 
 
Annexin-V FITC 
 Programmed cell death, most commonly known as apoptosis triggers a cascade of 
biological responses that induce cell death.42  The apoptotic response is characterized by 
the activation of caspases, chromatin condensation, and exposure of phosphatidyl serine 
(PS) on the cell surface amongst others.42  The exposure of PS can be monitored by 
fluorescence spectroscopy by using Annexin-V FITC.  This protein reversibly binds to PS 
when it is exposed to the outer leaflet of the cell and exhibits a green fluorescence.195 
 In order to determine the mechanism of cell death, HeLa cells were treated with 9, 
followed by incubation with Annexin-V FITC for 10 min.  The cells treated with 
compound 9 exhibit green fluorescence localized on the outer side of the cell membrane 
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(Figure 4.24).  These results taken in combination with the JC-1 assay support the 
conclusion that 9 induces apoptotic mediated cell death. 
 
 
 
Figure 4.24  Confocal microscopy images of HeLa cells treated with 9 followed by 
treatment with Annexin V-FITC. a) Phase contrast image, b) Annexin V-FITC, green 
fluorescence and c) Annexin V-FITC pseudo colored green image. 
 
 
Concluding Remarks 
 The head-to-head (H-H) isomers of cis-2,2-[Rh2(µ-
NOC4H6)2(Hpyrro)(CH3CN)5](BF4)2 and cis-2,2-[Rh2(µ-NOC4H6)2(pyrrol)(CH3CN)5]
2+ 
along with the oxidized form of cis-2,2-[Rh2(µ-NOC4H6)4]
+ were synthesized and 
characterized.  Compound 8 has one Hpyrro in the axial position, while 9 has a pyrrol 
molecule in the equatorial position trans to the O bridge as confirmed by X-ray studies.  
The UV-visible spectrum of 10 exhibits a band at 1033 nm and 1140 nm that was not 
reported by Bear and according to the TD-DFT results these bands are result of LMCT 
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and MC transitions, respectively.  The 1H NMR studies performed on 8 and 9 show that 
the axial Hpyrro ligand in 8 exchanges in the dark and that 9 does not exchange the eq 
pyrrol molecule for the deuterated solvent for up to 3 h. Compound 9 exchanges the 
CH3CN
O in the dark.  Compound 8 is more kinetically stable in the dark than 9 is and does 
not induce toxicity in HeLa cells upon irradiation with white light.  The 22-fold increase 
in toxicity of compound 9 upon irradiation is expected to be related to the release of the 
pyrrol molecule and the labilization of the eq CH3CN monodentate ligands upon 
irradiation.  The TD-DFT calculations indicate that the LUMO+1 orbital in both cases has 
Rh-Leq (σ*) antibonding character for the eq acetonitrile molecule trans to the O bridge 
which is responsible for the labilization of the eq CH3CN monodentate ligands.  This result 
supports the findings from 1H NMR spectroscopy studies performed in D2O in the dark 
and upon irradiation.  Compounds 8 and 9 are the first examples of dirhodium partial 
paddlewheels bearing photo-labile anticancer active ligands which render them good 
candidates for cancer therapy.  These compounds can be easily tuned and future efforts 
will be directed towards the design and synthesis dirhodium compounds bearing 
anticancer ligands and tumor targeting moieties.  
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CHAPTER V  
CONCLUDING REMARKS 
 
Medicinal inorganic chemistry is an attractive field of modern drugs but, in fact, 
metal compounds have been used for centuries to treat different ailments.  Coordination 
compounds offer a broad array of coordination numbers, ligand environments, and 
accessible redox states which poises them as good therapeutic agents.95 Although there 
are a number of promising and effective transition metal drugs currently in use around the 
world, there remains a pressing need to discover new therapies that target different 
organelles and biologically relevant molecules other than DNA.  Over the past 20 years, 
our laboratories have focused their efforts on the development of dirhodium compounds 
with cytostatic activity.  As part of our interest in metal anticancer agents we are exploring 
dirhodium(II,II) complexes with different types of bridging and chelating ligands in the 
same molecule,196  work that has led to the isolation of families of such compounds that 
are inactive towards cancer cells in the dark but which are toxic upon irradiation has been 
synthesized and characterized.   
In Chapter I, five new complexes with two different bridging ligands ([O2CCH3]
- 
and [F2form]
-) were reported.  Formamidinate compounds of the type 
[Rh2(F2form)(O2CCH3)(N-N)2][OAc]2 with electron accepting chelating ligands (N-N) 
(N-N = dpq (dipyrido[3,2-f:2',3'-h]-quinoxaline), dppz (dipyrido[3,2-a:2’,3’-c]phenazine) 
and dppn (benzo[i]dipyrido[3,2-a:2’,3’-h]quinoxaline)) were studied and their anti-
proliferative activity was evaluated against ovarian cancer and cervical cancer cell lines 
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in the dark and also upon irradiation.  In addition, the effects of these compounds on 
mitochondrial potential and type of cell death were studied.  Compounds 4 and 5 exhibit 
the highest activity against ovarian cancer cell lines OVCAR-8 and NCI-ADR/RES 
respectively, with LC50 values in the lower micromolar range after irradiation.  This new 
family of dirhodium compounds induces different types of cell death depending on the 
nature of the bridging ligands.  Earlier we had shown that [Rh2(µ-O2CCH3)2(dppn)(dppz)] 
and [Rh2(µ-O2CCH3)2(dppn)2] induce apoptotic and necrotic cell death respectively.  
Parallel results were not observed for this series of compounds; compound 2 induces an 
apoptotic response while compounds 3-5 exhibit signs of both apoptosis and necrosis in 
NCI-ADR/RES cells.  Cell death induced by 2-5 occurs in a very short time scale as 
evidenced by fast mitochondrial potential depletion from the JC-1 studies in HeLa cells.  
These results suggest that the ability of these compounds to generate ROS may be a key 
factor for the rapid cell death.   
We propose that these compounds may be oxidizing phospholipids or inducing 
endosomal lysis upon irradiation which would account for the rapid cell death.  In the 
future it would be very interesting to study the how ROS scavengers affect the activity of 
compounds 4 and 5.  In addition, considering the type of cell death induced by these 
compounds, a concentration dependent and a time lapse experiment with YO-PRO-1197 
and propidium iodide would help elucidate the mechanism of cell death induced by 4 and 
5.  Since most of the compounds in this study induce necrotic cell death to some extent it 
would be valuable to study how the inhibition of PARP-1 (nuclear enzyme that initiates 
cell necrosis)104 could be effected; by doing so necrotic cell death can be prevented and 
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this may affect the mechanism of cell death imparted by these compounds upon 
irradiation.   
Light induced toxicity by ligand dissociation is another strategy for the metal-
based drugs in this study, data that are presented in Chapter III.  Partially solvated 
compounds with two different bridging ligands were synthesized and their activity against 
HeLa cells was evaluated.  Compounds [Rh2(F2form)(µ-O2CCH3)(CH3CN)6]
2+(6) and 
[Rh2(PC6H4Ph2)(µ-O2CCH3)(CH3CN)6]
2+ (7) showed rapid ligand dissociation in the 
dark.  In particular, compound 6 is unstable although irradiation does not affect the rate of 
ligand dissociation.  The side product 6b was isolated in which the acetate group is 
missing.  Compound 7 exchanges the eq CH3CN ligands trans to the orthometallated 
phosphine but the signals corresponding to the eq CH3CN ligands trans to acetate do not 
exchange in the dark or upon irradiation under the experimental conditions.  Cytotoxicity 
studies reveal that neither of these compounds exhibit carcinostatic activity.  Although 
these compounds are not good candidates for PDT applications, 7 can be used as a 
precursor for further functionalization and applications in cancer therapy or photocatalytic 
reduction of H2O.
134   
 The results in Chapter IV focus on the synthesis of dirhodium partial paddlewheel 
compounds with 2-pyrrolidinone as a bridging ligand.  The 2-pyrrolidinone molecule is 
quite interesting as it has been studied for anticancer properties against HeLa (cervical) 
cells and PC-3 (prostate) cancer cells.186  In an effort to synthesize the partially solvated 
dirhodium compound with 2-pyrrolidinone as a bridging ligand, [Rh2(pyrro)4] was used 
as a precursor and reacted with the alkylating reagent triethyloxonium tetrafluoroborate.  
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This reaction afforded two different compounds, namely cis-2,2-[Rh2(µ-
NOC4H6)2(Hpyrro)(CH3CN)5]
2+ (8) and cis-2,2-[Rh2(µ-
NOC4H6)2(pyrrol)(CH3CN)5]
2+(9).  Compound 8 has a 2-pyrrolidione ligand in the axial 
position while in 9 a pyrrole is bound in the equatorial position trans to the O.  The toxicity 
of these compounds was evaluated against HeLa cells in the dark and upon irradiation.  
While compound 8 is not toxic, 9 showed a 22-fold increase in phototoxicity upon 
irradiation.  The toxicity of 9 may be attributed to the release of the eq pyrrole molecule 
upon irradiation.  These compounds do not show high toxicity, this may be due to low 
internalization in the cells.  Che and coworkers showed that functionalization of the 2-
pyrrolidinone with lipophilic groups improves toxicity when compared to 
[Rh2(pyrro)4].
184  These strategy may be useful with compounds 8 and 9 as well to improve 
their toxicity.  Although the toxicities of these compounds are not high, they are good 
examples of dirhodium compounds bearing photolabile organic drug molecules for which 
examples in literature for dirhodium (II,II) compounds are scarce.   
 
Future Directions 
In order to prevent side effects caused by chemotherapy many efforts have been 
devoted to the design of anticancer drugs that can target cancerous cells instead of healthy 
tissue.  Among the more studied systems are nanoparticles, which can be tailored in order 
to modify shape, size and surface modification to make them more specific towards a 
particular target.198-200  Another approach that has been pursued by the scientific 
community is the functionalization of anticancer agents with folic acid, in order to target 
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folic acid receptors on the cancerous cells.201  Folic acid receptors are glycoproteins that 
are anchored to the cell membrane and facilitate the uptake of folic acid by the cell.201-202  
It has been demonstrated by several research groups that these folic acid receptors are 
overexpressed in rapidly growing tissues.203-205  Mouse models of colon carcinoma 
showed increased proliferation of the cancer in the presence of folic acid.206  Due to the 
overexpression of folic acid receptors in many types of cancerous cells the conjugation of 
this ligand to anticancer agents  offers another means of targeting tumors cells 
selectively.201  
Dirhodium compounds offer a variety of possible coordination sites that can be 
available for reactions allowing the synthesis of a great number of derivatives.  In order to 
make our compounds more selective towards cancerous cells, folic acid could be 
incorporated into the bridging position of the dirhodium core.  The acid dissociation 
constants of folic acid makes the ligand accessible for the functionalization of the 
dirhodium core through the α carboxylic acid (pKa=4.7) of the folic acid.202,207  A 
dirhodium compound that could be used as a precursor for the synthesis of a targeted pro-
drug system can be [Rh2(Ph2P(C6H4))(O2CCH3)(1,8-naphtyridine)(CH3CN)4]
2+ (7b) 
which has been successfully synthesized (Figure 5.1a).   
The synthesis of 7b is a great example of controlled functionalization of dirhodium 
compounds by tuning the ligand environment around the dirhodium core to afford 
heteroleptic compound 7b.  Since the phosphine is a strong σ-donating ligand, it was 
predicted that 1 eqv. of 1,8-naphthyridine would bind trans to it (Figure 5.1a).  The 
reaction takes place at room temperature in CH3CN to afford 7b in good yields (75 %).  
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The purity of the compound was confirmed by 1H-NMR and X-ray crystallography 
methods (Figure 5.2).  The 1H NMR spectrum shows the characteristic multiplet 
resonances four for the phosphine at 6.76 ppm, 7.05 ppm, 7.33 ppm and 7.57 ppm, and 
four characteristic resonances for the naphthyridine ligand at 8.04 ppm, 8.83 ppm, 9.58 
ppm and 9.74 ppm (Figure 5.1b).  As in the case of 7, there are three singlet resonances 
in the aliphatic region corresponding to the bridging acetate (1.40 ppm) and the two eq 
CH3CN trans to acetate at 1.67 ppm and 1.78 ppm.   
 
 
 
Figure 5.1  a) Reaction scheme of 7 with 1,8-naphthyridine and b) 1H NMR spectrum of 
[Rh2(PC6H4Ph2)(µ-O2CCH3)(1,8-naphthyridine)(CH3CN)4]
2+ in CH3CN.  
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Figure 5.2  Thermal ellipsoid plot of compound 7b at the 50% probability level.  Anions 
and hydrogen atoms have been omitted for the sake of clarity. 
 
 
This molecule is of great importance since it poses as a great precursor for selective 
binding of biomolecules to the dirhodium core.  It would be expected that reactions of 7b 
with folic acid would afford a folic acid functionalized dirhodium complex that confers 
specificity to the dirhodium drug by targeting folate receptors in ovarian cancer cells 
(Figure 5.3).18 
One interesting molecule that could also be used in both cancer treatment and live 
cell imaging is curcumin ((1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-
3,5-dione).208  Curcumin is the active ingredient in the turmeric spice, it has been 
demonstrated that in combination with several chemotherapeutic drugs can elicit 
synergistic effects in cancer treatment amongst other uses (such as anti-viral and 
microbial, anti-inflammatory, etc.).209-210  One disadvantage though is the low 
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bioavailability due to its poor solubility and low stability in acidic environments.211   In 
order to circumvent this problem researchers have coordinated curcumin to transition 
metals and it has shown improved activity and accumulation in the cell.208  There is 
evidence that curcumin can work as a photosensitizer and induce cell death upon 
irradiation.208  Dirhodium compounds are very stable and robust compounds that can be 
used as delivery vehicles for curcumin.  The combination of the photochemotherapeutic 
effects of curcumin with that of the dirhodium compounds would enhance the therapeutic 
potential of these compounds.  The coordination of curcumin to dirhodium compounds 
like 7b or the synthesis of a partially solvated dirhodium compound containing curcumin 
as a bridging ligand should be explored (Figure 5.3 and Figure 5.4).   
 
 
 
Figure 5.3  Proposed reaction scheme of 7b with curcumin and folic acid.  
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Figure 5.4  Schematic representation of the proposed synthetic patch for the preparation 
of [Rh2(curcumin)2(CH3CN)6]
2+. 
 
 
The dirhodium compounds in this dissertation expand the knowledge of how 
different bridging ligands affect the toxicity of these compounds against different cancers 
and their mechanisms of cell death.  The dark stability of the equatorial CH3CN ligands 
and their lability upon irradiation are crucial for their potential applications as 
photodynamic therapy agents.  The work described in this thesis helps to expand the 
database of information available on how to design of dirhodium anticancer agents with 
new and improved properties.  
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